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 Introduction 
In recent years, the therapeutic use of antibodies has become a powerful new treatment 
option for various serious diseases including asthma, rheumatoid arthritis, Crohn's 
disease, different types of cancer and wet age related macular degeneration (AMD) 
[1–5]. Since the market launch of the first antibody muromonab-CD3 in 1986, the number 
of therapeutically successful antibodies has increased continuously. Nowadays, 
antibodies, antibody fragments, conjugates, and fusion proteins represent the most 
important and valuable product class within the biopharmaceutical market. These 
antibody products can be applied either systemically or locally. Although the systemic 
application of antibodies is associated with several disadvantages, including high dosing 
and serve side effects, most antibodies are currently administered by intravenous 
injections. The mentioned drawbacks can be overcome by local application in order to 
achieve higher drug concentrations at the application site. This results in lower required 
drug dosages and improved therapeutic effects. Moreover, the systemic antibody 
exposure is reduced causing less systemic side effects. Currently, a variety of potential, 
local antibody application sites are investigated or have already been established. For 
instance, antibodies are directly administered at the tumor site for anti-cancer application, 
are intraarticularly injected for the treatment of arthritic joint diseases or are being used 
to minimize or even cure injuries of the central nervous system after intrathecal 
delivery [6–8]. The most used method for local antibody delivery is the intravitreal 
administration of anti-vascular endothelial growth factor (VEGF) antibodies for the 
therapy of diseases at the posterior segment of the eye, such as AMD and proliferative 
diabetic retinopathy (PDR) [5,9]. In this case the blood-retina-barrier represents an 
insurmountable obstacle for the systemic application of macromolecules, such as 
antibodies. Thus, intraocular injections are essential for a successful antibody therapy 
(Figure 1.1). 
However, there are several limitations minimizing the success of those strategies: short 
drug residence times at the application site and hence frequent antibody administration as 
well as side effects of injections, such as pain and inflammation, reduce the 
compliance [10]. Consequently, suitable drug delivery systems for sustained antibody 
delivery are required to overcome these limitations and enable more effective 
therapies [11]. During the last decades different types of drug delivery systems based on  
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microparticles, nanoparticles, liposomes and hydrogels were investigated [12,13]. These 
drug delivery systems lower drug dosage and enhance drug efficacy while reducing 
systemic side effects. 
Figure 1.1. Sustained release of entrapped antibodies at the posterior segment of the eye after intraocular 
injection of an in situ gelling hydrogel. 
The use of hydrogels for antibody delivery offers several advantages, such as reduced 
antibody degradation [13,14]. Generally, hydrogels are regarded to be biocompatible 
because of their high water content and soft nature similar to the extracellular matrix. 
Their porous structure is extremely suitable to accommodate high loads of water-soluble 
proteins either by post-fabrication partitioning or in situ encapsulation [14,13]. The 
simple preparation procedures in aqueous medium at room temperature contribute to 
preserving protein stability. Moreover, the entrapped antibodies have limited mobility in 
hydrogel networks with high cross-linking density resulting in sustained release 
controlled by the swelling and degradation behavior of the gels. Finally, in situ gelling 
hydrogels can be easily injected and form drug delivery systems at the application site.  
Important for the success of the system is a precise control over the cross-linking density 
and hence the mechanical properties, the swelling capacity, the degradation behavior of 
the hydrogel and the release profile of entrapped antibodies [15]. However, it is more or 
less impossible to obtain a defined network structure through widespread radical 
photopolymerization [16]. Moreover, the use of photoinitiators generates free radicals 
during cross-linking, which may induce toxicity and affect the bioactivity and availability 
of proteins [14,17,18]. Additionally, a lower cross-linking conversion due to un-reacted 
functional groups and network non-idealities may negatively influence antibody release. 
Therefore, alternative cross-linking reactions have to be developed for the successful 
utilization of antibody release systems based on hydrogels. An appropriate reaction 
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should occur in water at body temperature without using any catalyst or initiator. A cross-
linking reaction that meets the criteria is the Diels-Alder (DA) click reaction. This [4 + 2] 
cyclo-addition is a highly effective reaction between electron-rich diens and dienophiles. 
Despite being widely used in organic chemistry for the synthesis of steroid hormones and 
six-membered rings, its application for hydrogel preparation is less common [19,20]. 
Nevertheless, few examples have been described in literature using natural polymers in 
combination with relatively short cross-linkers, which results in rather undefined 
networks [21,22]. Although natural polymers are regarded to be non-toxic and principally 
biodegradable, they are less suitable for hydrogel preparation due to their non-
reproducible chemical and physical properties. Therefore, synthetic polymers are favored 
for hydrogel preparation. Especially hydrogels based on poly(ethylene glycol) (PEG) are 
widespread because of their favorable polymer properties, such as high solubility, 
excellent biocompatibility and broad acceptance by regulatory agencies [14,23]. 
 Goal of the thesis 
This thesis is focused on the development and characterization of DA hydrogels as 
injectable drug delivery system for the intraocular application of antibodies. 
Currently, hydrogels are already used for a number of different applications in 
ophthalmology. For instance, they are used as in situ gelling eye drops, soft contact lenses 
(SCL), intraocular lenses (IOL) and adhesives for ocular wound repair or are investigated 
as vitreous substitutes and intravitreal drug delivery systems (Chapter 2). Although 
significant progress has been made in the field of SCL, in situ gelling eye drops and 
adhesives for ocular wound repair, many challenges remain to improve the safety and 
clinical performance of intraocularly applied hydrogels. More research is particularly 
needed to improve hydrogels as intravitreal drug delivery systems for the treatment of 
severe, vision-threatening diseases, such as AMD or PDR. 
There are a number of general requirements that intraocularly applied hydrogels must 
fulfill. Ideally, these hydrogels are injectable and offer sustained drug release over several 
weeks. So-called in situ gelling hydrogels, which are injected prior to gelation and form 
a semi-solid drug depot at the application site, offer such characteristics. After gelation 
the mechanical properties of the resulting hydrogel should be comparable to those of the 
environment in order to cause no foreign body sensation. Moreover, the hydrogel should 
be designed for simple and effective drug loading procedures, especially for proteins and 
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antibodies. Therefore, suitable cross-linking processes are necessary to permit fast 
gelation without inactivating the entrapped proteins. Besides appropriate loading 
procedures, a complete, yet sustained release of still active drugs is of particular 
importance. One of the main challenges of hydrogels is the control of drug release over 
several weeks due to their high water content. After complete drug release, the hydrogel 
should degrade without releasing any toxic degradation product. Although, a multitude 
of polymers and cross-linking possibilities have already been tested, there is no product 
commercially available until today. Promising materials are chemically cross-linked 
PEG-based hydrogels. Due to their excellent biocompatibility they are used for several 
biomedical applications. As in situ gelling systems they can be easily injected by 
minimally invasive techniques and hold great promise as drug delivery systems. 
Nevertheless, most established cross-linking mechanisms are associated with significant 
disadvantages, such as the formation of potentially harmful radicals or unwanted side 
reactions with incorporated protein drugs.  
To overcome these limitations, new cross-linking reactions for PEG-based hydrogels 
have to be developed. Since the DA reaction proceeds in water without any initiator or 
metal catalyst, it is considered as an effective and non-toxic cross-linking possibility 
(Chapter 3). For the hydrogel preparation, two complementary macromonomers were 
synthesized by functionalizing star-shaped PEG with furyl and maleimide groups 
(Figure 1.2). 
Figure 1.2. Principle of DA reaction for in situ hydrogel formation. Furyl- and maleimide functionalized 
star shaped PEG were dissolved in water and combined, e.g. by using a two-chamber syringe. Directly after 
mixing both components the formation of highly elastic hydrogels is initiated. 
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The influence of the macromonomer concentration, molecular weight and branching 
factor on gel characteristics, such as rheology and swelling behavior, were investigated. 
Surprisingly, the covalently cross-linked hydrogels dissolved within days to weeks. To 
investigate this unexpected degradation behavior of PEG-based DA hydrogels in detail, 
further experiments were performed (Chapter 4). UV spectroscopy was used to analyze 
the hydrolytic stability of maleimide functionalized star-shaped PEG as a function of 
temperature and pH. Finally, molecular modeling studies of DA and retro-Diels-Alder 
(rDA) moieties were performed to investigate the influence of these reactions for the 
degradation process. 
Besides the degradability, the permeability of entrapped drugs, such as proteins or 
antibodies, is crucial for success or failure of the system. The mesh size or correlation 
length ξ is an important parameter that characterizes the permeability. It is defined as “the 
average distance between consecutive cross-links” and indicates the maximum size of 
solutes that can pass through the gel network. In Chapter 5 swelling studies, rheology 
and low field NMR spectroscopy were used to calculate ξ of the prepared DA hydrogels. 
The knowledge of ξ, in combination with the size of the entrapped molecule, allows the 
estimation of the drug release rate and the evaluation of the general suitability of the 
resulting hydrogels for controlled release of entrapped, therapeutic antibodies. As a proof 
of concept, fluorescein-labeled dextrans of different molecular weight were entrapped 
into the hydrogel and release studies were performed. Finally, the data of those in vitro 
studies were compared to theoretical predictions. 
Figure 1.3 Modification of eight-armed PEG (A) by introducing Ahx spacer between PEG and reactive 
end-groups to increase hydrolytic stability (B). Modification with Lys and Ahx yields in doubled number 
of reactive end-groups and increased hydrolytic stability (C). 
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However, slow gelation and comparatively fast degradation may limit the application of 
DA hydrogels as injectable drug delivery systems. To overcome these limitations the 
macromonomers were modified with lysine (Lys) and/or 6-aminohexanoic acid residues 
(Ahx) in order to increase the hydrolytic stability of maleimide and to double the number 
of reactive groups per macromonomer (Chapter 6) (Figure 1.3). 
To prove the feasibility of the optimized DA hydrogels as drug delivery systems, the gels 
were loaded with bevacizumab, a VEGF-neutralizing antibody used in the treatment of 
AMD. Afterwards, the release profiles of the entrapped antibody were determined by 
fluorescence spectroscopy. 
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Chapter 2 
Hydrogels in Ophthalmic Applications 
This chapter was published as: S. Kirchhof, A. M. Goepferich and F. P. Brandl, Eur. J. 
Pharm. Biopharm. (2015), doi: org/10.1016/j.ejpb.2015.05.016
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Abstract 
More and more people worldwide are affected by severe eye diseases eventually leading 
to visual impairment or blindness. In most cases, the treatment involves the application 
of ophthalmic dosage forms such as eye drops, suspensions or ointments. Unfortunately, 
some of the therapeutic approaches have major shortcomings, especially in the treatment 
of the posterior segment of the eye, where many vision-threatening diseases originate. 
Therefore, research focuses on the development of new materials (e.g., for vitreous 
substitution) and more advanced drug delivery systems. Hydrogels are an extremely 
versatile class of materials with many potential applications in ophthalmology. They 
found widespread application as SCL, foldable IOL, in situ gelling formulations for 
ophthalmic drug delivery and ocular adhesives for wound repair; their use as vitreous 
substitutes and intravitreal drug delivery systems is currently under investigation. In this 
article, we review the different applications of hydrogels in ophthalmology with special 
emphasis placed on the used polymers and their suitability as ocular drug delivery 
systems.  
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 Introduction 
More and more people worldwide are affected by severe eye diseases, such as glaucoma, 
PDR and AMD [24–27]. Without adequate treatment, these diseases will eventually lead 
to severe visual impairment or blindness. Today, two major strategies for the treatment 
and management of ocular disorders can be identified: (1) the attempt to specifically 
deliver drug molecules to diseased ophthalmic tissues and (2) surgical procedures to 
repair or replace damaged tissues, such as the lens or the vitreous body [28–30]. 
Unfortunately, most currently available therapeutic approaches have major shortcomings, 
especially in the treatment of the posterior segment of the eye, where most vision-
threatening diseases originate. The main challenges are as follows: (1) poor adherence of 
patients to the currently available therapeutic regimens, (2) maintaining effective drug 
levels over extended time periods and extending the required dosing intervals, (3) the 
delivery of drug molecules to the posterior segment of the eye, (4) the administration of 
therapeutic proteins and nucleic acids, and (5) the repair or substitution of dysfunctional 
cells or tissues. For example, over 50% of 500 surveyed glaucoma patients were found to 
be either non-adherent to their therapeutic regimens or demonstrated improper 
administration techniques [31]. While patients can be educated on the importance of 
adherence and instructed on proper eye drop administration, the inherent shortcomings of 
eye drops, such as low ocular bioavailability of the applied drug, are less easy to 
overcome. For example, it has been shown that less than 5% of the administered dose 
reaches the target tissue due to drainage and limited corneal permeability [32–34]. 
Moreover, only the anterior segment of the eye can be treated by eye drop installation, 
whereas different application routes (e.g., intravitreal injections) and/or more complex 
drug delivery systems (e.g., intraocular implants) may be required to reach the posterior 
segment [35–38]. For example, the development of anti-VEGF drugs, such as monoclonal 
antibodies or antibody fragments, revolutionized the therapy of neovascular AMD and 
other vision-threatening diseases [5,9,39]. However, the required intravitreal injections 
are associated with significant discomfort and complications including endophthalmitis, 
retinal tears or detachment, and cataract [10]. It is obvious that sustained delivery systems 
for anti-VEGF drugs would make the current therapeutic regimens more patient-friendly 
and cost-effective. 
2.1
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Figure 2.1. Application sites of hydrogels in ophthalmology. 
The given examples illustrate the need for new developments in the field of ophthalmic 
drug delivery, and indicate the great market potential of those drug delivery systems. 
Compared to the different materials and dosage forms that have been developed for 
ophthalmic applications, such as colloidal drug delivery systems [40–42] or polymeric 
implants [43], hydrogels may offer several advantages. For example, the mild preparation 
conditions and high water content of hydrogels are beneficial in preserving the activity of 
biopharmaceuticals such as peptides, proteins or nucleic acids [13,14,44]. Moreover, 
many hydrogels, such as temperature-responsive or in situ chemically cross-linked 
systems, can be administered by minimally invasive methods [13,14,44,45]. Hydrogels 
have already been approved for several ophthalmic applications, with many more 
currently being under investigation. For instance, they are successfully marketed as 
corrective SCL [46], foldable IOL [47,48], or in situ gelling vehicles for ophthalmic drug 
delivery [49,50]. Most research efforts currently aim at improving existing formulations 
for antibiotics, anti-inflammatory drugs or β-blockers, or at developing sustained release 
formulations for therapeutic proteins and nucleic acids. Furthermore, hydrogels are 
investigated as adhesives for ocular wound repair [51] or potential vitreous substitutes 
[29,30]. A graphical overview on possible ophthalmic applications of hydrogels is given 
in Figure 2.1. 
In most of these applications, hydrogels are used because of their favorable 
physicochemical properties (e.g., transparency, high water content, and mechanical 
flexibility) or in combination with active pharmaceutical ingredients. In this review 
article, we present a general overview on ophthalmic applications of hydrogels with 
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special emphasis on drug delivery systems for the posterior segment of the eye. We 
particularly focus on the different gel-forming polymers, the physicochemical properties 
of the resulting hydrogels, and the challenges associated with the preparation of hydrogel-
based drug delivery systems. Recent developments in the field of ophthalmic drug 
delivery are presented and critically reviewed regarding the potential therapeutic benefits. 
 Methods of hydrogel preparation and properties of 
hydrogels 
Before discussing the diverse applications of hydrogels in ophthalmology, a short review 
on the different methods of hydrogel preparation will be presented along with an overview 
on the characteristic properties of hydrogels. According to the definition by the 
International Union of Pure and Applied Chemistry, a hydrogel is a polymer network that 
is expanded throughout its whole volume by water [52]. A wide range of natural, 
semisynthetic and synthetic polymers can be used as starting materials for hydrogels. 
Typical examples for polymers of natural origin include alginate, collagen, and 
hyaluronic acid (HA) (Figure 2.2). PEG, poly(vinyl alcohol) (PVA), polymers based on 
acrylate monomers, and siloxanes are important examples for synthetic gel-forming 
materials (Figure 2.3) [13,44,53–55]. 
Figure 2.2. Chemical structures of selected polymers from natural sources commonly used for the 
preparation of hydrogels. 
2.2
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Figure 2.3. Chemical structures of synthetic polymers commonly used for the preparation of hydrogels. 
Polymers of natural origin usually have the advantage of being non-toxic and 
biodegradable. Furthermore, natural polymers often interact with proteins and cells 
through non-specific or specific binding, which can be desired in hydrogel-based 
sustained release systems or cell carriers. However, hydrogels made from natural 
polymers may suffer from weak mechanical strength, high batch-to-batch variability, and 
immunogenicity. Synthetic polymers, on the other hand, allow for the preparation of 
hydrogels with well-defined network architecture, tunable mechanical properties, and 
prolonged stability. However, many synthetic polymers, such as PEG or PVA, do not 
inherently interact with proteins or cells; furthermore, biocompatibility and 
biodegradability must be carefully evaluated. 
Hydrogels can be further classified into physical and chemical gels, depending on how 
the polymer networks are formed [13,44,53–55]. In physical or reversible hydrogels, the 
networks are formed by physical aggregation of polymer chains, caused by molecular 
entanglements, hydrogen bonds, hydrophobic interactions, ionic bonding, or 
complexation. All of these interactions are reversible, and the stability of the formed 
hydrogels is susceptible to changes in the ionic strength, pH, temperature, or the 
application of mechanical stress. Chemical or permanent hydrogels, on the other hand, 
2.3 Design criteria for hydrogels and challenges associated with their preparation 
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contain covalently cross-linked polymer networks with tunable physicochemical 
properties such as equilibrium water content, permeability, mechanical strength, and 
degradability. Covalently cross-linked networks can be formed by radical polymerization 
of water-soluble monomers (e.g., 2-hydroxyethyl methacrylate or acrylamide) and 
suitable cross-linking agents (e.g., PEG diacrylate or bisacrylamide). Alternatively, pre-
formed polymers (e.g., HA or star-shaped PEG) can be functionalized with reactive 
groups suitable for polymerization and cross-linked via Schiff base formation, Michael-
type addition reaction, azide-alkyne cycloaddition, or DA reaction [13,14,44,45,56]. For 
a more comprehensive overview on the different hydrogel-forming polymers and cross-
linking mechanisms, the reader is referred to several excellent review 
articles [13,14,44,45,53–56]. 
 Design criteria for hydrogels and challenges associated with 
their preparation 
Cross-linked hydrogels are extremely versatile materials with many favorable properties 
such as transparency, high water content, good biocompatibility and mechanical 
flexibility. Consequently, hydrogels found widespread application in ophthalmology as 
SCL, foldable IOL, in situ gelling vehicles for ophthalmic drug delivery, and adhesives 
for ocular wound repair; their use as vitreous substitutes and intravitreal drug delivery 
systems is currently under investigation. All ophthalmic formulations must meet strict 
requirements regarding sterility and biocompatibility; however, the biocompatibility 
standards for topically or intraocularly applied hydrogels may be different. Besides these 
fundamental requirements, hydrogels used in ophthalmology must meet further criteria, 
which often depend on their specific applications. In the following section, we will 
discuss general design criteria for hydrogel-based drug delivery systems such as in situ 
forming hydrogels for topical drug delivery, drug-eluting SCL and intravitreal drug 
delivery systems. Design criteria for specific applications, such as ocular wound repair, 
vitreous substitution or cell transplantation, are separately discussed later in this article.  
When developing hydrogels for ophthalmic drug delivery, two major design criteria can 
be identified: availability and stability of the active ingredients [13,14,44]. Availability 
relates to the capability of delivering therapeutics at the right dosage; it depends on the 
method of drug loading, the type and molecular weight of the polymer, the polymer 
concentration, the cross-linking density, the hydrogel degradation rate, and the affinity of 
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the payload for the carrier. The stability of the active ingredients is again influenced by 
the method of drug loading, the type of the polymer, the cross-linking mechanism, the 
type and concentration of the initiator, and the use of stabilizing agents. Drugs can be 
loaded into hydrogels by incubating cross-linked gels in concentrated drug solutions 
(post-fabrication partitioning) or by in situ encapsulation, a method in which drug loading 
and cross-linking are carried out simultaneously [14]. The former method has the 
advantage of preserving drug stability, but offers less control over the amount of drug 
loading. On the other hand, in situ encapsulation permits the preparation of hydrogels 
loaded with large quantities of drugs in a fast and reproducible way. However, the 
polymerization reaction may induce undesired reactions between the encapsulated 
molecules and the polymer network, which negatively affects drug availability and 
stability [13,14,17,44]. Aside from the above-mentioned methods, drugs can be 
incorporated within gel matrices through tethering via pH- or enzyme-sensitive linkers, 
or through the addition of drug-loaded micro- or nanoparticles [13,14,44,57]. The drug 
release rate is mostly defined by the molecular weight of the active ingredient, the 
polymer concentration, the cross-linking density of the hydrogel, and the affinity of the 
active ingredient for the polymer network [13,14,44,58,59]. For example, the release of 
synthetic drugs, peptides, and small proteins is often diffusion-controlled. On the other 
hand, the release of large proteins, such as whole antibodies, may be swelling-controlled 
or chemically controlled if the gel matrix degrades. The release kinetics can be modulated 
to some degree by varying the concentration of the gel-forming polymers, by carefully 
adjusting the cross-linking density, by varying the molecular weight of the gel-forming 
polymers, or by altering the degradation rate. However, it should be kept in mind that this 
process may also change other parameters of the drug delivery system such as mechanical 
properties, biocompatibility, and drug stability. 
 Ophthalmic applications of hydrogels 
2.4.1 In situ forming hydrogels for ophthalmic drug delivery 
Liquid ophthalmic formulations usually show low bioavailability because of constant 
lachrymation and fast nasolacrimal drainage [34,60]. As a result, short dosing intervals 
and high drug concentrations are needed to reach effective therapeutic levels. This may 
result in non-adherence of patients [31]; moreover, absorption of the drug drained through 
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the nasolacrimal canal may cause systemic side effects. To extend the precorneal 
residence time of the applied therapeutics, various vehicles, such as suspensions, 
ointments and inserts, have been developed [38,40,42,61]. Even though some 
improvements over conventional liquid dosage forms have been reached, these drug 
delivery systems did not become widely accepted because of blurred vision and foreign 
body sensation. With regard to patient acceptability, liquid dosage forms that remain in 
contact with the cornea and sustain drug release over extended periods of time would be 
ideal. Such a behavior can be achieved by delivery systems that show a sol-gel phase 
transition due to changes in the pH, temperature, or ionic strength [38,49,50]. These in 
situ forming hydrogels are instilled in liquid form and shift to the gel phase once in the 
cul-de-sac of the eye. Cellulose acetate phthalate, which was first introduced in the 1980s, 
and poly(acrylic acid) (PAA, Carbomer, or Carbopol®) are among the polymers that 
reversibly gel in response to variations in the pH [62–65]. PAA exhibits a distinct sol-gel 
phase transition as the pH of the solution is raised above its pKa of about 5.5. Viscosity 
enhancing polymers, such as (hydroxypropyl)methyl cellulose (HPMC), can be added to 
reduce the irritant effect of highly concentrated PAA hydrogels [66,67]. Alternatively, 
temperature-responsive polymers, such as poloxamers (Pluronics®), poly(N-isopropyl-
acrylamide) (PNIPAAm), or polysaccharides, can be used to develop in situ gelling 
formulations. Poloxamers are triblock copolymers composed of a hydrophobic 
poly(propylene oxide) central block flanked by two hydrophilic poly(ethylene oxide) 
blocks; they exhibit a reversible sol-gel phase transition, with the phase transition 
temperature depending on the concentration, molecular weight and poly(ethylene 
oxide) : poly(propylene oxide) weight ratio. Poloxamer-based formulations were 
evaluated in multiple studies; the developed systems provided sustained release of timolol 
and pilocarpine over several hours [68–70]. The combination of pH and temperature-
responsive polymers is another promising approach to formulate in situ gelling delivery 
systems. For example, Lin and Sung [71] showed that physical mixtures of 0.3% 
Carbopol® and 14% Pluronic® F-127 gave in situ forming hydrogels. A similar 
formulation was shown to provide sustained release of puerarin over 8 h [72]. In addition 
to physical mixtures of poloxamers and PAA, graft copolymers of Pluronic® F-127 and 
PAA were proposed as in situ gelling vehicles for ophthalmic drug delivery [73]. 
Aqueous solutions of PNIPAAm also show a temperature-dependent sol-gel phase 
transition and may have therapeutic benefits in the treatment of glaucoma [74]. Cao et 
al. [75] developed a novel PNIPAAm-chitosan copolymer for potential use in ophthalmic 
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drug delivery. In comparison with conventional timolol eye drops, the in situ gelling 
formulation showed improved pharmacokinetic parameters such as maximum plasma 
concentration (cmax), time to reach cmax, and area under the curve; it had a stronger 
capacity to reduce the intraocular pressure over a period of 12 h. Besides PAA, poloxamer 
and PNIPAAm-based formulations, temperature-responsive materials of natural origin 
have been investigated as potential alternative. For example, Miyazaki et al. [76] 
developed a temperature-sensitive system containing 1.5% xyloglucan for the sustained 
release of pilocarpine, which showed a miotic response similar to hydrogels containing 
25% Pluronic® F-127. Despite this success, there are currently no pH or temperature-
sensitive hydrogels approved for human use. Among all stimuli-responsive systems, 
hydrogels sensitive to the ionic strength are most widespread and have proven to be most 
successful. Aqueous solutions of certain polymers, such as gellan gum (Gelrite®) or 
alginate, form hydrogels after instillation into the conjunctival sac through the presence 
of cations in the tear fluid. Gellan gum is a linear, anionic heteropolysaccharide consisting 
of glucose, glucuronic acid and rhamnose [77]. A solution of 0.6% gellan gum was 
demonstrated to enhance the precorneal residence time and, hence, the bioavailability of 
timolol [78]. These formulations proved to be extremely successful and resulted in the 
approval of two products (Timoptol® XE and Timoptic® XE). Moreover, delivery 
systems based on gellan gum were developed for methylprednisolone [79], and the two 
antibiotics ciprofloxacin [80] and pefloxacin [81]. Similar to gellan gum, alginate forms 
hydrogels at physiological levels of cations. Alginate was used in combination with 
HPMC as viscosity-enhancing agent to develop sustained release systems for 
antibiotics [82,83]. The fluoroquinolone antibiotic gatifloxacin was released from 
alginate/HPMC hydrogels over a period of 8 h with excellent ocular tolerance [83]. 
Mixtures of gellan gum and alginate could further improve the bioavailability of 
matrine [84]. Furthermore, combinations of alginate and Pluronic® have been described 
for the ophthalmic delivery of pilocarpine [85]. 
2.4.2 Drug-eluting contact lenses 
Corrective SCL are without doubt the most common and most successful commercial 
application of hydrogels. The idea of using poly(2-hydroxyethyl methacrylate) (pHEMA) 
hydrogels for corrective SCL was first reported in 1960 by Otto Wichterle [86]. Since 
that time, new developments have occurred and further improvements of existing 
materials have been made [46]. Selected hydrogel materials used for the manufacture of 
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corrective SCL are listed in Table 2.1. Most research efforts currently aim at improving 
the oxygen permeability and wearing comfort of SCL [87,88]. Another field of activity is 
the development of new polymers with antifouling properties to reduce the adsorption of 
proteins and cells on the lens surface [89]. This may help to improve the biocompatibility 
of SCL, especially during long-term wear. The second major innovation has been the 
development of poly(dimethyl siloxane) (PDMS) based lens materials (Table 2.2) [46]. 
These silicone hydrogels combine the extremely high oxygen permeability of PDMS and 
the wearing comfort of conventional pHEMA hydrogels. Besides their application as 
corrective lenses, SCL may serve as drug delivery system for the anterior segment of the 
eye [90–93], or as protective devices or “bandage lenses” for the treatment of corneal 
injuries [94]. Although there are currently no approved products on the market, the use 
of SCL as drug delivery system is an interesting yet challenging approach. The main 
challenge is to reach adequate levels of drug loading while ensuring controlled drug 
release at the same time. To achieve this goal, different possibilities of drug loading have 
been investigated. The applied techniques range from simply soaking the lenses in 
concentrated drug solutions to more sophisticated approaches such as molecular 
imprinting, piggybacking of drug-polymer films on SCL, loading with liposomes, surface 
modification with nanoparticles, and the use of ionic ligands [90–93]. Although most 
studies used commercial SCL, the development of new lens materials has been described 
as well. For example, Ribeiro et al. [95] reported the synthesis of bio-inspired pHEMA-
based hydrogels for potential application as drug-eluting SCL. By copolymerizing 
HEMA, 4-vinylimidazole, and zinc methacrylate, hydrogels with high affinity for 
carbonic anhydrase inhibitors were obtained. In comparison with plain pHEMA 
hydrogels, the bio-inspired hydrogels showed a higher drug loading efficiency and 50% 
lower release rates for acetazolamide and ethoxzolamide. However, further aspects such 
as optical transparency, influence of the thickness on drug release, and long-term stability 
of the drug-polymer interactions, need to be studied to evaluate the applicability of bio-
inspired hydrogels as drug-eluting SCL. The given example illustrates the challenges 
researchers face in the development of drug-eluting SCL. Even though well-established 
polymers are used, biocompatibility, transparency, and oxygen permeability of drug-
loaded SCL have to be proven again. However, finding effective ways of drug loading 
and maintaining therapeutic drug concentrations over extended time periods are by far 
the greatest challenge. Exhaustive in vitro and in vivo studies will be required to prove 
the safety and efficacy of the developed drug delivery system. 
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Table 2.1. Conventional hydrogel materials used for the preparation of corrective SCL (Sources: USAN 
dictionary, data from the manufactures). 
a USAN: United States adopted name 
b Dk represents the oxygen permeability (barrers = 10-11 cm2 O2 s-1 mmHg) 
AMA: allyl methacrylate; EGDMA: ethylene glycol dimethacrylate; HEMA: 2-hydroxyethyl methacrylate; 
MAA: methacrylic acid; MAEBTP: 4-(2-methacryloyloxyethyl)-2-(2H-benzotriazol-2-yl)phenol; MPC: 2-
methacryloxyethyl phosphorylcholine; NVP: N-vinylpyrrolidone; PEPGDMA: poly(ethylene propylene 
glycol) dimethacrylate; PVA: poly(vinyl alcohol); TBHMA: 4-tert-butyl-2-hydroxycyclohexyl 
methacrylate; SMA: sodium methacrylate; TRIM: 1,1,1-tris(hydroxymethyl)propane trimethacrylate 
Table 2.2. Silicone hydrogels used for the preparation of corrective SCL (Sources: USAN dictionary, data 
from the manufactures). 
a USAN: United States adopted name 
b Dk represents the oxygen permeability (barrers = 10-11 cm2 O2 s-1 mmHg) 
EGDMA: ethylene glycol dimethacrylate; DMAA: N,N’-dimethyl acrylamide; HEMA: 2-hydroxyethyl 
methacrylate; mPDMS: monofunctional polydimethylsiloxane; NCVE: N-carboxyvinyl ester; NVP: N- 
vinylpyrrolidone; PBVC: poly(dimethylsiloxyl)di-(silylbutanol)bis-(vinyl carbamate); SiGMA: methylbis-
(trimethylsiloxy)silylpropylglyceryl methacrylate; TEGDMA: tetraethylene glycol dimethacrylate; TPVC: 
tris(trimethylsiloxy)silylpropylvinyl carbamate; TRIS: methacryloxypropyl tris(trimethylsiloxy silane) 
USANa name Main components 
Water 
content / % 
Dk value / 
barrersb 
Examples of trade 
names 
Etafilcon A HEMA/SMA/TRIM 58 28 ACUVUE®2® 
Hilafilcon B HEMA/EGDMA/AMA/NVP 59 22 SofLens®59 
Nelfilcon A PVA, partially acetalized with 
N-(formylmethyl)acrylamide 
69 26 DAILIES® 
AquaComfort Plus® 
Nesofilcon A HEMA/NVP/EGDMA/AMA/ 
PEPGDMA/TBHMA/MAEBTP 
78 42 Biotrue® ONEday 
Ocufilcon D HEMA/MAA/EGDMA 55 20 Biomedics® 1 Day 
extra 
Omafilcon A HEMA/MPC/EGDMA 62 33 Proclear® 
Polymacon B HEMA/EGDMA 38 9 SofLens®38 
USANa name Main components 
Water 
content / % 
Dk value / 
barrersb 
Examples of trade 
names 
Balafilcon A PBVC/NCVE/TPVC/NVP 36 99 Pure Vision®2 
Galyfilcon A mPDMS/SiGMA/HEMA/ 
DMAA/ EGDMA/NVP 
47 60 ACUVUE®  
ADVANCE ® 
Lotrafilcon A siloxane macromere/ 
TRIS/DMAA 
24 140 AIR OPTIX ®  
Night & Day® 
Lotrafilcon B siloxane macromere/ 
TRIS/DMAA 
33 110 AIR OPTIX ® 
AQUA 
Narafilcon A mPDMS/DMAA/HEMA/ 
TEGDMA/ NVP 
46 100 1-DAY ACUVUE®
TruEye®
Senofilcon A mPDMS/SiGMA/HEMA/ 
DMAA/TEGDMA/NVP 
38 103 ACUVUE® 
OASYS ® 
Sifilcon A siloxane macromere/DMAA/ 
TRIS/styrene 
32 82 AIR OPTIX®  
INDIVIDUAL 
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2.4.3 Tissue adhesives for ocular wound repair 
Another possible application for hydrogels is in the treatment of surgical or traumatic 
ocular wounds that are routinely sutured with thin nylon threads. Unfortunately, this 
standard treatment is associated with several disadvantages including infections, 
inflammation, corneal neovascularization, and impaired wound healing. To overcome the 
drawbacks of ocular sutures, tissue adhesives have been developed [96]. Tissue adhesives 
are materials, which are able to glue tissue surfaces together, either by mechanical 
adhesion or by forming chemical bonds. Soft and flexible hydrogels are among the most 
promising materials that are currently suggested as ophthalmic adhesives [97]. Many 
different polymers, either of natural or of synthetic origin, have been investigated for their 
suitability as ophthalmic sealants [51]. For example, hydrogels were prepared from 
polysaccharides, such as HA or chondroitin sulfate, gelatin, and different derivatives of 
PEG. The applied cross-linking reactions were, among other reactions, photoactivated 
processes and nucleophilic substitutions. For an optimal performance, ophthalmic 
adhesives must meet a number of requirements. Based on the available literature, Oelker 
and Grinstaff [51] defined essential design requirements for ideal ophthalmic adhesives, 
including leak pressure (> 80 mmHg), cross-linking time (< 30 s), mechanical properties 
(5–200 kPa), swelling (< 200%), diffusion coefficient (2 · 10-7 cm2 s-1), refractive index 
(1.32–1.40), adhesion strength (> 0.1 kPa), viscosity (5–100 cP), and degradation time 
(1 week–6 months). Very recently, the U.S. Food and Drug Administration approved 
ReSure® Sealant; the in situ forming hydrogel is based on PEG and trilysine amine, has a 
water content of approximately 90% after polymerization, and has been approved for 
sealing corneal incisions after cataract surgery. Although most tissue adhesives were 
developed for sealing corneal incisions, a few studies investigated their intraocular use in 
retinal detachment surgery [98–100]. Moreover, the possibility of incorporating drug 
molecules into hydrogel-based tissue adhesives has been studied. In particular, 
doxycycline-loaded hydrogels were investigated for the treatment of corneal injuries 
resulting from exposure to chemical warfare agents, such as sulfur mustard and nitrogen 
mustard [101,102]. In comparison with equally dosed doxycycline solutions, in situ 
forming doxycycline-loaded PEG hydrogels could improve epithelial healing in a 
vesicant-exposed corneal organ culture model [101]. In a follow-up study, rabbit corneas 
were exposed to sulfur mustard in vivo; the instillation of doxycycline eye drops resulted 
in faster edema reduction, but the hydrogels significantly reduced 
neovascularization [102]. In addition, hydrogels loaded with epidermal growth factor 
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(EGF) were developed for the treatment of corneal epithelial wounds. As a first proof of 
concept, Sheardown et al. [103] examined the effects of EGF on corneal epithelial wound 
healing in rabbits. Compared to control gels without EGF, the treatment with EGF-loaded 
PAA hydrogels resulted in significant wound healing enhancement. More recently, 
sustained release of EGF from chemically cross-linked cationized gelatin hydrogels has 
been reported [104]. The applied hydrogels gradually degraded over 1 week with 
concomitant release of EGF; the controlled release of EGF accelerated corneal epithelial 
wound healing in comparison with topically applied EGF solutions. Compared to 
physically cross-linked hydrogels, such as hydrogels based on gellan gum or alginate, 
these chemically cross-linked hydrogels are advantageous because they offer a much 
more prolonged drug release. Furthermore, high levels of drug loading can be reached, 
which is an advantage over drug-eluting SCL. 
2.4.4 Intraocular lenses 
In addition to these topical applications, hydrogels may also serve as IOL, vitreous 
substitutes, or intravitreal drug delivery systems. These intraocular applications are 
particularly relevant since most vision-threatening diseases, such as cataract, PDR or 
AMD, originate from the lens or the posterior segment of the eye. In cataract surgery, 
which is the most frequently performed eye surgery worldwide, the impaired lens is 
removed and subsequently substituted with an artificial IOL [28]. The first IOL were 
manufactured from rigid poly(methyl methacrylate). Today, more flexible materials, 
including hydrophobic acrylate polymers, hydrophilic acrylate polymers (i.e., hydrogels), 
siloxanes, and collamer (i.e., a copolymer of collagen and HEMA with a water content of 
34%), are generally preferred [47,105]. These highly elastic materials are used to 
manufacture foldable IOL, which can be implanted through smaller incisions. The most 
frequent complication of cataract surgery is posterior capsule opacification (PCO), which 
has been associated with the abnormal proliferation of residual lens epithelial cells in the 
capsular bag [48]. As a consequence, several strategies to prevent PCO have been 
developed. For example, coating the lens surface with PEG or “bioactive” polymers 
exhibiting sulfonate and carboxylate groups could successfully prevent cell adhesion and 
proliferation [106,107]. Surface modification with porphyrins, which generate cytotoxic 
singlet oxygen, may also improve the biocompatibility of IOL [108]. Another approach 
to improve the biocompatibility of IOL and reduce the risk for PCO is the incorporation 
and controlled release of drug molecules. The available studies on drug-loaded IOL have 
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been reviewed in two recent articles; the different approaches were compared with regard 
to the administered drug molecules, the used drug loading method, and potential 
therapeutic benefits [109,110]. In general, there are three possibilities for drug loading: 
soaking the lens in concentrated drug solutions, coating of the lens surface (e.g., by 
spraying or chemical modification), and coating of the haptics that hold the lens in place. 
Apart from the optical portion, IOL are not required to be fully transparent. For example, 
the haptics can be coated with non-transparent polymers, drug suspensions, or molecules 
that stain certain regions of the lens material [109]. Such drug-loaded IOL may have 
potential benefits in the prevention of endophthalmitis, a frequent complication of 
cataract surgery; they may prevent postoperative inflammation and reduce the risk for 
PCO. Nevertheless, there are no products approved for human use at the moment. 
2.4.5 Hydrogel-based vitreous substitutes 
Besides cataract, severe vitreoretinal diseases, such as diabetic retinopathy or retinal 
detachment, affect more and more people in industrialized nations. After surgical 
intervention and removal of the dysfunctional vitreous, the injection of vitreous 
substitutes may be required, either for short-term or for long-term treatment. Because of 
the complex function of the vitreous and delicate nature of the intraocular environment, 
potential vitreous substitutes have to meet particular requirements [111]. An ideal 
vitreous substitute should (1) be clear and transparent, (2) be biologically and chemically 
inert, (3) possess a refractive index and density comparable to those of the natural 
vitreous, (4) possess sufficient mechanical rigidity, (5) allow the transfer of metabolites, 
(6) be non-absorbable and non-biodegradable, (7) be hydrophilic, and (8) be injectable
through small-gauge needles. At the moment, various materials are used in clinical
practice, including gases (e.g., air, sulfur hexafluoride or perfluoropropane),
perfluorocarbon liquids, fluorosilicone, and silicone oils [29,111–114]. However, none of
these substances are ideal for long-term or permanent vitreous substitution due to their
fast intraocular absorption, toxic reactions or other adverse effects, such as the formation
of post-operative cataract or glaucoma. Therefore, alternative vitreous substitutes, based
on natural, semisynthetic and synthetic polymers, have been investigated; the tested
polymers included HPMC [115], ADCON-L [116], HA/gellan gum [117],
pHEMA [118], poly(glycerol methacrylate) [119] Pluronic® [120], siloxanes [121],
PVA [122] and poly(vinyl pyrolidone) [123]. In the early days, uncross-linked polymer
solutions were investigated; however, these substances had major drawbacks and adverse
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effects, such as short retention time, opacification and inflammation, and were, therefore, 
not useful as long-term vitreous substitutes [29,111,113]. Today’s experimental vitreous 
substitutes are mostly cross-linked hydrogels; these materials show an enhanced retention 
time in the eye and are capable to act as a tamponade agent. A comprehensive overview 
on these polymeric vitreous substitutes is given elsewhere and, therefore, not subject of 
this article [29]. Recently, new developments and improvements of existing hydrogel-
based vitreous substitutes have been reported. For example, Leone et al. [124] reported 
the synthesis of PVA hydrogels through cross-linking with non-toxic trisodium 
trimetaphosphate (STMP). Using a STMP : PVA molar ratio of 1 : 8 resulted in 
rheological properties similar to those of the natural vitreous body. More importantly, 
these properties were preserved after injection. The developed PVA gel met the 
requirements for vitreous substitutes regarding transparency, swelling capacity, 
permeability, and cytotoxicity. However, in vivo studies to prove the long-term 
compatibility of this promising material remain to be done. Swindle-Reilly et al. [125] 
copolymerized acrylamide with bisacryloylcystamine. The disulfide-containing cross-
linker was then reduced to give an injectable polymer solution; once inside the eye, the 
disulfide cross-links reformed by air oxidation to produce a stable hydrogel that matched 
the mechanical properties of the natural vitreous humor. One week after injection into the 
vitreous cavity of rabbits, slit lamp examination, dilated fundus examination, 
electroretinography, and histopathological examination showed no signs of 
inflammation. Although this pilot study has indicated the biocompatibility of the gel, 
further in vivo studies on the long-term compatibility and stability are required. A 
different cross-linking approach was pursued by Tao et al. [126]. A mixture of two 
reactive PEG derivatives was injected into vitrectomized eyes of rabbits; cross-links were 
introduced in situ by Michael-type addition reaction. The formed hydrogel was stable 
during the study period of 9 months; the mechanical and optical properties were very 
similar to the natural vitreous body. No adverse reactions were detected by measurement 
of the intraocular pressure (IOP), fundus fluorescein angiography, electroretinography, 
histopathological examination, and B-scan ultrasound. Altogether, this comprehensive 
study demonstrated that chemically cross-linked PEG hydrogels might be suitable as 
long-term vitreous substitute. Besides synthetic polymers, the use of natural polymers for 
vitreous replacement has been investigated in two recent studies. With HA being an 
essential part of the human vitreous body [127], the use of this polymer for vitreous 
substitution seems obvious, even though the injection of uncross-linked HA solutions has 
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proven to be unsuccessful [111]. Schramm et al. [128] compared two different HA 
hydrogels regarding their suitability as vitreous substitute; the cross-links were introduced 
either with adipic dihydrazide (ADH) and 1-ethyl-3-(3-dimethylaminopropyl)carbodi-
imide (EDC), or by photopolymerization of glycidyl methacrylate groups. In cell culture 
experiments, ADH/EDC cross-linked hydrogels induced mild cytotoxicity, whereas 
photopolymerized HA gels showed no toxicity. These photopolymerized gels showed 
excellent in vivo biocompatibility during the study period of 6 weeks, without significant 
degradation or loss of transparency. In contrast to the results of Schramm et al., another 
study found no toxic effects of similar ADH cross-linked HA hydrogels, both in vitro and 
in vivo [129]. In addition to these conventional approaches of using polymeric hydrogels 
for vitreous replacement, Feng et al. [130] recently proposed using a foldable vitreous-
shaped capsule to address the unknown long-term compatibility of these materials. The 
thin capsule was implanted into the vitreous cavity and subsequently filled with a PVA 
hydrogel; a prolonged in vivo stability was observed during the investigation period of 
180 days. Moreover, the authors mentioned the possibility of incorporating drug 
molecules into the system. Although significant improvements have been achieved over 
the past years, there are up until now no artificial vitreous substitutes that reach the 
properties of the natural vitreous body. Even in situ cross-linkable hydrogels, which are 
generally favored due to the absence of shear thinning, do not meet all of the requirements 
to act as long-term vitreous substitute [29,111,113]. 
2.4.6 Intravitreal drug delivery systems 
As mentioned earlier, PDR and AMD are among the leading causes of visual impairment 
or blindness in industrialized nations [131]. Characteristic for both diseases is an 
abnormal neovascularization due to increased levels of VEGF [132]. Besides 
photodynamic therapy and photocoagulation, current therapeutic approaches aim at 
neutralizing VEGF by intravitreal injections of anti-VEGF antibodies or antibody 
fragments every 4-6 weeks. These frequent intravitreal injections are associated with high 
healthcare costs, significant discomfort, and rare complications including 
endophthalmitis, retinal detachment, and uveitis [10]. Furthermore, it has been shown that 
VEGF plays an important role in supporting the adult subretinal vasculature, which is 
important for nurturing the photoreceptors and maintaining central vision [132–134]. 
Therefore, caution may be required when patients receive long-term treatment with anti-
VEGF agents. One promising approach to solve these problems would be the local release 
Chapter 2 
26 
of anti-VEGF agents from controlled release systems over extended time periods. Besides 
implants, microspheres and nanoparticulate systems, hydrogels may serve as drug 
delivery systems in the posterior segment of the eye [35–37]. For obvious reasons, in situ 
forming hydrogels that can be injected by minimally invasive techniques are particularly 
favorable. In contrast to vitreous substitutes, hydrogel-based drug delivery systems 
usually occupy only a small part of the vitreous cavity, they are not required to be 
transparent, and degradability is often desired. Achieving high levels of drug loading and 
preserving the stability of the active ingredients are significant challenges in the 
development of intravitreal drug delivery systems. Furthermore, the cross-linking density, 
swelling capacity, and degradation rate of hydrogels need to be fine-tuned to ensure 
controlled drug release during the period of application. Special care has to be taken that 
the applied hydrogel does not increase the IOP in order to avoid severe complications, 
such as glaucoma. For these reasons, the use of temperature-responsive PNIPAAm 
hydrogels, which were additionally cross-linked with PEG diacrylate, has been 
suggested [135,136]. At room temperature, the highly swollen gels can be easily injected 
through small gauge needles. In the body, above the volume phase transition temperature, 
the hydrogels collapse resulting in an initial burst release of encapsulated drug followed 
by sustained release over several weeks. The non-degradability of cross-linked 
PNIPAAm hydrogels and the use of potentially harmful radical initiators are 
disadvantages of this material. Therefore, poly(ethylene glycol)-poly-(serinol 
hexamethylene urethane) (ESHU) hydrogels have been developed [137]. In contrast to 
PNIPAAm gels, the synthesis of ESHU does not require radical initiators; furthermore, 
ESHU is biodegradable and does not require surgical removal after drug release. ESHU 
hydrogels could be easily injected through 31-gauge needles. The gels were well tolerated 
in vivo; they did not affect the IOP and there was no evidence of inflammation. ESHU 
hydrogels sustained the release of incorporated bevacizumab for over 9 weeks; the drug 
concentration was on average 4.7 times higher than in eyes receiving bolus injections of 
bevacizumab. Brandl et al. [138] suggested using four-armed PEG-succinimidyl 
propionate that can be cross-linked in situ with PEG-amines to yield transparent 
hydrogels with high water content. The performed in vitro tests, including rheological 
characterization of mechanical properties, cytotoxicity studies and release experiments, 
suggested the suitability of PEG hydrogels as ophthalmic drug delivery system. In a 
similar approach, four-armed PEG was cross-linked via Michael-type addition reactions 
between sulfhydryl and maleimide groups [139]. Incorporated bevacizumab was released 
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over 14 days; the hydrogels might, therefore, be suitable to treat intraocular 
neovascularization. And very recently, Yu et al. [59,140] reported the preparation of in 
situ chemically cross-linked hydrogels from vinyl sulfone functionalized HA and 
thiolated dextran. To reduce the covalent binding of proteins, both the concentration and 
the degree of modification of the thiolated dextran were increased relative to the vinyl 
sulfone functionalized HA. The incorporated bevacizumab was released over 3 months 
in vitro; the release rate was found to depend on the polymer concentration but not the 
degree of modification. First in vivo studies demonstrated the biocompatibility of the 
hydrogel; the hydrogel was able to prolong the retention of bevacizumab at 
therapeutically relevant concentrations for at least 6 months. Hydrogels have also been 
proposed for the treatment of retinal detachment. Neffe et al. [141] have synthesized a 
cross-linked HA hydrogel that can be applied as a patch to cover retinal breaks. The gel 
patches could be injected into the vitreous cavity, showed excellent intraocular 
biocompatibility, and good retinal adherence; the developed patches were slowly 
degrading and provided controlled release of incorporated triamcinolone. 
2.4.7 Cell-based approaches 
While intravitreal injections of anti-VEGF drugs are able to delay the progression of PDR 
and AMD, patients who have already lost vision due to severe ocular diseases or trauma 
may profit from cell-based therapeutic approaches. For example, it has been shown that 
the implantation of stem cells may have benefits in the treatment of corneal injuries and 
certain retinal diseases [142–145]. The cornea consists of three major layers: an outer 
stratified squamous epithelium, a thick stromal layer, and an inner monolayer of 
specialized endothelial cells. These endothelial cells play an important role in maintaining 
corneal clarity by regulating fluid and solute transport between the aqueous humor and 
the corneal stroma [146]. Tissue-engineered corneal epithelial cell sheets have already 
been used to treat patients with total limbal stem cell deficiencies [147]. Furthermore, the 
implantation of endothelial cell sheets has proven to be successful in animal 
models [148]. Human corneal endothelial cells were cultured on thermoresponsive 
PNIPAAm surfaces for 3 weeks at 37 °C and harvested as transplantable cell sheets by 
lowering the temperature to 20 °C. The subsequent transplantation to endothelium-
denuded rabbit corneas could restore corneal function and clarity [148,149]. Ozcelik 
et al. [150] developed ultrathin chitosan-PEG hydrogel films for corneal tissue 
engineering. The films were approximately 50 µm thick, had desirable mechanical and 
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optical properties, and facilitated the attachment and proliferation of ovine corneal 
endothelial cells. In addition, attempts to regenerate the corneal stroma have been 
reported; however, none of these approaches have been deemed clinically feasible. 
Mimura et al. [151] suggested the implantation of fibroblast precursors in combination 
with gelatin hydrogels as possible strategy for corneal stromal regeneration. When 
implanted into corneal stromal pockets, the developed gelatin hydrogels remained 
transparent and promoted the deposition of extracellular matrix. In a similar approach, 
hydroxypropyl chitosan was cross-linked with gelatin and chondroitin sulfate to 
synthesize a scaffold that mimics the stromal layer of the cornea; the obtained material 
was able to support the adhesion and proliferation of keratocytes [152]. While tissue-
engineered corneal epithelial cell sheets may enter clinical use in the near future, 
approaches to regenerate the retina are still in the early stages of development [153]. It 
has been shown that photoreceptor precursor cells can be successfully transplanted into 
the adult or degenerating retina. The transplanted cells differentiated into rod 
photoreceptors, formed synaptic connections and improved visual function [154]. 
Furthermore, the transplantation of retinal stem cells (RSC) or retinal progenitor cells 
(RPC) has shown promise for the treatment of retinal degeneration. However, survival of 
the grafted cells and integration into the host tissue remain major barriers to functional 
cell replacement [155]. To promote the survival and differentiation of RPC, 
biodegradable poly(lactic acid)/poly(lactic-co-glycolic acid) substrates have been 
used [156]. While significant progress has been made, polymer matrices do not match the 
elastic modulus of the retina and lack the flexibility required for subretinal injection. To 
overcome these limitations, a temperature-responsive hydrogel composed of HA and MC 
has been developed; the material supported the survival and proliferation RSC/RPC in 
vitro. After injection into the subretinal space of mice, RSC and RPC delivered in HA/MC 
gels were evenly distributed; hydrogels may, therefore, help to improve cell integration 
into the retina [157]. A similar approach has been described by Liu et al. [158]; in situ 
cross-linkable HA hydrogels promoted an even distribution of RPC in the subretinal space 
without causing major disruption to the host retina. After 3 weeks, the hydrogels were 
completely degraded; the transplanted cells expressed the mature photoreceptor marker 
recovering. Using biodegradable HA-based hydrogels as a vehicle, intravitreally injected 
mesenchymal stem cells were successfully transplanted into the retina of rats; the 
transplanted cells induced Müller cells to produce nerve growth factor and brain-derived 
neurotrophic factor [159]. To improve the gelation kinetics of HA-based materials, 
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oxidized glutathione has been proposed as biocompatible cross-linking agent. Thiolated 
hyaluronan could be cross-linked with oxidized glutathione in less than 5 minutes; the 
hydrogel was able to support the proliferation of adipose-derived stem cells in vitro and 
showed biocompatibility in preliminary in vivo experiments [160]. Temperature-
responsive hydrogels were obtained from copolymers of NIPAAm and acrylic acid N-
hydroxysuccinimide. The copolymers were conjugated with HA and cell adhesive 
peptides; the hydrogels demonstrated excellent compatibility with retinal pigment 
epithelial cells [161]. Hertz et al. [162] developed a library of hydrogels made from PEG 
and poly(L-lysine); the synthesized hydrogels exhibited a wide range of chemical and 
mechanical properties. Hydrogels with a 3:1 or 4:1 ratio of amines to hydroxyls and an 
elastic modulus between 3.8 kPa and 5.7 kPa were able to support the survival, migration 
and neurite outgrowth of retinal ganglion cells and amacrine cells. In conclusion, 
significant advances have been made by using hydrogels for cellular delivery to the 
degenerating retina. Hydrogels may promote survival, differentiation and integration of 
the delivered cells; however, further in vivo studies are required before potential benefits 
of stem cell transplantation can be definitely judged. 
 Limitations of hydrogel-based drug delivery systems 
Although hydrogels have many possible applications in ophthalmology, comparatively 
few products have been brought on the market. While hydrogel-based SCL and foldable 
IOL have proven to be extremely successful, the clinical use of hydrogel-based vitreous 
substitutes or intravitreal drug delivery systems is still not feasible. The reasons for this 
are manifold: first of all, hydrogels are notoriously difficult to sterilize [163,164]. Most 
natural and synthetic polymers are degraded during heat sterilization; radiation or 
chemical sterilization may induce side reactions that affect the gel properties. These 
problems are exacerbated when proteins or other biopharmaceuticals are incorporated. In 
addition, the shelf life of preformed hydrogels is generally limited; likewise, the reactivity 
of in situ cross-linkable polymers may decrease during storage. Further limitations arise 
from the type and quantity of drugs that can be incorporated into hydrogels [44]. While 
hydrophilic low-molecular-weight drugs are easily loaded into hydrogels by partitioning 
from concentrated drug solutions, this process is ineffective in case of hydrophobic drugs 
(e.g., corticosteroids) or macromolecular drugs (e.g., proteins or nucleic acids). 
Hydrophobic drugs are poorly soluble in the gel matrix; thus, drug loading can be 
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improved by introducing hydrophobic domains or cyclodextrins. In contrast to that, the 
uptake of macromolecular drugs is typically limited by restricted diffusion. This can be 
addressed by in situ encapsulation of macromolecular drugs; however, cross-linking of 
hydrogels in the presence of biopharmaceuticals is still a formidable 
challenge [13,14,17,44,45,]. While physical cross-linking may preserve the stability of 
encapsulated biopharmaceuticals, it provides less control over gel degradation and drug 
release. On the other hand, chemical cross-linking permits the preparation of hydrogels 
with well-defined properties; however, it may affect the stability and availability of 
biopharmaceuticals. Furthermore, toxic reagents must be completely removed prior to 
application, which may also leach part of the drug out of the hydrogel. Another 
disadvantage is that preformed hydrogels must be implanted, since the high elastic 
modulus of cross-linked materials generally excludes their extrusion through needles. For 
that reason, there is considerable interest in hydrogels that are cross-linked in situ, i.e., 
inside the vitreous cavity [13,14,44,45]. However, many cross-linking reactions, such as 
radical polymerization, may have toxic side effects in vivo; this may prevent approval of 
in situ gelling formulations unless extensive biocompatibility studies are done. 
Alternative cross-linking reactions, such as Michael-type additions, strain-promoted 
azide-alkyne cycloadditions or DA reactions, might not be fast enough to effectively 
entrap the drug after injection. Conversely, rapidly gelling formulations may clog the 
needle and prevent injection of the hydrogel. However, the most important reason why 
many developments did not get beyond the early stages is the unknown long-term 
performance of hydrogels. Since only limited drug amounts can be incorporated, it is 
debatable whether hydrogels will be useful in the treatment of chronic eye diseases such 
as PDR and AMD. Furthermore, the high water content of hydrogels typically results in 
rapid drug release unless certain strategies, such as molecular imprinting or covalent 
bonding, are used [13,14,44]. Increasing the polymer concentration or cross-linking 
density may not be effective in controlling the diffusion of small molecules. Moreover, 
both methods can reduce the hydrophilicity and hence the biocompatibility of the 
hydrogel [14]. Antibodies or antibody fragments, which are more slowly released from 
hydrogels, may not be stable over several weeks or months [165,166]. Once the drug 
depot has been formed, the degradation rate of the hydrogel becomes a critical factor. The 
observed degradation rate may depend on the underlying diseases and vary among 
patients; consequently, it might be difficult to predict the release rate of the incorporated 
drug substances. An increased degradation rate may result in rapid drug release or dose 
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dumping, whereas delayed degradation may cause incomplete drug release and 
subtherapeutic drug levels. Furthermore, it should be considered that degradation of 
hydrogels is usually associated with an increasing degree of swelling. The increasing 
swelling pressure may possibly cause occlusion of the retinal vasculature and raise the 
IOP [29,167,168]. 
 Concluding remarks and future perspectives 
Hydrogels have many possible applications in ophthalmology. Hydrogel-based SCL, 
foldable IOL and in situ gelling drug formulations are already approved for human use 
and well established; furthermore, hydrogel-based tissue adhesives, vitreous substitutes 
and intravitreal drug delivery systems have shown to be promising in preclinical studies. 
However, more research is needed to improve the treatment of severe, vision-threatening 
diseases such as PDR or AMD. The intraocular application of hydrogels may lead to 
significant advances in this field. While a plethora of different materials has been tested 
in the past, a catalogue of general requirements would promote a more rational design of 
intraocularly applied hydrogels. For example, intravitreal drug delivery systems should 
be injectable and permit controlled drug release over several weeks or months. This may 
be achieved by in situ forming hydrogels, which are injected prior to gelation and form a 
semi-solid drug depot inside the vitreous cavity. After complete drug release, the hydrogel 
should degrade without significant swelling. Similar requirements are imposed on 
hydrogel-based vitreous substitutes; however, these materials must be fully transparent 
and mechanically stable during the entire application period. If hydrogels are used for 
stem cell transplantation, additional aspects must be taken into account: the scaffold 
material should promote survival, differentiation and integration of the transplanted cells. 
Although significant progress has been made, many challenges remain to improve the 
safety and clinical performance of intraocularly applied hydrogels. First of all, polymers 
and cross-linking reactions must be identified that have been proven safe for human use. 
While most studies evaluated the mechanical properties, the in vitro drug release and 
cytotoxicity of the proposed materials, data showing their long-term compatibility and 
clinical performance are frequently missing. In the light of these facts, it might be more 
appropriate to fully characterize the existing hydrogels rather than developing new 
polymers or materials. Special emphasis should be placed on the long-term tolerability of 
the applied hydrogels, their biodegradability, and possible excretion routes of the 
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degradation products. The gained results will be extremely helpful in improving the 
existing hydrogels and may ultimately lead to clinically approved products. And finally, 
the existing injection devices, such as two-chamber syringes and mixing systems, should 
be improved to enable easy and safe handling of in situ forming hydrogels in clinical 
settings.
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Abstract 
The DA reaction was investigated as a cross-linking mechanism for PEG based 
hydrogels. Two complementary macromonomers were synthesized by functionalizing 
star-shaped PEG with furyl and maleimide groups. Gel formation occurred in water at 
37 °C; the gelation time ranged between 171 ± 25 min and 14 ± 1 min depending on the 
used hydrogel formulation. The complex shear modulus was dependent on the 
concentration, branching factor and molecular weight of the macromonomers; values 
between 2821 ± 1479 Pa and 37097 ± 6698 Pa were observed. Hydrogel swelling and 
degradation were influenced by the same parameters; the degradation time varied 
between a few days and several weeks. Gel dissolution was found to occur by rDA 
reaction and subsequent hydrolysis of maleimide groups. Calculations of the network 
mesh size revealed that the prepared hydrogels would be suitable for the controlled release 
of therapeutic proteins. 
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 Introduction 
Over the past two decades, polymeric hydrogels received much interest in the scientific 
community and a great deal of potential applications of these versatile materials has been 
proposed [169]. Amongst others, hydrogels were investigated as liquid-absorbing wound 
dressings [170], as injectable drug delivery systems [13,14,44,171], or as three-
dimensional scaffolds for cell transplantation [172–174]. In most of these applications, 
precise control over the cross-linking density, and hence the swelling capacity, 
mechanical properties and degradability of the hydrogel, is crucial for success or failure 
of the system [15]. For example, by decreasing the cross-linking density of hydrogels, the 
release profiles of incorporated drug molecules dramatically change due to the increasing 
swelling ratio, mesh size and degradation rate [175]. The same physicochemical 
parameters were shown to influence cell morphology, proliferation and differentiation in 
tissue engineering applications [176–178]. For example, mesenchymal stem cells were 
shown to differentiate into neurogenic, myogenic or osteogenic cell lineages depending 
on the stiffness of their supportive matrix [179]. 
However, by means of classical chain-growth polymerization techniques, such as the free 
radical cross-linking of polymers with acrylate or methacrylate groups, it is rarely 
possible to obtain gel networks of defined architecture [16]. The produced hydrogels 
often suffer from poor reproducibility and incomplete cross-linking that potentially poses 
a toxicological risk. Much better control over cross-linking density can be achieved by 
step-growth polymerization of star-shaped polymers or multifunctional dendrimers that 
have been functionalized with one or two different types of reactive end-groups. An 
extremely versatile cross-linking reaction would be the copper(I)-catalyzed azide-alkyne 
cycloaddition that occurs in aqueous solution at room temperature with extraordinary 
efficiency and specificity [180,181]. Major drawbacks, however, are the toxicity and 
protein denaturizing effects of the copper(I) catalyst [182]. Therefore, the catalyst needs 
to be completely removed before protein loading, cell encapsulation, or any other 
application of the hydrogels. To circumvent these expensive purification procedures and 
expand the scope of this reaction, research focused on alternative, copper(I)-free “click” 
reactions [183–185]. 
The DA reaction is another chemical reaction that meets the criteria of “click” chemistry 
outlined by Sharpless [181]. This [4+2] cycloaddition between a conjugated diene and a 
substituted alkene is highly specific and occurs in water without any catalysts or initiators. 
Although the DA reaction is widely used in organic chemistry [19,20], its application in 
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the field of biomaterials is less common and only a few examples of hydrogels have been 
described in the literature [21,22,186,187,188]. The existing hydrogels were 
predominantly prepared from linear polymers with pendant functional groups and 
relatively short bifunctional cross-linkers, which typically results in rather undefined, 
highly cross-linked networks. Although the DA reaction is reversible at higher 
temperatures, the described hydrogels were permanent at body temperature due to the low 
rate of the rDA reaction and the high cross-linking density. In contrast, our concept is 
based on the step-growth polymerization of star-shaped, PEG-derived macromonomers. 
This approach provides better control over the network architecture and allows for the 
synthesis of hydrogels that readily degrade at body temperature. PEG was chosen as raw 
material due to its high solubility in water, excellent biocompatibility and broad 
acceptance by regulatory agencies [14,23]. In this paper, we first describe a 
straightforward way to functionalize PEG with furyl and maleimide groups; the thus 
obtained macromonomers were then used for gel preparation. The cross-linked hydrogels 
were characterized by rheological experiments, swelling and degradation studies. The 
hydrogel network mesh size was calculated and the obtained data was interpreted with 
regard to potential applications in protein delivery. To the best of our knowledge, this is 
the first example of hydrogels that readily degrade by rDA reactions at body temperature. 
 Experimental Section 
3.2.1 General procedure 
1H-NMR spectra were recorded in CDCl3 (purchased from Sigma-Aldrich, Taufkirchen, 
Germany) at room temperature on a Bruker Avance 300 spectrometer (Bruker BioSpin 
GmbH, Rheinstetten, Germany) unless otherwise stated.  
3.2.2 Materials 
N,N’-Dicyclohexylcarbodiimide (DCC), diisopropyl azodicarboxylate (DIAD), furan, 
3-(2-furyl)propanoic acid, N-hydroxysuccinimide (HOSu), maleimide and N-methoxy-
carbonylmaleimide were purchased from Sigma-Aldrich (Taufkirchen, Germany). 
Dichloromethane (DCM), 1,4-dioxane (anhydrous), sodium bicarbonate, sodium sulfate 
(anhydrous) and triphenylphosphine were received from Acros Organics (Geel, 
Belgium). Four-armed poly(ethylene glycol), molecular weight 10 kDa (pentaerythritol 
3.2
3.2 Experimental Section 
37 
core, 4armPEG10k-OH), eight-armed poly(ethylene glycol), molecular weight 10 kDa 
(hexaglycerol core, 8armPEG10k-OH) and eight-armed poly(ethylene glycol), molecular 
weight 20 kDa (hexaglycerol core, 8armPEG20k-OH) were received from JenKem 
Technology (Allen, TX, USA). Diethyl ether was of technical grade and purchased from 
CSC Jäcklechemie (Nuremberg, Germany). Water was obtained using a Milli-Q water 
purification system from Millipore (Schwalbach, Germany). All other chemicals were 
purchased from Merck KGaA (Darmstadt, Germany). 
Scheme 3.1. Chemical structures of 4armPEG-maleimide (A) and 8armPEG-furan (B). 
3.2.3 Synthesis of branched PEG-amines (4armPEG10k-NH2, 8armPEG10k-
NH2 and 8armPEG20k-NH2) 
Branched PEG-amines were prepared according to previously established 
protocols [138]. 
3.2.4 Synthesis of furyl-substituted four-armed PEG (4armPEG10k-furan) 
3-(2-furyl)propanoic acid (1.6 mmol, 224.2 mg), HOSu (1.6 mmol, 184.2 mg) and DCC 
(1.6 mmol, 330.1 mg) were dissolved in 10 mL of anhydrous 1,4-dioxane. After stirring 
for 6 h at room temperature, the precipitated dicyclohexylurea byproduct was filtered off. 
The filtrate was combined with a solution of 4armPEG10k-NH2 (0.2 mmol, 2.18 g) and 
NaHCO3 (1.6 mmol, 134.4 mg) in 10 mL of water and stirred overnight at 50 °C. The 
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next day, the solvent was evaporated and the residue was taken up in 20 mL of water. The 
raw product was extracted with DCM (4 × 20 mL). The combined organic phases were 
dried over anhydrous Na2SO4, filtered and concentrated to approx. 5 mL. The product 
was crystallized at 0 °C under vigorous stirring by dropwise addition of 50 mL of diethyl 
ether. The precipitate was collected by filtration, washed with cold diethyl ether and dried 
under vacuum to yield 2.01 g (88%) of 4armPEG10k-furan. 1H-NMR (CDCl3, 300 MHz): 
δ 2.50 ppm (t, 8H,–NHC(O)CH2CH2–), 2.97 ppm (t, 8H, –NHC(O)CH2CH2–), 3.39 ppm 
(s, 8H, R3CCH2O–), 3.62 ppm (s, –OCH2CH2–), 6.00 ppm (s, 4H, Ar), 6.25 ppm (s, 4H, 
Ar), 7.27 ppm (s, 4H, Ar). The degree of end-group conversion was about 77% as 
determined by 1H-NMR spectroscopy. 
3.2.5 Synthesis of furyl-substituted eight-armed PEG, molecular weight 
10 kDa (8armPEG10k-furan) 
8armPEG10k-furan was synthesized from 8armPEG10k-NH2 in 78% yield (1.69 g) as 
described for 4armPEG10k-furan. 1H-NMR (CDCl3, 300 MHz): δ 2.50 ppm (t, 16H, 
–NHC(O)CH2CH2–), 2.97 ppm (t, 16H, –NHC(O)CH2CH2–), 3.62 ppm (s, –OCH2CH2–),
6.00 ppm (s, 8H, Ar), 6.25 ppm (s, 8H, Ar), 7.27 ppm (s, 8H, Ar). The degree of end-
group conversion was about 67% as determined by 1H-NMR spectroscopy.
3.2.6 Synthesis of furyl-substituted eight-armed PEG, molecular weight 
20 kDa (8armPEG20k-furan) 
8armPEG20k-furan was synthesized from 8armPEG20k-NH2 in 90% yield (1.91 g) as 
described for 4armPEG10k-furan. 1H-NMR (CDCl3, 300 MHz): δ 2.50 ppm (t, 16H, 
–NHC(O)CH2CH2–), 2.97 ppm (t, 16H, –NHC(O)CH2CH2–), 3.62 ppm (s, –OCH2CH2–),
6.00 ppm (s, 8H, Ar), 6.25 ppm (s, 8H, Ar), 7.27 ppm (s, 8H, Ar). The degree of end-
group conversion was about 79% as determined by 1H-NMR spectroscopy.
3.2.7 Synthesis of 3,6-epoxy-1,2,3,6-tetrahydrophthalimide (ETPI) 
ETPI was synthesized according to previously reported procedures with the following 
modifications [189,190]. A mixture of maleimide (42 mmol, 4.0 g) and furan (156 mmol, 
18.6 mL) in 32 mL of ethyl acetate was stirred for 3 days at room temperature. The white 
precipitate that formed during the reaction was filtered off, washed with cold diethyl ether 
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and dried under vacuum to yield 5.78 g (84%) of ETPI. The adduct was a mixture of the 
endo (61.5%) and the exo (38.5%) form. 1H-NMR (CDCl3, 300 MHz): δ 2.89 ppm (s, 2H, 
–C(O)CHRCHRC(O)–, exo), 3.56 ppm (s, 2H, –C(O)CHRCHRC(O)–, endo), 5.30 ppm
(s, 2H, –RCHOCHR–), 6.50 ppm (s, 2H, –CH=CH–).
3.2.8 Synthesis of ETPI-substituted four-armed PEG (4armPEG10k-ETPI) 
The protocol was adapted from a previously described procedure [191]. Briefly, 
4armPEG10k-OH (0.2 mmol, 2.06 g) was dried under vacuum at 45 °C and dissolved 
together with ETPI and triphenylphoshine in 15 mL of DCM. Then, a solution of DIAD 
(in 5 mL of DCM) was added dropwise. After stirring for 48 h at room temperature, the 
solvent was evaporated under reduced pressure. For purification, the raw product was 
dissolved in 50 mL of water, filtered and washed two times with 50 mL of diethyl ether. 
After the water had been evaporated, the raw product was dissolved in 5 mL of DCM and 
crystallized at 0 °C under vigorous stirring by dropwise addition of 50 mL of diethyl 
ether. The precipitate was collected by filtration, washed with cold diethyl ether and dried 
under vacuum to yield 1.85 g (89%). 1H-NMR (CDCl3, 300 MHz): δ 2.84 ppm (s, 4H, 
–C(O)CHRCHRC(O)–, exo), 3.39 ppm (s, 8H, R3CCH2O–), 3.62 ppm (s, –OCH2CH2–),
5.24 ppm (s, 4H, –RCHOCHR–, endo), 5.29 ppm (s, 4H, –RCHOCHR–, exo), 6.40 ppm
(s, 4H, –CH=CH–, endo), 6.50 ppm (s, 4H, –CH=CH–, exo). The degree of end-group
conversion was about 82% as determined by 1H-NMR spectroscopy.
3.2.9 Synthesis of 4armPEG10k-maleimide 
The protocol for the synthesis of 4armPEG10k-maleimide was adapted from a previously 
published procedure [192]. In brief, 4armPEG10k-ETPI was dissolved in 25 mL of 
toluene and the solution was heated to reflux for 2 h under argon atmosphere. The solution 
was then concentrated under reduced pressure and cooled to room temperature. The raw 
product was dissolved in 4 mL of DCM and crystallized at 0 °C under vigorous stirring 
by dropwise addition of 40 mL of diethyl ether. The precipitate was collected by filtration, 
washed with cold diethyl ether and dried under vacuum to yield 1.76 g (86%) of 
4armPEG10k-maleimide. 1H-NMR (CDCl3, 300 MHz): δ 3.39 ppm (s, 8H, R3CCH2O–), 
3.62 ppm (s, –OCH2CH2–), 6.69 ppm (s, 8H, –C(O)CH=CHC(O)–). The degree of end-
group conversion was about 82% as determined by 1H-NMR spectroscopy. 
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3.2.10 Synthesis of 8armPEG10k-maleimide 
For the synthesis of 8armPEG10k-maleimide, a previously established protocol was 
modified as follows [193]. 8armPEG10k-NH2 (0.27 mmol, 2.65 g) was dissolved in a 
saturated solution of sodium bicarbonate in water (100 mL). The solution was stirred and 
treated with N-methoxycarbonylmaleimide (4.32 mmol, 670 mg) under ice cooling. After 
30 min, the ice bath was removed and the solution was allowed to warm up to room 
temperature. The aqueous solution was extracted with DCM (3 × 115 mL) and the 
combined organic layers were dried over anhydrous Na2SO4. The solvent was evaporated 
under reduced pressure. The residue was dissolved in 6 mL of DCM and crystallized at 
0 °C under vigorous stirring by dropwise addition of 60 mL of diethyl ether. The 
precipitate was collected by filtration, washed with cold diethyl ether and dried under 
vacuum to yield 1.66 g (64%). 1H-NMR (CDCl3, 300 MHz): δ 3.62 ppm (s, –OCH2CH2–), 
6.69 ppm (s, 16H, –C(O)CH=CHC(O)–). The degree of end-group conversion was about 
68% as determined by 1H-NMR spectroscopy. 
3.2.11 Synthesis of 8armPEG20k-maleimide 
8armPEG20k-maleimide was synthesized from 8armPEG20k-NH2 in 92% (1.92 g) yield 
as described for 8armPEG10k-maleimide. 1H-NMR (CDCl3, 300 MHz): δ 3.62 ppm (s, 
–OCH2CH2), 6.69 ppm (s, 16H, –C(O)CH=CHC(O)–). The degree of end-group
conversion was about 70% as determined by 1H-NMR spectroscopy.
3.2.12 Preparation of Diels-Alder hydrogels 
DA hydrogels were prepared by reacting equal molar amounts of furyl and maleimide-
substituted PEG of same molecular weight and branching factor in water (Scheme 3.2). 
Scheme 3.2. DA reaction of a PEG-maleimide and a furyl-substituted PEG in water at 37 °C. Only one arm 
of the branched macromonomers is shown for clarity. 
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The overall polymer concentrations were 5, 10 and 15% (w/v). For example, to prepare 
750 µl of a 5% (w/v) 4armPEG10k-hydrogel, 19.1 mg of 4armPEG10k-furan and 
18.4 mg of 4armPEG10k-maleimide were separately dissolved in 375 µL of water each. 
The two liquid precursor solutions were then mixed to initiate gel formation. 
3.2.13 Rheological characterization of Diels-Alder hydrogels 
To study gelation kinetics and mechanical properties, oscillatory shear experiments were 
performed on a TA Instruments AR 2000 rheometer (TA Instruments, Eschborn, 
Germany) with 40 mm parallel plate geometry. Storage (G’) and loss moduli (G”) were 
recorded as a function of time at 37 °C at a constant frequency of 1.0 Hz. Hydrogels with 
5, 10 and 15% (w/v) polymer content were prepared as described above. Upon casting 
the hydrogel precursors (750 µl in total) onto the lower plate of the rheometer, the upper 
plate was immediately lowered to a gap size of 500 µm and the experiment was started. 
The cross-over of G’ and G” was regarded as the gel point; the absolute value of the 
complex shear modulus (|G*|) was determined at the end of the measurement. Water 
evaporation was minimized by using a solvent trap. All experiments were carried out in 
triplicate and the results are given as means ± standard deviations. 
3.2.14 Calculation of hydrogel network mesh size 
Hydrogels with 5, 10 and 15% (w/v) polymer content were prepared as described above. 
Directly after mixing, 375 µL of the liquid precursor solutions were cast into cylindrical 
glass molds (7 mm inner diameter) and allowed to gel for 72 h under standard cell culture 
conditions (37 °C, 95% relative humidity and 5% CO2). The gel samples were then 
weighed in air and hexane before and after swelling for 24 h in 10 mL of pure water using 
a density determination kit (Mettler-Toledo, Gießen, Germany). The gel cylinders were 
then freeze-dried to determine the mass of dry PEG in each sample. From these data, the 
volume of the gel directly after cross-linking (𝑉𝑉𝑔𝑔𝑔𝑔) and after swelling (𝑉𝑉𝑔𝑔𝑔𝑔) was calculated 
using Archimedes’ principle of buoyancy. The volume of the dry polymer, 𝑉𝑉𝑝𝑝 , was 
determined from the mass of the freeze-dried sample and the density of PEG (taken as 
1.12 g/mL). With these parameters, the polymer fraction of the gel after cross-linking, 
𝑣𝑣2𝑔𝑔 = 𝑉𝑉𝑝𝑝/𝑉𝑉𝑔𝑔𝑔𝑔, and in the swollen state, 𝑣𝑣2𝑔𝑔 = 𝑉𝑉𝑝𝑝/𝑉𝑉𝑔𝑔𝑔𝑔, was determined. Using a modified 
version of the Flory-Rehner equitation, the number of moles of elastically active chains 
in the hydrogel network, 𝜈𝜈𝑒𝑒, was calculated [194–196]: 
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𝜈𝜈𝑒𝑒 = − 𝑉𝑉𝑝𝑝𝑉𝑉1𝑣𝑣2𝑔𝑔 ⋅ [ln(1 − 𝑣𝑣2𝑔𝑔) + 𝑣𝑣2𝑔𝑔 + 𝜒𝜒1𝑣𝑣2𝑔𝑔2 ]
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(3.1) 
In this equation, 𝜒𝜒1 is the Flory-Huggins interaction parameter for PEG in water (taken 
as 0.43), 𝑉𝑉1 is the molar volume of the swelling agent (18 cm3/mol) and ƒ is the branching 
factor of the macromonomers (4 in case of 4armPEG and 8 in case of 8armPEG). The 
average molecular weight between cross-links, 𝑀𝑀�𝑔𝑔 , was calculated by 𝑀𝑀�𝑔𝑔 = 𝑚𝑚𝑝𝑝 ∕ 𝜈𝜈𝑒𝑒 , 
where 𝑚𝑚𝑝𝑝 is the total mass of polymer in the hydrogel. The average network mesh size 
(ξ) was calculated by [197]: 
ξ = 𝑣𝑣2𝑔𝑔−13𝑙𝑙 �2𝑀𝑀�𝑔𝑔𝑀𝑀𝑟𝑟 �12 𝐶𝐶𝑛𝑛12 (3.2) 
where 𝑙𝑙 is the average bond length along the PEG backbone (taken as 0.146 nm), 𝑀𝑀𝑟𝑟 is 
the molecular mass of the PEG repeating unit (44 g/mol) and 𝐶𝐶𝑛𝑛 is the Flory characteristic 
ratio (taken as 4 for PEG) [198]. All experiments were carried out in triplicate and the 
results are given as means ± standard deviations. 
3.2.15 Swelling and degradation of Diels-Alder hydrogels 
Hydrogel samples were prepared as described above. The gel cylinders were weighed 
directly after gelation (t = 0 d), immersed in 10 mL of phosphate buffer (50 mmol, pH 
7.4) and incubated at 37 °C in a shaking water bath (approximately 10 rpm). To determine 
hydrogel swelling and degradation, the vials were emptied over 24 mm NetwellTM Inserts 
(500 µm mesh size, Corning GmbH, Kaiserslautern, Germany) at periodic time points. 
The gel cylinders were weighed and incubated again with 10 mL of fresh buffer solution. 
Gel degradation was assumed to be complete when no macroscopic gel residues could be 
detected on the NetwellTM Inserts. All experiments were performed in triplicate and the 
results are presented as means ± standard deviations.  
For 1H-NMR analysis, 19.1 mg of 4armPEG10k-furan and 18.4 mg of 4armPEG10k-
maleimide were separately dissolved in 375 µL of D2O each. The two liquid precursor 
solutions were mixed and transferred into a NMR tube. To follow the cross-linking 
reaction, 1H-NMR spectra were recorded on a Bruker Avance 300 spectrometer (Bruker 
BioSpin GmbH, Rheinstetten, Germany) immediately after mixing (t = 0 h) and after 72 h 
of incubation at 37 °C. To investigate gel degradation, a 5% (w/v) 4armPEG10k-hydrogel 
was prepared in D2O as described above and incubated in 10 mL of deuterated phosphate 
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buffer (50 mmol, pD 7.4) at 37 °C until dissolution. The solution was concentrated using 
Amicon® Ultra centrifugal filters (3 kDa molecular weight cut-off, Millipore, 
Schwalbach, Germany) and analyzed by 1H-NMR spectroscopy. 
 Results and discussion 
3.3.1 Synthesis of furyl- and maleimide-substituted PEG-derivatives 
All syntheses were straightforward and the desired products were obtained in high yields. 
The end-group conversion varied on a high level, as determined by 1H-NMR. 
Nevertheless, the end-group conversion was lower for 8armPEG10k-furan (67%) in 
comparison to 4armPEG10k-furan (77%) and 8armPEG20k-furan (79%). One possible 
reason therefore could be the divergences in chemical synthesis, such as the use of 
different PEGs, new batches of solvents and reactants.  
Moreover, two different routes were used to synthesize the maleimide-substituted PEG-
derivatives. 4armPEG10k-maleimide was obtained after an rDA reaction of 
4armPEG10k-ETPI. However, this synthesis was not successful for the modification of 
the 8armPEGs. Therefore, a second route, the reaction with N-methoxy-
carbonylmaleimide, had to be established.  
3.3.2 Rheological characterization of Diels-Alder hydrogels 
To study the gelation kinetics and mechanical properties of DA hydrogels, the evolution 
of loss (G”) and storage modulus (G’) was followed at 37 °C. G” represents the viscous 
part of the system whereas G’ corresponds to the elastic part. A representative rheogram 
of a 15% (w/v) 4armPEG10k-hydrogel is shown in Figure 3.1. At early time points, G” 
was higher than G’ (G” > G’), which is characteristic for free-flowing liquids. With 
beginning cross-linking, both moduli increased with G’ increasing faster than G”. After 
about 60 min, the cross-over of G’ and G” was observed (G’ = G”) and the liquid 
transformed into a gel. During the course of the experiment, G’ further increased until a 
highly elastic hydrogel had formed (G’ >> G”). This time-dependent sol-gel transition 
makes DA hydrogels ideal for biomedical applications in which injection of the 
biomaterial is required. The material would be injected as a liquid precursor before the 
cross-over point and then cross-linked in situ to form a stable hydrogel. 
3.3
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Figure 3.1. Rheogram of a 15% 
(w/v) 4armPEG10k-hydrogel. The 
measurement was performed at 
37 °C and 1.0 Hz oscillatory 
frequency using a 40 mm parallel 
plate geometry with 500 µm gap 
size. 
The gelation time was controlled by the concentration, branching factor and molecular 
weight of the macromonomers. As shown in Figure 3.2A, the gelation time could be 
reduced by increasing the polymer concentration. For example, the gelation times of 
4armPEG10k-hydrogels decreased from 171 ± 25 min to 59 ± 5 min by increasing the 
polymer concentration from 5% (w/v) to 15% (w/v). Using macromonomers of higher 
branching factor also resulted in lower gelation times. By doubling the branching factor 
and keeping all other factors unchanged, the gelation times of 10% (w/v) hydrogels 
decreased from 106 ± 14 min (4armPEG10k-hydrogels) to 24 ± 1 min (8armPEG10k-
hydrogels). The molecular weight of the macromonomers also had a distinct influence on 
gelation kinetics. The gelation times of 8armPEG20k-hydrogels were generally higher 
than those of 8armPEG10k-hydrogels. For example, the gelation times of 15% (w/v) 
hydrogels increased from 14 ± 1 min to 34 ± 1 min by doubling the molecular weight of 
the macromonomers. 
Figure 3.2. Dependence of gelation time (A) and stiffness (B) on concentration, branching factor and 
molecular weight of the macromonomers. The measurements were performed at 37 °C and 1.0 Hz, and the 
results are presented as means ± standard deviations (n = 3). 
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The observed effects are characteristic for step-growth polymerizations and the different 
gelation times can be explained as follows [199,200]. In theory, gelation kinetics would 
only depend on the molar concentration of macromonomers and the number of reactive 
groups per macromonomer. By increasing the macromonomer concentration and keeping 
all other factors unchanged, the probability that two different macromonomers react with 
each other and form an elastically active chain is increasing. This was observed for all 
tested macromonomers (4armPEG10k, 8armPEG10k and 8armPEG20k). Likewise, the 
probability of forming an elastically active chain increases when increasing the number 
of reactive groups per macromonomer (increasing the branching factor) and keeping the 
molar concentration of macromonomers constant. In practice, incomplete 
functionalization of the macromonomers and loss of functional groups (e.g., due to 
hydrolysis) will also affect gelation kinetics. Because of the lower branching factor, this 
effect is more pronounced when using 4armPEG-macromonomers for gel formation. For 
example, by decreasing the number of functional groups by 50%, 4armPEG-
macromonomers can only act as chain extenders and were not active as cross-linking 
agents while 8armPEG-macromonomers still contribute to cross-linking. This might 
explain why 4armPEG10k-hydrogels show longer gelation times than 8armPEG20k-
hydrogels. 
Oscillatory shear experiments were also used to measure the stiffness of the formed 
hydrogels (Figure 3.2B). As expected, the use of higher macromonomer concentrations 
led to significantly stiffer hydrogels. By raising the polymer concentration from 5% (w/v) 
to 15% (w/v), the absolute value of complex shear modulus (|G*|) of 4armPEG10k-
hydrogels increased from 2821 ± 1479 Pa to 18950 ± 3511 Pa. The same effect was 
observed for 8armPEG10k-hydrogels, where |G*| increased from 4973 ± 1798 Pa to 
37097 ± 6698 Pa and for 8armPEG20k-hydrogels, where |G*| ranged between 
2152 ± 144 Pa and 19057 ± 1002 Pa. Similar to the gelation time, the mechanical 
properties were also influenced by the branching factor of the macromonomers. By using 
8armPEG10k instead of 4armPEG10k, |G*| of 10% (w/v) hydrogels increased from 
8447 ± 2492 Pa to 24797 ± 8678 Pa. And by increasing the molecular weight of the used 
macromonomers from 10 kDa to 20 kDa, the stiffness of the resulting gels decreased 
likewise. For example, |G*| of 10% (w/v) 8armPEG10k-hydrogels was determined to be 
24797 ± 8678 Pa whereas only 8969 ± 2271 Pa were measured for the corresponding 
8armPEG20k-hydrogels, which is comparable to the value of 4armPEG10k-hydrogels 
(8447 ± 2492 Pa). 
Chapter 3 
46 
These findings can be explained by the theory of rubber elasticity which relates the 
equilibrium modulus to the number of elastically active chains within the 
network [199,200]. In the case of 8armPEG10k-hydrogels, the number of elastically 
active chains that can be formed during cross-linking is highest at a given polymer 
concentrations (Figure 3.3). Consequently, these gels show the highest stiffness of all 
tested hydrogels. In the case of 4armPEG10k and 8armPEG20k-hydrogels, the number 
of elastically active chains that can be formed during cross-linking is equal at a given 
polymer concentrations and half the value of 8armPEG10k-hydrogels (Figure 3.3). As a 
result, 4armPEG10k and 8armPEG20k-hydrogels both have nearly the same stiffness. 
The results of the rheological experiments indicated that in some cases, gelation time and 
mechanical properties could be controlled independently from each other. For example, 
8armPEG20k-hydrogels generally showed faster gelation kinetics than the corresponding 
4armPEG10k-hydrogels, whereas |G*| of both gel types was almost the same. The 
possibility of controlling gelation time and stiffness independently from each other 
clearly demonstrates the enormous versatility of our approach. The DA reaction is a 
valuable cross-linking mechanism for many biomedical applications where gel formation 
and mechanical properties must be precisely controlled. 
3.3.3 Calculation of hydrogel network mesh size 
Besides mechanical properties, the hydrogel network mesh size is an important parameter 
that characterizes the network architecture on a sub-microscopic level. Knowing this 
parameter allows estimating the diffusivity of macromolecules within the gels, which is 
of significance for the development of hydrogel-based drug delivery systems. To 
determine the average network mesh size (ξ), the gel samples were swollen in water; 
Figure 3.3. Correlation between the 
theoretical number of moles of 
elastically active chains (νe) and the 
observed stiffness after cross-linking. 
The value of νe was calculated 
according to Elbert et al. [186] and 
Metters et al. [189]. Data is presented 
as means ± standard deviations. 
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equations (3.1) and (3.2) were then used for calculation. The highest value of 
ξ (44.0 ± 17.3 nm) was determined for 5% (w/v) 4armPEG10k-hydrogels (Table 3.1). 
With increasing polymer content and hence increasing cross-linking density, the 
determined values of ξ decreased accordingly. For example, 10% and 15% (w/v) 
4armPEG10k-hydrogels had mesh sizes of 17.8 ± 0.5 nm and 14.8 ± 0.1 nm. Similar 
trends were observed for all tested hydrogel samples (Table 3.1). Due to the fact that 
4armPEG10k- and 8armPEG10k-hydrogels had the same stiffness and the same number 
of elastically active chains, similar mesh sizes for those hydrogels would be expected. 
Nevertheless increased values for 4armPEG10k-hydrogels were determined. This became 
particularly obvious in case of 5% 4armPEG10k- and 8armPEG20k-hydrogels. A mesh 
size of 16.1 ± 0.1 nm was determined for 5% 8armPEG20k-hydrogels, whereas a 
dramatically increased value of 44.0 ± 17.3 nm was determined for 5% 4armPEG10k-
hydrogels. The reason for this increased values, is the already started degradation of 
4armPEG10k-hydogels, followed by weighing errors, which results in an increased mesh 
size and a large standard deviation. Besides the concentration and the branching factor of 
the macromonomers, their molecular weight had a clear influence on the network 
architecture. The mesh size of 8armPEG20k-hydrogels was nearly twice the mesh size of 
8armPEG10k-hydrogels (Table 3.1). For example, 15% (w/v) 8armPEG20k-hydrogels 
had a mesh size of 11.1 ± 0.1 nm, whereas for 15% (w/v) 8armPEG10k-hydrogels, a 
mesh size of 5.5 ± 0.0 nm was determined. This is explained by the different molecular 
weights of the PEG chains originating from each branching point, which are 2500 Da for 
8armPEG20k and 1250 Da for 8armPEG10k. 
Table 3.1. Calculated network mesh sizes of the prepared hydrogels. The experiments were carried 
out in triplicate and the results are presented as means ± standard deviations. 
Polymer Polymer concentration / 
% (w/v) 
Mesh size / nm 
4armPEG10k 5 44.0 ± 17.3 
10 17.8 ± 0.5 
15 14.8 ± 0.1 
8armPEG10k 5 8.9 ± 0.8 
10 5.5 ± 0.0 
15 5.4 ± 0.4 
8armPEG20k 5 16.1 ± 0.1 
10 12.9 ± 0.6 
15 11.1 ± 0.1 
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The determined mesh sizes can be used to evaluate the size of incorporated therapeutic 
peptides or proteins that can be released. Smaller peptides, such as insulin (hydrodynamic 
radius of the hexamer 2.7 nm) [201], are expected to be released from all hydrogels 
because their mesh sizes are generally above 5.0 ± 0.3 nm. Larger proteins, such as 
immunoglobulin G (hydrodynamic radius 5.3 nm) [202], are expected to be released from 
4armPEG10k-hydrogels (mesh sizes generally above 11.7 ± 0.0 nm) and 8armPEG20k-
hydrogels with up to 10% (w/v) polymer content (mesh sizes generally above 
11.0 ± 0.5 nm). Based on our calculations, no release from 8armPEG10k-hydrogels is 
expected because of the small mesh sizes of these hydrogels (generally below 
8.9 ± 0.8 nm). However, their mesh sizes will increase during gel degradation and 
incorporated proteins will eventually be released. 
3.3.4 Swelling and degradation of Diels-Alder hydrogels 
Swelling and degradation behavior are other important factors that must be considered 
when developing hydrogels for biomedical applications. For this purpose, gel cylinders 
were incubated in phosphate buffer pH 7.4 at 37 °C and their masses were determined at 
predetermined time points.  
Surprisingly, all 4armPEG10k-hydrogels completely dissolved within two days of 
incubation (Figure 3.4A). This was not expected given that the dynamic equilibrium of 
the DA reaction greatly lies on the side of the cycloaddition products at 37 °C. Increasing 
the branching factor of the macromonomers could considerably prolong the stability of 
DA hydrogels. Depending on the used macromonomer concentration, the mass of 
8armPEG10k-hydrogels steadily increased before they dissolved after four (5%), seven 
(10%) and nine (15%) weeks of incubation (Figure 3.4B). By increasing the molecular 
weight of the macromonomers, the stability of the gel cylinders decreased again 
(Figure 3.4C). 8armPEG20k-hydrogels were stable for two (5%), three (10%) and four 
weeks (15%), respectively.Although the rDA reaction has been reported to require 
temperatures above 60 °C in order to occur at significant rate [203], we still believe that 
this process is responsible for gel dissolution. To prove this hypothesis, a 5% (w/v) 
4armPEG10k-hydrogel was prepared in D2O, swollen in deuterated phosphate buffer at 
pD 7.4 until dissolution and analyzed by 1H-NMR spectroscopy. Directly after mixing 
the two gel-forming polymers, the 1H-NMR spectrum showed the characteristic signals 
of 4armPEG10k-maleimide (signal a in Figure 3.5A) and 4armPEG10k-furan (signals b, 
c, d, e and f in Figure 3.5A). 
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After 72 h of cross-linking, the signals of the educts had decreased and three groups of 
signals (g, h and i in Figure 3.5B) had appeared that were assigned to the cycloaddition 
product. In the dissolved gel, these signals were still present, although their integrals had 
decreased (integrals not shown in Figure 3.5C). Furthermore, we were able to detect the 
signals of 4armPEG10k-furan in the dissolved hydrogel (signals b, c, d, e and f in 
Figure 3.5C). Interestingly, no signal of 4armPEG10k-maleimide could be detected. 
Instead, we observed two new signals (j and k in Figure 3.5C) that were assigned to the 
hydrolyzed (ring-open) form of 4armPEG10k-maleimide.  
These findings explain the degradability of DA hydrogels. Although the dynamic 
equilibrium of the DA reaction greatly lies on the side of the cycloaddition products at 
37 °C, a small amount of the reactants (maleimide and furyl groups) will always be 
present. The maleimide groups can react with furyl groups in close proximity and form a 
DA adduct again, or they can be hydrolyzed to maleamic acid derivatives that do not form 
Figure 3.4. Swelling and degradation of DA 
hydrogels as a function of polymer 
concentration and branching factor. (A) 5% 
(), 10% () and 15% (w/v) 4armPEG10k-
hydrogels (×) dissolved after 1 to 2 days of
swelling in buffer. (B) 5% (), 10% () and 
15% (w/v) 8armPEG10k-hydrogels (×)
dissolved after 4, 7 and 9 weeks of swelling
in buffer. (C) 5% (), 10% () and
15% (w/v) 8armPEG20k-hydrogels (×)
dissolved after 2, 3 and 4 weeks of swelling
in buffer. The experiments were carried out
in triplicate and the results are presented as
means ± standard deviations.
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Figure 3.5. 1H-NMR spectra of 5% (w/v) 4armPEG10k-hydrogels in D2O. Spectra were recorded directly 
after mixing the two precursor solutions (A), after 72 h of gelation at 37 °C (B), and after dissolution of the 
hydrogel (C). 
cycloaddition products under the experimental conditions (data not shown). Because of 
hydrolysis to unreactive maleamic acid derivatives, the existing maleimide groups are 
continuously removed from the dynamic equilibrium and the DA reaction is ultimately 
reversed. As a consequence, the average network mesh size and swelling capacity of the 
hydrogels gradually increase until a critical number of elastically active chains have been 
broken and the gels finally dissolve (Figure 3.4). Once a macromonomer is completely 
released from the gel network, more starting material is removed from the equilibrium by 
diffusion into the surrounding medium. This additionally accelerates the rDA reaction 
independently from the hydrolysis of maleimide groups [204].  
With increasing macromonomer concentration, more elastically active chains need to be 
broken to cause dissolution of the hydrogel network (Figure 3. 6). This explains the 
longevity of 8armPEG10k-hydrogels, which contain the highest number of 
elasticallyactive chains of all hydrogels at given polymer concentrations. Furthermore, 
gel swelling and degradation are also influenced by the branching factor of the gel-
forming macromonomers. In case of 4armPEG10k-hydrogels, the probability of releasing 
macromonomers is increased compared to 8armPEG20k-hydrogels due to the lower 
concentration of functional groups per branching point. The fast release of 
macromonomers accelerates the rDA reaction and explains the extremely low stability 
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of 4armPEG10k-hydrogels. By combining macromonomers of different branching factor 
and different molecular weights, it should be possible to tailor the degradation rate and 
control the release of incorporated proteins.  
 Conclusion 
We successfully synthesized branched, maleimide and furyl-substituted PEG 
macromonomers of two different molecular weights that were subsequently used for 
hydrogel preparation. We demonstrated that the DA cycloaddition is a straightforward 
and effective reaction for the step-growth polymerization of PEG macromonomers; no 
catalysts or initiators were required for hydrogel cross-linking. Gelation time and gel 
stiffness were found to depend on the concentration, branching factor and molecular 
weight of the used macromonomers. The calculated values of the average network mesh 
size were in a size range that makes DA hydrogels interesting for applications involving 
the controlled release of therapeutic peptides or proteins. Unexpectedly, the prepared 
hydrogels dissolved within days to several weeks with the degradation rate depending on 
the polymer concentration and the type of the used macromonomers. Hydrogel 
degradation was found to occur by rDA reaction and subsequent hydrolysis of the formed 
maleimides to unreactive maleamic acid derivatives. To the best of our knowledge, this 
is the first report on hydrogels that degrade by rDA reactions at body temperature. The 
enormous versatility of the DA reaction and the possibility of precisely controlling the 
properties of the resulting hydrogels make our approach an alternative to conventional 
cross-linking reactions. Potential applications of DA hydrogels are seen as wound 
dressings, as injectable drug delivery systems or in the field of tissue engineering. 
Especially, in case of injectable applications the degradability of the hydrogels has to be 
Figure 3.6. Correlation between the 
theoretical number of moles of 
elastically active chains (νe) after 
cross-linking and the observed 
degradation time. The value of νe was 
calculated according to Elbert et al. 
[186] and Metters et al. [189].
4armPEG10k-hydrogels are not
displayed since these gels degraded
considerably faster than expected (see
text for discussion).
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mentioned as a special benefit. Thus, the patient can get rid of the implanted gel in an 
elegant way after release of the therapeutic agent. The applicability of DA hydrogels for 
the controlled release of proteins is currently under investigation and will be subject of 
an upcoming publication. Particularly, 8armPEG10k-hydrogels promise a very 
interesting slow release mechanism. 
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Chapter 4 
New Insights into the Cross-Linking and 
Degradation Mechanism of Diels-Alder 
Hydrogels 
This chapter was published as: S. Kirchhof, A. Strasser, H.-J. Wittman, V. Messmann, N. 
Hammer A. M. Goepferich and F. P. Brandl, J. Mater. Chem. B 2 (2015) 449–457, doi: 
10.1039/c4tb01680g.  
Data which were not obtained or analyzed by S. Kirchhof were highlighted at the 
appropriate points. 
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Abstract 
Eight-armed poly(ethylene glycol) was functionalized with furyl and maleimide groups. 
The two macromonomers were cross-linked by DA reactions and the degradation 
behavior of the formed hydrogels was investigated. UV spectroscopy showed that 
maleimide groups were subject to ring-opening hydrolysis above pH 5.5, with the 
reaction rate depending on the pH and temperature. As a result of this, the gelation 
kinetics and stiffness of DA hydrogels were dependent on the temperature and the pH of 
the cross-linking medium, as demonstrated by rheological experiments. The gel time 
varied between 87.8 min (pH 3.0, 37 °C) and 374.7 min (pH 7.4, 20 °C). Values between 
420 Pa (pH 9.0, 37 °C) and 3327 Pa (pH 3.0, 37 °C) were measured for the absolute value 
of the complex shear modulus. Hydrogel swelling and degradation were influenced by 
the same parameters. With increasing pH and temperature the degradation time was 
reduced from 98 days (pH 7.4, 20 °C) to 2 days (pH 7.4, 50 °C); no degradation was 
observed at pH 3.0 and 5.5. Molecular modeling studies of the DA and rDA moieties 
revealed that hydrogel degradation occurred by rDA reaction followed by OH–-catalyzed 
ring-opening hydrolysis of maleimide groups to unreactive maleamic acid derivatives.
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 Introduction 
The concept of click chemistry has, without doubt, revolutionized macromolecular 
synthesis and materials science [56,205–207]. The reasons for the importance of click 
reactions are their wide scope, their high efficiency and selectivity, and the ease of 
purification of the resulting products. Furthermore, it is advantageous that click reactions 
can be conducted in aqueous media under mild conditions (e.g., at room temperature). 
Besides azide-alkyne cycloadditions and thiol-ene reactions, DA reactions, which rely on 
carbon-carbon bond formation between conjugated dienes and substituted alkenes, have 
been frequently applied in macromolecular synthesis [19,208]. For instance, the DA 
reaction has been used for the synthesis of block copolymers and dendrimers, the surface 
modification of nanoparticles [209], and the preparation of hydrogels [21,210–213]. 
Interestingly, the DA reaction and its counterpart, the rDA reaction, are reversible under 
certain conditions (e.g., at elevated temperature or in organic solvents). The DA/rDA 
equilibrium has been exploited, e.g., for the synthesis of recyclable, mendable or self-
healing materials [214–216]. Furthermore, the DA/rDA reaction has been used for the 
protection/deprotection of maleimide groups, which allowed the preparation of 
methacrylate-based thiol-reactive hydrogels [192,217,218]. The rDA fragmentation has 
also been explored for the purpose of binding and release drugs from macromolecular 
carriers [219]. And recently, the DA/rDA system has been proposed as a mechanism to 
control the release of drug molecules from PEG-based hydrogels [204,220]. 
Despite the reversibility of the DA/rDA reaction, hydrogels cross-linked by DA reactions 
did not readily degrade by rDA reactions as the rate of these reactions is too slow at body 
temperature. In order to achieve degradation, multiple rDA reactions must occur 
simultaneously at significant rate, which is unlikely in highly cross-linked networks. This 
limited the scope of the DA/rDA reaction to situations compatible with high temperatures 
and required the introduction of hydrolytically or enzymatically cleavable sites to render 
the hydrogels biodegradable. For example, hydrogels with hydrolytically cleavable ester 
bonds decomposed in acid or basic media, with the degradation rate being controlled by 
the pH of the solution [210]. In a slightly different approach, furan-modified hyaluronic 
acid (HA) derivatives were cross-linked with dimaleimide PEG [21,221] or maleimide-
functionalized HA [211]. The resulting hydrogels degraded in the presence of 
hyaluronidase and might be suitable for applications in regenerative medicine. 
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In our previous work, we investigated the DA reaction as a cross-linking mechanism for 
PEG-based hydrogels [212]. Two complementary macromonomers were synthesized by 
functionalizing star-shaped PEG of two different branching factors (four-armed and 
eight-armed PEG) and two different molecular weights (10 kDa and 20 kDa) with furyl 
and maleimide groups. Hydrogels were prepared by step-growth polymerization of the 
synthesized macromonomers and characterized with regard to their mechanical 
properties, average network mesh size and swelling behavior. Somewhat surprising, the 
cross-linked hydrogels degraded in phosphate buffer, pH 7.4 at 37 °C, with the 
degradation time depending on the number of moles of elastically active chains. NMR 
analysis of the degradation products revealed the presence of furyl groups whereas no 
maleimide groups could be detected. Instead we observed two new signals that were 
assigned to newly generated maleamic acid groups. While maleimide is a strong 
dienophile, maleamic acid (ring-open form of maleimide) is much less reactive in DA 
reactions [204,222] and no hydrogel formation is observed. Based on these findings, two 
potential pathways for the degradation of DA hydrogels can be formulated (Scheme 4.1). 
Scheme 4.1. Potential degradation pathways of DA hydrogels. 
In pathway A, the DA adduct first undergoes rDA reaction (reaction I). In a second step, 
OH– is added to the carbonyl moiety of the formed maleimide (reaction IIa), which is then 
subject to a ring-opening reaction yielding furan and unreactive maleamic 
acid (reaction IIIa). In pathway B, OH– is first added to the carbonyl moiety of the DA 
4.2 Experimental section 
57 
adduct (reaction IIb). The formed complex is then subject to ring opening (reaction IIIb) 
and subsequent rDA reaction yielding furan and unreactive maleamic acid (reaction IV). 
Herein we present new insights into the cross-linking and degradation mechanism of 
PEG-based DA hydrogels. In the first experiment, the hydrolytic stability of PEG-
maleimide was investigated at different pH-values and temperatures. Next, we studied 
the influence of pH and temperature on the cross-linking kinetics and stiffness of DA 
hydrogels. Based on the obtained results, in-depth degradation studies were performed at 
different pH-values and temperatures. The experiments were supplemented with semi-
empirical molecular dynamics (SEMD) simulations of the DA and rDA complexes at 
basic pH. In the following, we will present the results of these studies and discuss which 
pathway (Scheme 4.1) hydrogel degradation most likely follows.  
 Experimental section 
4.2.1 Materials 
Eight-armed PEG, molecular weight 10 kDa (hexaglycerol core, 8armPEG10k-OH) was 
purchased from JenKem Technology (Allen, TX, USA) and functionalized with 
furyl (8armPEG10k-furan) and maleimide groups (8armPEG10k-maleimide) as 
previously described [212]. Citric acid and sodium dihydrogen phosphate monohydrate 
were received from Merck KGaA (Darmstadt, Germany). 2-(N-Morpholino)-
ethanesulfonic acid (MES) was purchased from Sigma-Aldrich (Taufkirchen, Germany). 
Water was obtained by using a Milli-Q water purication system from 
Millipore (Schwalbach, Germany). 
4.2.2 Hydrolytic stability of 8armPEG10k-maleimide 
The hydrolytic stability of 8armPEG10k-maleimide was determined by UV spectroscopy. 
For stability testing, 20 mg of 8armPEG10k-maleimide were dissolved in 2 mL of 50 mM 
citrate buffer (pH 3.0), 50 mM MES buffer (pH 5.5) or 50 mM phosphate buffer (pH 7.4, 
pH 9.0 and pH 11.0). The samples were placed in a Kontron UVIKON® 941 
spectrophotometer (Kontron Instruments S.p.A, Milan, Italy) equipped with a 
temperature-controlled cell changer; 10 mm quartz cuvettes were used. The decrease in 
the absorbance at 299 nm (UV maximum of 8armPEG10k-maleimide) was monitored for 
1200 min at 37 °C. To determine the temperature dependence of hydrolysis, 20 mg of 
4.2
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8armPEG10k-maleimide were dissolved in 2 mL of 50 mM phosphate buffer (pH 7.4). 
The decrease in the absorbance was monitored at 20 °C, 30 °C, 40 °C and 50 °C as 
described above. All measurements were performed in triplicate and the obtained data 
was normalized. Assuming that the pH of the buffered solutions does not change during 
hydrolysis (constant OH– concentration), pseudo-first-order kinetic models were least-
squares fitted to the experimental data to determine the hydrolysis rate constants (kobs) 
and half-lives (t½) of 8armPEG10k-maleimide. The plateau value was shared between all 
groups and kobs was set greater than zero. 
4.2.3 Rheological characterization of DA hydrogels 
To study the influence of the pH of the cross-linking medium on gelation kinetics and 
mechanical properties, oscillatory shear experiments were performed on a TA 
Instruments AR 2000 rheometer (TA Instruments, Eschborn, Germany) with parallel 
plate geometry (40 mm in diameter, 500 µm gap size). For the measurements, equal molar 
amounts of 8armPEG10k-furan (19.0 mg) and 8armPEG10k-maleimide (18.5 mg) were 
dissolved in 750 µL of 50 mM citrate buffer (pH 3.0), 50 mM MES buffer (pH 5.5) or 
50 mM phosphate buffer (pH 7.4, pH 9.0 and pH 11.0). After the hydrogel precursor 
solution had been cast onto the lower plate of the rheometer, the upper plate was 
immediately lowered to a gap size of 500 µm and the experiment was started. A solvent 
trap was used to minimize water evaporation. The time evolution of storage modulus (G’) 
and loss modulus (G”) was recorded at 37 °C and an oscillatory frequency of 1.0 Hz. The 
crossover of G’ and G” was regarded as the gel point; the absolute value of the complex 
shear modulus (|G*|) was determined after the maximum value had been reached. To 
study the influence of the temperature, the rheological measurements were repeated in 
50 mM MES buffer (pH 5.5) and 50 mM phosphate buffer (pH 7.4) at 20 °C. All 
experiments were performed in triplicate and the results are shown as means ± standard 
deviations. 
4.2.4 Swelling and degradation of DA hydrogels 
For swelling and degradation studies, equal molar amounts of 8armPEG10k-furan 
(114.3 mg) and 8armPEG10k-maleimide (110.7 mg) were dissolved in 4500 µL of water. 
Directly after mixing, 375 µL of the liquid precursor solutions were filled into cylindrical 
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glass molds (7 mm inner diameter) and allowed to gel for 72 h under standard cell culture 
conditions (37 °C, 95% relative humidity and 5% CO2). The gel cylinders were weighed 
(t = 0 days), immersed in 10 mL of 50 mM citrate buffer (pH 3.0), 50 mM MES buffer 
(pH 5.5) or 50 mM phosphate buffer (pH 7.4, pH 9.0 and pH 11.0) and incubated at 37 °C 
in a shaking water bath (approximately 10 rpm). To determine the influence of 
temperature on hydrogel degradation, gel cylinders were prepared as described above, 
immersed in 10 mL of 50 mM phosphate buffer (pH 7.4) and incubated at 20 °C, 30 °C, 
40 °C or 50 °C. The vials were emptied over 24 mm Netwell-Inserts (500 µm mesh size, 
Corning GmbH, Kaiserslautern, Germany) at periodic time points, the gel cylinders were 
weighed, and incubated again with 10 mL of fresh buffer solution. The experiment was 
continued until no macroscopic gel residues could be detected on the Netwell-Inserts. All 
experiments were performed in triplicate and the results are presented as means ± standard 
deviations. 
4.2.5 Molecular modeling studies 
To minimize the calculation time, the polymer structures of 8armPEG10k-furan and 
8armPEG10k-maleimide were reduced to 2-methylfuran and N-methylmaleimide, 
respectively. All complexes were constructed with SYBYL 7.0 (Tripos Inc., St. Louis, 
MO) and preminimized using the Tripos force field. Subsequently, the resulting structures 
were converted into a MOPAC (Stewart Computational Chemistry, Colorado Springs, 
CO) input file. Using the keyword line “t = 1000 am1 pdb mmok gnorm = 0.1 eps = 
78 charge = -1” the complexes were minimized in order to obtain the enthalpy of 
formation. In setting up the system for the SEMD simulation using the MOPAC 2009 
package, the complex of interest was solvated with a water shell consisting of about 60 
water molecules and showing the density of water at 25 °C. The relative molar mass of 
the atoms of the water molecules in the outer hydration shell was set to 9999 in order to 
avoid expansion of the system. The simulations were performed for > 10 ps in all cases. 
4.2.6 Statistical analysis 
The results of the rheological characterization were analyzed by means of one-way 
ANOVA followed by Tukey’s post-hoc test (GraphPad Prism, Version 5.01, GraphPad 
Software Inc., La Jolla, CA). The differences were considered statistically significant at 
p < 0.05. 
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 Results and discussion 
4.3.1 Hydrolytic stability of 8armPEG10k-maleimide 
To investigate the possible degradation pathways, we first studied the hydrolytic stability 
of 8armPEG10k-maleimide. It is well known from the literature that maleimides and 
N-alkylmaleimides hydrolyze in alkaline solution [223–225]. However, data on the
hydrolytic stability of 8armPEG10k-maleimide is still missing. The hydrolytic ring
opening of 8armPEG10k-maleimide is a key step in degradation pathway A and can be
easily followed by UV spectroscopy (Figure 4.1A). When 8armPEG10k-maleimide was
incubated at pH 3.0 or pH 5.5, the absorbance at 299 nm slowly decreased indicating high
stability of the maleimide. At pH 7.4, the absorbance decreased more rapidly indicating
faster hydrolysis of the maleimide in comparison to pH 3.0 and pH 5.5. When the pH was
further increased to pH 9.0, 8armPEG10k-maleimide was subject to fast ring opening as
indicated by the rapidly decreasing absorbance. At pH 11, the hydrolytic ring opening of
8armPEG10k-maleimide was extremely fast and reliable measurements could not be
made (data not shown). Besides the pH, the stability of 8armPEG10k-maleimide was
found to depend on the incubation temperature. When the temperature was increased from
20 °C to 50 °C, the rate of hydrolysis increased likewise (Figure 4.1B).
Figure 4.1. Hydrolytic stability of 8armPEG10k-maleimide at 37 °C and different pH-values (A), and at 
pH 7.4 and different temperatures (B). The experimental data is indicated by symbols; the solid lines 
represent the least-squares fits of pseudo-first-order kinetic models. The experiments were carried out in 
triplicate and the results are presented as means ± standard deviations. 
Since the concentrations of OH– and H3O+ are constant during the reaction in buffered 
solutions, it is reasonable to assume that the hydrolysis of 8armPEG10k-maleimide 
follows the pseudo-first-order equation (4.1). 
4.3
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(4.1) 
(4.2) 
Rate constants (kobs) and half-lives (t½) were calculated by fitting the integrated form of 
equation (4.1) to the experimental data (Table 4.1 and 4.2). Our results clearly show that 
the rate of the ring-opening reaction increases with increasing pH and temperature. Since 
the reaction rate is not negligible at neutral pH and room temperature, hydrolysis of 
maleimide groups to unreactive maleamic acid derivatives may play an important role 
during cross-linking and degradation of DA hydrogels. 
Table 4.1. Pseudo-first-order rate constants (kobs) of the ring-opening hydrolysis and half-lives (t½) of 
8armPEG10k-maleimide at 37 °C and different pH-values. 
Table 4.2. Pseudo-first-order rate constants (kobs) of the ring-opening hydrolysis and half-lives (t½) of 
8armPEG10k-maleimide at pH 7.4 and different temperatures. 
T / °C kobs / s–1 t½ / min 3∙t½ / days R2 
20 1.24·10–5 929 1.9 0.9969 
30 3.81·10–5 303 0.6 0.9979 
40 1.47·10–4 79 0.2 0.9926 
50 3.85·10–4 30 0.1 0.9652 
4.3.2 Rheological characterization of DA hydrogels 
The influence of the pH on cross-linking kinetics and stiffness of DA hydrogels was 
investigated by oscillatory shear experiments at 37 °C. As shown in Figure 4.2A, the gel 
time was not significantly different at pH 3.0, pH 5.5 and pH 7.4; values between 
87.8 ± 8.2 min (pH 3.0) and 97.2 ± 6.5 min (pH 7.4) were observed. The gel time 
increased to 207.6 ± 21.5 min at pH 9.0, which was significantly longer compared to the 
three lower pH-values (p < 0.05). When the pH was further increased to 11.0, no gel 
formation was observed within 4 h (data not shown). The stiffness of the cross-linked 
pH kobs / s–1 t½ / min 3∙t½ / days R2 
3.0 4.83·10–7 26358 54.9 0.7630 
5.5 1.92·10–6 6020 12.5 0.9989 
7.4 6.55·10–5 177 0.4 0.9813 
9.0 2.60·10–4 44 0.1 0.9764 
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hydrogels generally decreased with increasing pH (Figure 4.2B). The absolute value of 
G* (3328 ± 373 Pa) was significantly higher at pH 3.0 than in all other experimental 
groups (p < 0.05). When the pH was raised to 5.5, the absolute value of G* decreased to 
2517 ± 176 Pa; however, this value was still significantly higher than at pH 7.4 and 
pH 9.0 (p < 0.05). Further increasing the pH resulted in mechanically weaker hydrogels. 
The magnitude of G* decreased to 685 ± 169 Pa at pH 7.4, which was not significantly 
different from that value at pH 9.0 (420 ± 205 Pa). 
Figure 4.2. Influence of the pH on the gel time (A) and stiffness (B) of DA hydrogels at 37 °C. Influence 
of the temperature on the gel time (C) and stiffness (D) of DA hydrogels at pH 5.5 and 7.4. The 
measurements were performed in triplicate and the results are presented as means ± standard deviations; * 
indicates statistically significant differences versus all other experimental groups (p < 0.05). 
For step-growth polymerizations of f-functional species, the conversion of functional 
groups at the gel point (α) can be calculated according to the Flory-Stockmayer 
theory [226]: 
(4.3) 
According to equation (4.3), gelation of DA hydrogels made from eight-armed PEG 
(f = 8) occurs at approximately 15% conversion of both furyl and maleimide groups. The 
time to reach the gel point, which is approximated by the crossover of G’ and G”, can be 
used to describe the kinetics of cross-linking. In cross-linked networks, the absolute value 
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of G* relates to the number of elastically active chains, which can be calculated from the 
degree of cross-linking or conversion of functional groups [226]. Oscillatory shear 
experiments can, therefore, be used to describe the kinetics of cross-linking and to 
approximate the conversion of functional groups. In our experiments, both the kinetics of 
cross-linking and the conversion of functional groups were greatly influenced by the 
pH (Figure 4.2A and B). While Brønsted acid catalysis of DA reactions was reported in 
both polar and nonpolar organic solvents [227–229], no general Brønsted acid catalysis 
was observed in water. The rate constants for the DA reaction between cyclopentadiene 
and dienophiles with basic sites were considerably faster in 0.01 M HCl than in pure 
water; however, no Brønsted acid catalysis was detected in the DA reaction of 
cyclopentadiene with non-basic naphthoquinones [230]. Since neither furan nor 
maleimide contain any basic sites, acid catalysis of the DA reaction between 
8armPEG10k-furan and 8armPEG10k-maleimide is unlikely. Furthermore, acid catalysis 
may explain the faster reaction kinetics at acidic pH but not the higher magnitude of G*. 
However, pH-dependent ring opening of maleimide groups and generation of unreactive 
maleamic acid derivatives can explain the observed results. In the sol state at pH 3.0, 
pH 5.5 and pH 7.4, the ring-opening reaction is slow compared to the DA reaction and 
the gel time is basically independent from the pH. However, the cross-linking process 
considerably slows down after gelation and the competitive reaction becomes 
increasingly important. As discussed above, the rate of the ring-opening reaction 
increases with increasing pH; consequently, the degree of cross-linking decreases with 
increasing pH. At pH 9.0 and pH 11.0, the ring-opening reaction is fast compared to the 
DA reaction. This results in significantly prolonged gel times and low degrees of cross-
linking. 
Besides the pH, the temperature is expected to influence the gelation kinetics and the 
degree of cross-linking of DA hydrogels. The observed gel times (332.5 ± 21.1 min at 
pH 5.5 and 374.7 ± 2.5 min at pH 7.4) were significantly longer at 20 °C than at 37 °C 
(Figure 4.2C). In contrast to the gel time, the absolute value of G* was strongly influenced 
by the pH; values between 2992 ± 347 Pa (pH 5.5) and 1369 ± 148 Pa (pH 7.4) were 
measured at 20 °C (Figure 4.2D). Our results clearly demonstrate that increasing the 
temperature accelerates the DA reaction. Gelation was more than three times faster at 
37 °C than at 20 °C. Despite the lower reaction rate at 20 °C, the absolute value of G* 
was equally high or higher than at 37 °C. This can be explained by the changed hydrolytic 
stability of maleimides at different pH-values and temperatures. At pH 5.5, the ring-
Chapter 4 
64 
opening hydrolysis of maleimides is extremely slow for both tested 
temperatures (Figure 4.1A). Consequently, the absolute values of G* and hence the 
degrees of cross-linking were comparable at 20 °C and 37 °C. At pH 7.4, however, the 
rate of the ring-opening reaction is strongly influenced by the temperature (Figure 4.1B). 
The observed rate constants were approximately five times higher at 37 °C than at 
20 °C (6.55·10-5 s-1 vs. 1.24·10-5 s-1, Table 4.1 and 4.2). As a result of this, the 
magnitude of G* was approximately two times higher at 20 °C than at 37 °C 
(1369 ± 148 Pa vs. 685 ± 169 Pa). It can be concluded from our rheological experiments 
that cross-linking of DA hydrogels is best performed in slightly acidic solutions (e.g., at 
pH 5.5) to ensure high cross-linking degrees. Furthermore, cross-linking should be 
performed above room temperature (e.g., at 37 °C) to fasten gel formation. 
4.3.3 Swelling and degradation of DA hydrogels 
DA hydrogels prepared from star-shaped PEG macromonomers degraded in phosphate 
buffer, pH 7.4 at 37 °C as reported in our previous publication [212]. This was surprising 
since the described hydrogels, unlike other degradable DA hydrogels [21,210,211,213], 
did not contain labile ester bonds or enzymatically degradable substrates. To investigate 
factors influencing the stability of DA hydrogels, cross-linked gel cylinders were 
incubated at 37 °C and different pH-values (Figure 4.3A). At pH 3.0 and pH 5.5, the mass 
of the incubated gel samples remained nearly constant. After approximately 10 months, 
the mass of hydrogels incubated at pH 5.5 had slightly increased compared to those at 
pH 3.0. In contrast to that, hydrogels incubated at pH 7.4, pH 9.0 or pH 11.0 showed pH-
dependent swelling behavior. The mass of the samples increased exponentially until the 
gels dissolved after 4 days (pH 11.0), 18 days (pH 9.0) and 25 days (pH 7.4). Our 
experiment demonstrates that the stability of DA hydrogels strongly depends on the pH 
of the incubation medium. The equilibrium of the DA/rDA reaction between furan and 
maleimide is thermally controlled (reaction I); temperatures up to 60 °C favor the forward 
(DA) reaction and adduct formation (complex 1b), whereas temperatures above 100 °C 
induce the reverse (rDA) reaction and the regeneration of furan and maleimide 
moieties (complex 1a) [231–234]. Therefore, hydrogel degradation at 37 °C is most 
likely not solely driven by an rDA process as the reaction kinetics is too slow at body 
temperature. Furthermore, a DA/rDA mechanism cannot explain the observed pH 
dependence of the gel stability. The few studies investigating the pH dependence of the 
DA/rDA reaction point towards an increased rate of the rDA reaction in the presence of 
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Figure 4.3. Swelling and degradation of 10% (w/v) 8armPEG10k-hydrogels. Hydrogels incubated at 37 °C 
dissolved after 4 days (pH 11.0), 18 days (pH 9.0) and 25 days (pH 7.4); gels incubated at pH 5.5 and 
pH 3.3 were stable for more than 300 days (A). Hydrogels incubated at pH 7.4 dissolved after 
2 days (50 °C), 8 days (40 °C), 36 days (30 °C) and 98 days (20 °C) (B). The inset shows the relative mass 
increase during the first 5 days of incubation. The experiments were carried out in triplicate and the results 
are presented as means ± standard deviations. 
Brønsted acids [234], which contradicts our observations. However, the experimental 
results could be explained by a DA/rDA mechanism in combination with ring-opening 
hydrolysis of the generated maleimide groups (Scheme 1, degradation pathway A). 
Removal of maleimide groups from the DA/rDA equilibrium, e.g., by conversion into 
unreactive maleamic acid derivatives (reaction IIa and IIIa), causes the DA 
adduct (complex 1b) to revert to the starting materials (complex 3a). In this way, the rate 
of the rDA reaction is increased according to Le Châtelier’s principle and gel degradation 
is incited [219]. The higher the pH of the incubation medium gets, the faster the 
maleimide groups are consumed and the faster the hydrogels dissolve. Another possible 
mechanism that could explain the experimental results would be the direct addition of 
OH– to the carbonyl moiety of the DA adduct (reaction IIb) followed by a ring-opening 
reaction (reaction IIIb) and rDA reaction (reaction IV, Scheme 1, degradation 
pathway B). 
To verify our hypothesis, cross-linked hydrogels were incubated at pH 7.4 and different 
temperatures (Figure 4.3B). Although all incubation temperatures were below the 
temperature usually required for the rDA reaction to proceed at a significant 
rate [231–233], hydrogel degradation was observed at all conditions. The gel samples 
dissolved after 2 days (50 °C), 8 days (40 °C), 36 days (30 °C) and 98 days (20 °C). 
Assuming that hydrogel degradation follows a simple first-order process, the hydrogels 
should dissolve after 85% of the DA linkages have been broken, i.e., after approximately 
three half-lives [225]. If the degradation process was actually controlled by ring-opening 
Chapter 4 
66 
hydrolysis of maleimide groups, it should be possible to predict the degradation time from 
the observed rate constants. However, the observed values were approximately 50 times 
higher than the predicted values (Figure 4.4). Therefore, the ring-opening reaction is most 
likely not the rate-determining step in the degradation process; hydrogel degradation is 
most likely not controlled by the ring-opening reaction. Furthermore, it should be 
emphasized that hydrogel degradation is most likely not adequately described by a single 
first-order process; additional factors, such as the cross-linking density and the branching 
factor of the macromonomers, must be taken into account. For example, it has been shown 
that the stability of hydrogels made from four-armed PEG (10 kDa molecular weight) and 
eight-armed PEG (20 kDa molecular weight) differs, even though the number of 
elastically active chains should be identical in both systems [212]. In hydrogels made 
from four-armed PEG, the number of functional groups per branching point is lower than 
in eight-armed PEG gels. Consequently, the cross-linking density of four-armed PEG 
hydrogels decreases faster during degradation; the gel stability is greatly reduced. The 
experimental findings would fully support the proposed degradation pathway A. The 
degradation of DA hydrogels is based on the DA/rDA equilibrium, with the rDA reaction 
most likely being the rate-determining step. Increasing the temperature catalyzes the ring-
opening hydrolysis of maleimide groups; consequently, the rate of the rDA reaction is 
increased and gel degradation is incited without requiring elevated temperatures. 
Figure 4.4. Comparison of the 
predicted (3·t½) and observed 
degradation times at pH 7.4 and 
different temperatures. The solid line 
represents a least-squares fit of a linear 
equation to the data points. The 
observed values were approximately 
50 times higher than the predicted 
values. 
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4.3.4 Molecular modeling studies 
Modeling the actual degradation process of hydrogels is a great challenge because of the 
extremely large box size and, consequently, large number of sites that are required to 
describe the system. Even qualitative results can hardly be achieved, especially if 
formation and breaking of bonds should be taken into account. Therefore, only the 
reactive moieties were considered in the SEMD simulations. Further extending the 
system, e.g., by adding ethylene glycol units, may produce artificial results. In SEMD 
simulations, side chains next to the reactive center are flexible; oxygen atoms may form 
hydrogen bonds with water to direct the addition of OH– to the maleimide portion of the 
DA adduct. In highly swollen gel networks, however, the polymer chains are stretched 
and restricted in their movement. Therefore, it is acceptable to reduce the polymer 
structures of 8armPEG10k-furan and 8armPEG10k-maleimide to 2-methylfuran and 
N-methylmaleimide, respectively, without compromising the validity of the model.
Figure 4.5 shows possible reaction pathways connecting different maleimide/furan-
complexes in the presence of a water molecule and an OH–-ion. Furthermore, a
corresponding schematic energy diagram based on the semi-empirical calculation of the
enthalpy of formation is depicted in the center of Figure 4.5. The calculations predict that
the DA adduct 1b is enthalpically favored compared to complex 1a. This is in agreement
with the experimental results showing the formation of the DA adduct from maleimide
and furan. Addition of OH– to the carbonyl moiety of the DA adduct would lead to a
further enthalpic stabilization (complex 2b), as indicated by semi-empirical calculations.
The calculations further indicate that the ring-open complex 3b would be enthalpically
favored compared to complex 2b. In addition to the exo adduct, the formation of the endo
isomer also has to be considered. However, semi-empirical calculations predicted no
significant differences in the standard enthalpy of formation between the corresponding
endo and exo isomers. Because of the DA/rDA equilibrium, a second pathway must be
considered. Addition of the OH– to the carbonyl moiety of the maleimide (complex 2a)
and the subsequent ring opening would lead to a strong enthalpic stabilization
(complex 3a). Since no hydrogel formation was observed between 8armPEG10k-furan
and the ring-open form of 8armPEG10k-maleimide (results of the rheological experiments
not shown), the formation of complex 3b from complex 3a cannot be suggested.
Chapter 4 
68 
Figure 4.5.* Possible reaction pathways connecting different maleimide/furan-complexes in the presence 
of a water molecule and an OH–-ion. The schematic energy diagram in the center is based on the semi-
empirical calculation of the enthalpy of formation. The exo isomer is marked by red dots and the endo 
isomer is marked by blue dots; no significant energetic differences were observed between the two isomers. 
For reasons of clarity, only the chemical structures of the exo isomers are shown. 
* Data were obtained and analyzed by A. Strasser and H.-J. Wittmann, Department of Pharmaceutical and
Medicinal Chemistry II, University of Regensburg.
To investigate which pathway hydrogel degradation most likely follows, the OH–-
catalyzed ring-opening hydrolysis of maleimide was simulated (reaction IIIa). 
Figure 4.6A shows the progress in the ring-opening reaction, based upon the distances of 
relevant atoms marked by C, H, O and N, as a function of time for the model system 
N-methylmaleimide. At an early state of the reaction, the length of the C–O bond
decreases, whereas the distance between the carbon and the nitrogen atom increases,
indicating the cleavage of the C–N bond. After a period of about 1750 fs, the hydrogen
atom of the OH–-group approaches the nitrogen atom, resulting in a significant step of the
H–N-distance function. Afterwards, the proton transfer from the oxygen atom to the
nitrogen atom takes pleace, yielding the product N-methylmaleamic acid anion. In
contrast to the semi-empirical MD simulation of N-methylmaleimide, ring opening of
complex 2b was not observed (Figure 4.6B), although the ring-open complex 3b would
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be enthalpically favored compared to complex 2b. Thus, it can be concluded that the 
formation of the DA adduct 1b from complex 1a may be kinetically controlled. A reason 
for the resistance of complex 2b towards ring opening may be a large change in the 
dihedral angle δ. As observed for N-methylmaleimide, the dihedral angle δ undergoes a 
strong change from ~ 1 ° to ~ 56 ° (Figure 4.6A). In contrast to that, such a large change 
in the dihedral angle is not possible for complex 2b because of the rigid ring system. 
Based on SEMD simulations it can be concluded that hydrogel degradation most likely 
follows pathway A (Scheme 4.1). Addition of OH– to the carbonyl moiety of the DA 
adduct followed by a ring- opening reaction and rDA reaction (Scheme 4.1, degradation 
pathway B) cannot be suggested. 
Figure 4.6.* Semi-empirical MD simulations of the ring-opening reaction. The distances of relevant atoms 
marked by C, H, O and N are shown as a function of time for the model systems N-methylmaleimide (A) 
and complex 2b (B). 
* Data were obtained and analyzed by A. Strasser and H.-J. Wittmann, Department of Pharmaceutical and
Medicinal Chemistry II, University of Regensburg.
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 Conclusion 
In this study we investigated the influence of pH and temperature on the cross-linking 
and degradation behavior of DA hydrogels. Rheological experiments and swelling studies 
were supplemented with SEMD simulations. Taken together, the results of our studies 
show that degradation of DA hydrogels occurs by rDA reaction and subsequent OH–-
catalyzed ring-opening hydrolysis of the formed maleimides to unreactive maleamic acid 
derivatives (Scheme 4.1, degradation pathway A). The instability of the involved 
maleimides directly affects the cross-linking and degradation behavior of DA hydrogels, 
with pH and temperature being the main influencing factors. These findings have 
implications for other biomaterials that are cross-linked by DA reactions, especially 
hydrogels. Cross-linking is best performed in slightly acidic solutions (e.g., at pH 5.5) to 
ensure high degrees of conversion. Furthermore, cross-linking should be performed above 
room temperature (e.g., at 37 °C) to fasten the gelation process. When placed into a 
physiological environment (e.g., in aqueous solution at pH 7.4 and 37 °C), degradability 
of the cross-linked hydrogels must be considered. Removal of maleimide groups from the 
DA/rDA equilibrium by ring-opening hydrolysis increases the rate of the rDA reaction 
according to Le Châtelier’s principle. This evades the need for high temperatures to incite 
the rDA reaction, allowing the synthesis of biomaterials that readily degrade at 
physiological conditions. We are fully aware that in vitro experiments cannot exactly 
predict the degradation behavior of DA hydrogels in potential applications, e.g. when 
applied as a biomaterial in vivo. Nevertheless, we expect that DA hydrogels will be 
degraded in vivo, with the pH of the tissue having a major influence on the degradation 
time. Further experiments to investigate the in vivo compatibility and degradability of 
PEG-based DA hydrogels will be run in the near future and presented in an upcoming 
publication. 
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Chapter 5 
Diels-Alder Hydrogels for Controlled 
Antibody Release: Correlation between 
Mesh Size and Release Rate 
This chapter was published as: S. Kirchhof, M. Abrami, V. Messmann, N. Hammer, A. 
M. Goepferich, M. Grassi and F. P. Brandl, Mol. Pharm. 12 (2015) 3358-3368, doi:
10.1021/acs.molpharmaceut.5b00375.
Data which were not obtained or analyzed by S. Kirchhof were highlighted at the
appropriate points.
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Abstract 
Eight-armed PEG, molecular mass 10 kDa was functionalized with furyl and maleimide 
groups, respectively; the obtained macromonomers were cross-linked via DA chemistry. 
The mesh size (ξ) of the prepared hydrogels was determined by swelling studies, rheology 
and low field NMR spectroscopy. The in vitro release of fluorescein isothiocyanate 
labeled dextrans (FD) and bevacizumab was investigated. The average mesh size (ξavg) 
increased from 5.8 ± 0.1 nm to 56 ± 13 nm during degradation, as determined by swelling 
studies. The result of the rheological measurements (8.0 nm) matched the initial value of 
ξavg very well. Low field NMR spectroscopy enabled the determination of the mesh size 
distribution; the most abundant mesh size was found to be 9.2 nm. In combination with 
the hydrodynamic radius of the molecule (Rh), the time-dependent increase of ξavg was 
used to predict the release profiles of incorporated FDs applying an obstruction-scaling 
model. The predicted release profiles matched the experimentally determined release 
profiles when Rh < ξavg. However, significant deviations from the theoretical predictions 
were observed when Rh ≥ ξavg, most likely due to the statistical distribution of ξ in real 
polymer networks. The release profile of bevacizumab differed from those of equivalently 
sized FDs. The delayed release of bevacizumab was most likely a result of the globular 
structure and rigidity of the protein. The observed correlation between ξ and the release 
rate could facilitate the design of controlled release systems for antibodies. 
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 Introduction 
Controlled release technology has the potential to improve the safety and efficacy of 
antibody-based therapies. For example, controlled release systems can improve the local 
bioavailability of antibodies, maintain effective antibody concentrations over extended 
periods of time, lower the required antibody dose, and reduce systemic side effects [11]. 
Compared to other dosage forms, such as implants or microspheres, hydrogels may offer 
several advantages. For example, the high water content of hydrogels is extremely 
suitable to accommodate high loads of hydrophilic antibodies. Furthermore, hydrogels 
are capable of preserving the bioactivity of antibodies, since protein denaturing conditions 
(i.e., the use of organic solvents and/or high shear forces) are usually avoided during the 
fabrication process. The mobility of physically entrapped antibodies is limited by the 
polymer network; the hydrogel forms a reservoir from which the antibody is released in 
a controlled manner. Depending on the size of the incorporated antibody and the cross-
linking density of the hydrogel, the release will be controlled by diffusion, swelling, 
degradation, or a combination of these mechanisms [13,14]. 
An important parameter that characterizes the permeability of hydrogels is the mesh size 
or correlation length, ξ. The mesh size depends on the polymer concentration and is 
defined as “the average distance between consecutive cross-links” [197]; it indicates the 
maximum size of solutes that can pass through the gel network. Besides the diffusivity of 
solutes, the mesh size determines the mechanical strength and degradability of hydrogels. 
In combination with the size of the entrapped molecule, knowledge of ξ allows to estimate 
the rate of drug release from hydrogels. Based on Flory’s theory of rubber elasticity, 
information about the average mesh size of swollen, cross-linked hydrogels can be 
derived from the elastic modulus or the equilibrium polymer volume fraction [197,235]. 
While ideal networks are adequately described by the average mesh size, most real 
hydrogels are characterized by a broad range of mesh sizes that affect the release rate of 
entrapped drugs. The morphology and network density of hydrogels can be visualized by 
optical methods such as cryogenic transmission electron microscopy; however, care must 
be taken during sample preparation to avoid artifacts [236,237]. Other methods that allow 
the evaluation of the mesh size include confocal laser scanning microscopy [238,239], 
small angle neutron scattering [240,241], small-angle X-ray scattering [242], and pulsed 
field gradient NMR spectroscopy [243]. Moreover, the mesh size distribution can be 
determined by differential scanning calorimetry [244–246] and low field NMR 
spectroscopy [246,247]. 
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In this manuscript, we focus on the correlation between the mesh size of degradable, PEG 
based hydrogels and the release rate of macromolecules. In particular, we aim at 
establishing a theoretical framework that may facilitate the rational design of controlled 
release systems for antibodies. To this end, eight-armed PEG, molecular weight 10 kDa 
(8armPEG10k) was functionalized with furyl and maleimide groups, respectively; the 
obtained macromonomers were cross-linked via DA reaction. As previously reported, the 
hydrogels degraded under physiological conditions by rDA reaction and subsequent ring-
opening hydrolysis of the generated maleimide groups [212,248]. The mesh size of 
8armPEG10k-hydrogels was determined using swelling studies, rheology and low field 
NMR spectroscopy. The calculated values of ξ allowed us to estimate the release rate of 
fluorescein isothiocyanate-labeled dextran (FD); four different molecular masses (4 kDa, 
20 kDa, 150 kDa and 500 kDa) were studied. To verify the validity of the model, the 
predicted release profiles were compared to the results of in vitro release experiments. 
Finally, the hydrogels were loaded with bevacizumab, which served as a model 
compound. Bevacizumab is a monoclonal antibody that inhibits angiogenesis by 
neutralizing VEGF. It is approved for the treatment of various types of cancer; 
furthermore, it is used off label in the treatment of neovascular AMD [5,249]. Since the 
bioavailability of antibodies in the posterior segment of the eye is generally low, 
bevacizumab is administered every four to six weeks by intravitreal injection. However, 
these injections are associated with significant discomfort and rare but severe 
complications  [10]. To reduce the injection frequency and improve the compliance, the 
use of controlled release systems for bevacizumab seems obvious. Therefore, the in vitro 
release of bevacizumab from 8armPEG10k-hydrogels was studied and compared with the 
release profiles of dextran molecules of equivalent size. 
 Materials and methods 
5.2.1 Materials 
Eight-armed PEG (10 kDa molecular mass, hexaglycerol core) was purchased from 
JenKem Technology (Allen, TX, USA) and functionalized with furyl (8armPEG10k-
furan) and maleimide groups (8armPEG10k-maleimide) as previously described [212]. 
The degree of functionalization with furyl and maleimide groups was 67% and 68%,  
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respectively, as determined by 1H-NMR spectroscopy. Fluorescein isothiocyanate-
labeled dextrans with molecular masses of 4 kDa, 20 kDa, 150 kDa and 500 kDa (FD4, 
FD20, FD150 and FD500) were obtained from Sigma-Aldrich (Taufkirchen, Germany). 
Bevacizumab (Avastin®, 25 mg mL-1, Roche, Basel, Switzerland) was kindly provided 
by the hospital pharmacy, University of Regensburg, Germany. Ultrapure water was 
freshly prepared every day using a Milli-Q water purification system (Merck Millipore, 
Darmstadt, Germany). 
5.2.2 Swelling studies 
For the preparation of hydrogels, equal molar amounts of 8armPEG10k-furan (19.0 mg) 
and 8armPEG10k-maleimide (18.5 mg) were dissolved in 375 µL of water, cast into 
cylindrical glass molds (7 mm inner diameter), and allowed to gel over night at 37 °C. 
The gel cylinders were weighed in air and hexane using a density determination kit 
(Mettler-Toledo, Gießen, Germany), and the gel volume after cross-linking (Vgc) was 
calculated. The volume of the dry polymer (Vp) was calculated from the mass of the 
polymer in the hydrogel (mp) and the density of PEG (taken as 1.12 g mL-1) [250]. To 
study the swelling behavior, the gel cylinders were immersed in 10 mL of 50 mM 
phosphate buffer, pH 7.4 and incubated at 37 °C. The gel volume in the swollen state 
(Vgs) was determined at regular time points as described above. From these data, the 
polymer fraction of the gel after cross-linking, υ2c = Vp / Vgc, and after swelling, υ2s = 
Vp / Vgs, was calculated. The number of moles of elastically effective chains in the 
hydrogel network, νe, was calculated using the Peppas-Merrill equation, which is a 
modified form of the Flory–Rehner equation for highly swollen hydrogels cross-linked 
in solution [195,196]: 
(5.1) 
where V1 is the molar volume of the swelling agent (taken as 18 mL mol-1), and χ1 is the 
Flory-Huggins interaction parameter for PEG in water. The value of χ1 was found to be 
nearly independent of the polymer fraction (𝜐𝜐2 ranging from 0.04 to 0.2); therefore, the 
average value (0.43) was used in all calculations [251]. The branching factor of the 
macromonomers, f, was taken as 8, assuming 100% functionalization with furyl and 
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maleimide groups, respectively 100% reaction during cross-linking The average mesh 
size (ξavg) was then calculated according to eqn. (5.2) [197]: 
(5.2) 
where l is the average bond length along the PEG backbone (taken as 
0.146 nm) [198,251], Mr is the molecular mass of the PEG repeating unit (taken as 
44 g mol-1), and Cn is the Flory characteristic ratio (taken as 4 for PEG) [198,251]. 
5.2.3 Rheological characterization 
Oscillatory shear experiments were performed on a TA Instruments AR 2000 rheometer 
(TA Instruments, Eschborn, Germany) with parallel plate geometry (40 mm diameter). 
For the measurements, equal molar amounts of 8armPEG10k-furan (38.0 mg) and 
8armPEG10k-maleimide (37.0 mg) were dissolved in 750 µL of water, and cast onto the 
lower plate of the rheometer. The upper plate was immediately lowered to a gap size of 
500 µm, and the sample was allowed to gel over night at 37 °C. A solvent trap was used 
to minimize the evaporation of water. After full gelation, a stress sweep experiment was 
run at 1 Hz oscillatory frequency to determine the linear viscoelastic region of the sample. 
Afterwards, a frequency sweep experiment was run at 1000 µNm torque (equivalent to a 
stress of 79.5 Pa and within the linear viscoelastic region, see results and discussion) 
following the same procedure. 
5.2.4 Low field NMR measurements 
Equal molar amounts of 8armPEG10k-furan (51.0 mg) and 8armPEG-maleimide 
(49.0 mg) were dissolved in 1000 µL of water and transferred into an NMR tube. Low 
field NMR measurements were performed at 37 °C using a Bruker Minispec mq20 
(Bruker Italy, Milan, Italy). A Carr-Purcell-Meiboom-Gill pulse sequence with a 90°–
180° pulse separation time of 0.25 ms was used to measure the transverse relaxation time, 
T2 (4 scans, 5 s delay). To determine the discrete distribution of T2, the signal intensity, 
Is, related to the decay of the transverse component of the magnetization vector was fitted 
by: 
(5.3) 
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where t is the time, Ai are the dimensionless pre-exponential factors proportional to the 
number of protons with the relaxation time T2i, and ⟨1/T2⟩ is the average value of the 
inverse relaxation time. Based on a statistical procedure, m was determined by 
minimizing the product χ2 · 2m, where χ2 is the sum of the squared errors and 2m 
represents the number of fitting parameters of eqn. (5.3). The determined T2i value 
represents the transverse relaxation time of protons of water molecules entrapped in 
polymer meshes of size ξi. To evaluate the mesh size distribution, the continuous 
distribution of T2 was considered. To this end, although another approach can be 
followed [252,253], eqn. (5.4) was fitted to the decay of the signal (Is): 
(5.4) 
where a(T2) is the unknown amplitude of the spectral component at relaxation time T2, 
e–t/T2 represents the decay term, and T2min – T2max indicates the range of the T2 distribution 
(here T2min = 40 ms, T2max = 4000 ms and N = 200). The initial values of all unknowns (Ai) 
were set to zero and a constrained fitting was performed imposing that Ai ≥ 0 (negative 
values would be physically meaningless). The fitting parameters, Ai and 
ai = Ai / (T2i+1 – T2i), were determined by minimizing the smoothed sum of the squared 
error (χs2): 
(5.5) 
where σi is the standard deviation of the noise, and μ is the weight of smoothing 
term [254,255]. The optimal value of μ was determined as described by Wang and Ni 
(here μ = 200)  [255]. The average value of the inverse relaxation time, ⟨1/T2⟩, was then 
calculated by eqn. (5.6): 
(5.6) 
To study the mobility of water molecules inside the gel network, pulsed gradient spin-
echo (PGSE) measurements were performed at 37 °C. A Carr-Purcell-Meiboom-Gill 
sequence with two equal gradient pulses (δ = 1 ms) occurring at x1 = 1 ms and x2 = 1 ms 
after the 90° and 180° pulses, respectively, was applied. The interval between the gradient 
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pulses, indicated by Δ (≈ τ – x1 – δ + x2), is related to the diffusion time of the water 
molecules (td) according to td ≈ Δ – δ / 3. The self-diffusion coefficient of the water 
molecules was determined by fitting eqn. (5.7) to the experimental data: 
(5.7) 
where At and A0 are the measured amplitudes of the echo with and without the gradient 
applied, γ is the gyromagnetic ratio of the protons, g is the known magnetic field gradient, 
and A0i are the fractions of water molecules characterized by a self-diffusion coefficient 
Di. In case of homogenous systems, the summation is limited to the first term (p = 1), as 
all water molecules are characterized by the same self-diffusion coefficient. In case of 
heterogeneous systems, however, p > 1 occurs. In this case, p was determined by 
minimizing the product χ2 · 2p, where χ2 is the sum of the squared errors and 2p represents 
the number of fitting parameters (A0i and Di) of eqn. (5.7). 
5.2.5 In vitro release of fluorescein isothiocyanate-labeled dextran 
Hydrogels were loaded with fluorescein isothiocyanate-labeled dextran (FD); different 
molecular masses (4 kDa, 20 kDa, 150 kDa and 500 kDa) were investigated. For the 
preparation of hydrogels, equal molar amounts of 8armPEG10k-furan (61.0 mg) and 
8armPEG10k-maleimide (59.0 mg) were dissolved in 1080 µL of water; 120 µL of an FD 
stock solution (c = 10 mg mL-1) were added. Directly after mixing, 375 µL of the 
prepared solution were cast into cylindrical glass molds (7 mm inner diameter) and 
allowed to gel over night at 37 °C. The gel cylinders were carefully removed from the 
glass molds, immersed in 5 mL of 50 mM phosphate buffer, pH 7.4, and incubated at 
37 °C in a shaking water bath. Samples of 1000 µL were withdrawn at regular time points 
and replaced with fresh buffer. The samples were stored at 4 °C until completion of the 
release experiment. The amount of released FD (λex = 485 nm and λem = 510 nm) was 
determined on a fluorescence microplate reader (BMG LABTECH, Ortenberg, Germany) 
using standard calibration curves. 
5.2.6 In vitro release of bevacizumab 
For the preparation of bevacizumab-loaded hydrogels, equal molar amounts of 
8armPEG10k-furan (38.0 mg) and 8armPEG10k-maleimide (37.0 mg) were dissolved in 
600 µL of water; 150 µL of a bevacizumab stock solution (c = 25 mg mL-1) were added. 
5.3 Results and discussion 
79 
Directly after mixing, 250 µL of the prepared solution were cast into cylindrical glass 
molds (7 mm inner diameter) and allowed to gel over night at 37 °C. The gel cylinders 
were carefully removed from the glass molds, covered with 5 mL of 50 mM phosphate 
buffer, pH 7.4, and incubated at 37 °C in a shaking water bath. Samples of 300 µL were 
withdrawn at regular rime points and replaced with fresh buffer. The samples were stored 
at 4 °C until completion of the release experiment. The amount of released bevacizumab 
(λex = 280 nm and λem = 335 nm) was determined on a PerkinElmer LS 55 Fluorescence 
spectrometer (Perkin Elmer, Wiesbaden, Germany) using a standard calibration curve. 
 Results and discussion 
5.3.1 Determination of the network mesh size 
In order to determine the time-curve of ξavg, DA hydrogels consisting of 10% (w/v) 
8armPEG10k were incubated in 50 mM phosphate buffer, pH 7.4 at 37 °C. The 
volumetric swelling ratio, Q = Vgs / Vp, was determined at regular time points until 
complete degradation of the hydrogel (Figure 5.1A); ξavg was calculated according to 
eqn. (5.1) and (5.2), and the results are shown in Figure 5.1B. 
Figure 5.1. Volumetric swelling ratio (A) and average mesh size (B) of 10% (w/v) 8armPEG10k hydrogels 
in 50 mM phosphate buffer, pH 7.4 at 37 °C. The high standard deviations of the last two data points 
indicate the beginning dissolution of the hydrogel. To describe the increase of Q and ξ over time, 
exponential equations were fitted to the experimental data by minimizing the sum of the squared errors. 
Data is expressed as mean ± standard deviation based on the results of n = 3 samples. The error bars are 
smaller than the symbols, except for the last two data points. 
5.3
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After 1 day of swelling, an initial ξavg value of 5.8 ± 0.1 nm was determined. During 
degradation, the number of elastically effective chains in the gel network is decreasing; 
as a consequence, both Q and ξavg were increasing during the incubation period. The high 
standard deviations of the last two data points indicate the beginning dissolution of the 
hydrogel; the maximum ξavg value (56 ± 13 nm) was determined at day 35. Since the 
swelling of DA hydrogels was observed to increase exponentially during the first 30 days, 
Q can be described by the exponential function: 
(5.8) 
where Q0 is the initial volumetric swelling ratio (here Q0 = 11), and kQ is the rate constant 
of the process (here kQ = 0.040 d-1). In the same way, ξavg can be described during the first 
30 days by the exponential function: 
(5.9) 
where ξ0 is the average mesh size at time t = 0 (here ξ0 = 5.7 nm), and kξ is the rate 
constant of the process (here kξ = 0.054 d-1). Thus, Q and ξavg can be predicted throughout 
the degradation time. 
Rheological experiments were performed to validate the result of the swelling studies. 
The stress sweep shown in Figure 5.2A indicates a broad linear viscoelastic region of 
10% (w/v) 8armPEG10k-hydrogels. 
Figure 5.2.* (A) Absolute value of the complex shear modulus vs. oscillatory stress for 10% (w/v) 
8armPEG10k hydrogels. (B) Storage and loss modulus vs. oscillatory frequency for 10% (w/v) 
8armPEG10k hydrogels. The filled and open symbols represent G’ and G”, respectively; The solid line 
represents the best fit of eqn. (5.10) and (5.11) to the experimental data. The result of the frequency sweep 
represents the mean of n = 3 samples.  
* Data of Figure 5.2 B were fitted by by M. Abrami, Department of Life Sciences, University of Trieste
and M. Grassi, Department of Engineering and Architecture, University of Trieste
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The absolute value of the complex shear modulus (|G*|) was independent from the applied 
oscillatory stress (σ) between 1 Pa and 200 Pa. The subsequent frequency sweep 
experiments (σ = 79.5 Pa) were run within the linear viscoelastic region of the hydrogels. 
As shown in Figure 5.2B, 10% (w/v) 8armPEG10k-hydrogels are strong, fully elastic 
hydrogels. The storage modulus (G’), which represents the elastic portion of the hydrogel, 
was two orders of magnitude higher that the loss modulus (G”), which represents the 
viscous portion of the hydrogel. Moreover, both G’ and G” were virtually independent 
from the angular frequency (ω), which is characteristic for covalently cross-linked, 
permanent hydrogels. To determine ξavg, the generalized Maxwell model was fitted to the 
experimental data of G’ and G” [246,247]: 
(5.10) 
(5.11) 
where n is the number of considered Maxwell elements; Gi, ηi and λi represent the spring 
constant, the viscosity of the dashpot component and the relaxation time of the ith 
Maxwell element, respectively, while Ge is the spring constant of the last Maxwell 
element, which is supposed to be purely elastic. The simultaneous fitting of eqn. (5.10) 
and (5.11) to the experimental data of G’ and G” was performed assuming that the 
relaxation times (λi) are scaled by a factor of 10. Hence, the parameters of the model are 
Gi, Ge and λi. Based on a statistical procedure, n was selected in order to minimize the 
product χ2 · (n + 2), where χ2 is the sum of the squared errors. In this way, the shear 
modulus (G) can be calculated from the sum of all elastic contributions by G = Ge + ΣGi. 
According to Flory’s theory of rubber elasticity, the cross-link density (defined as the 
number of moles of cross-links per volume), ρx, can be calculated from G: 
(5.12) 
where R is the universal gas constant, and T is the temperature. The “equivalent network” 
approach allows calculating ξavg according to eqn. (5.13) [256]: 
(5.13) 
where NA is the Avogadro constant, and 1 / (ρx · NA) is the spherical volume competing 
with each cross-link. In the case of 10% (w/v) 8armPEG10k-hydrogels, n = 4 Maxwell 
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elements were necessary to describe the mechanical spectrum. On the basis of eqn. (5.10) 
through (5.12), the values of λ1 (0.03 s), G (15,988 Pa) and ρx (6.21·10-6 mol cm-3) were 
calculated. Using eqn. (5.13), a ξavg value of 7.99 nm was calculated, which is in good 
agreement with the value derived from swelling studies.  
To estimate the statistical distribution of ξ, low field NMR measurements were 
performed. The transverse relaxation time (T2) of the water protons was measured over 
24 h, starting from the time point of gel preparation; however, no significant changes in 
T2 were recorded. Thus, it is conceivable that a physical gel is formed initially, which is 
then reinforced by chemical cross-links. The discrete distribution of T2 was determined 
by fitting eqn. (5.3) to the relaxation data. Two different relaxation times were identified, 
with T21 being the longest and most abundant one, and T22 being the shortest and least 
abundant one. The determined T2i values and their relative weights, Ai, are reported in 
Table 5.1. 
Table 5.1.* Transverse relaxation times (T2i) of protons of water molecules entrapped in polymer meshes 
of size ξi; Ai represent the relative weights of T2i and ξi, respectively. The reported T2i values represent the 
average of all measurements performed during 24 h.  
i = 1 i = 2 
T2i (ms) 2567.6 ± 95.6 603.1 ± 109.3 
Ai (%)a 90.8 ± 1.6 9.2 ± 1.6 
ξi (nm) 11.1 ± 2.1 1.0 ± 0.3 
a Calculated by A1% = A1·100% / (A1 + A2) and A2% = A2·100% / (A1 + A2) 
* Data were obtained and analyzed by M. Abrami, Department of Life Sciences, University of Trieste and
M. Grassi, Department of Engineering and Architecture, University of Trieste.
Since the transverse relaxation time of protons of water molecules near the surface of 
polymer chains is shorter than the transverse relaxation time of protons of bulk water, 
T2H2O, ξi can be estimated from T2i [257,258]. The mesh size of an ideal network, ξideal, 
can be calculated on the basis of the Scherer theory by eqn. (5.14) [259,260]: 
(5.14) 
where φ is the polymer volume fraction of the hydrogel (taken as 0.082), and Rf is the 
radius of the polymer chain (taken as 0.51 nm) [261]. According to the “fiber cell” theory, 
the average of the inverse relaxation time of the water protons entrapped within the 
polymer network, ⟨1/T2⟩, is given by eqn. (5.15) [258]: 
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(5.15) 
where ⟨ℳ ⟩ (length / time) is an empirical parameter (relaxation sink strength) 
accounting for the effect of the polymer chain surface on proton relaxation. As ⟨1/T2⟩, 
T2H2O and ξideal are known, eqn. (5.15) allows the determination of ⟨ℳ ⟩. Furthermore, by 
knowing T2i and ⟨ℳ ⟩, ξi can be calculated for each class of network meshes by 
eqn. (5.16): 
(5.16) 
Using this strategy, the ξi values of 10% (w/v) 8armPEG10k-hydrogels were estimated. 
The value of ξ1, which represents about 91% of all network meshes, was found to be 
11.1 ± 2.1 nm; the value of ξ2, which represents the remaining 9% of all network meshes, 
was 1.0 ± 0.3 nm (Table 5.1). The weighted average mesh size, ξavg = 100% / (A1% / 
ξ1 + A2% / ξ2), was calculated to be 5.4 nm, which is close to the value derived from the 
swelling experiments (5.8 nm, Table 5.2). 
Table 5.2. Mesh size of 10% (w/v) 8armPEG10k hydrogels as determined by swelling studies, rheological 
experiments and low field NMR measurements. 
Type of mesh size Method Determined value 
Average size (ξavg) Swelling studies 5.8 ± 0.1 nmb 
Average size (ξavg)* Rheological experiments 8.0 nm 
Most abundant size (ξ1)* Low field NMR (discrete) 11.1 ± 2.1 nm 
Least abundant size (ξ2)* Low field NMR (discrete) 1.0 ± 0.3 nm 
Average size (ξavg)* Low field NMR (discrete) 5.4 nmc 
Most abundant size (ξ)* Low field NMR (continuous) 9.2 nm 
b Determined after 24 h of swelling 
c Calculated by ξavg = 100% / (A1% / ξ1 + A2% / ξ2) 
* Data were obtained by M. Abrami, Department of Life Sciences, University of Trieste and M. Grassi,
Department of Engineering and Architecture, University of Trieste.
To evaluate the continuous distribution of the mesh size, the relaxation time distribution, 
a (T2), was determined by fitting eqn. (5.4) to the relaxation data. The result reveals the 
presence of two peaks occurring at relaxation times similar to T21 and T22, respectively 
(Figure 5.3A). 
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Figure 5.3.* (A) Signal intensity, related to the decay of the transverse component of the magnetization 
vector, vs. time. The open symbols represent the relaxation data, and the dashed line represents the best fit 
of eqn. (5.4). The solid line represents the continuous distribution of the relaxation time, a (T2). (B) 
Continuous distribution of the mesh size, A (ξ), of 10% (w/v) 8armPEG10k hydrogels. The results represent 
the average of all measurements performed during 24 h.  
* Data were obtained and analyzed by M. Abrami, Department of Life Sciences, University of Trieste and
M. Grassi, Department of Engineering and Architecture, University of Trieste.
Once a (T2) or A (T2) are known, ⟨ℳ ⟩ can be derived from eqn (5.14) and (5.15), with 
the only difference that ⟨1/T2⟩ is calculated according to eqn. (5.6). Using eqn. (5.16), 
A (T2) is converted into the mesh size distribution, A (ξ), where Ai (ξ) = Ai (T2). To allow 
the comparison of mesh size distributions of different systems, Ai is normalized according 
to: 
(5.17) 
As shown in Figure 5.3B, A (ξ) spanned over three orders of magnitude; meshes as large 
as 300 nm were observed, even if this probability, Ai, is very low. Two distinct peaks were 
identified: a small peak at around 1 nm and a larger one at around 10 nm. Interestingly, the 
proportion between the two peaks matched the result found in the discrete approach (about 
9% smaller meshes and 91% larger meshes, Table 5.1); however, the continuous 
distribution provided more information than the discrete one. The most abundant mesh size 
(Ai = 5.2%) was found to be 9.2 nm, which is in good agreement with the values derived 
from the discrete approach (11.1 ± 2.1 nm, Table 5.2). These conclusions are supported by 
the measurements of the water self-diffusion coefficient. PGSE studies revealed that two 
exponential terms in eqn. (5.7) are required to properly describe the experimentally 
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Figure 5.4.* (A) High (D1) and low (D2) self-diffusion coefficients of water molecules versus the square 
root of the diffusion time, td. The self-diffusion coefficient of free water at 37 °C is 3.04·10-9 m2 s-1 [262]. 
(B) A1% and A2% represent the relative abundance of the fast and slow diffusing species, respectively.
* Data were obtained and analyzed by M. Abrami, Department of Life Sciences, University of Trieste and
M. Grassi, Department of Engineering and Architecture, University of Trieste.
determined ratio of At / A0 to q2 for every td considered (7.6 ms < td < 44 ms). Figure 5.4 
shows the existence of two species of water molecules with different mobility. The fastest 
species is characterized by a self-diffusion coefficient of D1 ≈ 2.7·10-9 m2 s-1, which is close 
to the self-diffusion coefficient of free water at 37 °C (3.04·10-9 m2 s-1) [262], and represents 
about 94% of all water molecules. The slowest species is characterized by a self-diffusion 
coefficient of D2 ≈ 5.4·10-10 m2 s-1 and represents the remaining 6% of water molecules. 
While D1 is connected to the existence of wide network meshes (with respect to the size of 
the water molecule), D2 is most likely due to the presence of narrow meshes that 
significantly hinder the diffusion of water molecules. Interestingly, these findings match 
the results of the T2 measurements (about 91% larger meshes and 9% smaller meshes, 
Table 5.1). Moreover, it is worth mentioning that, as D1 and D2 are essentially independent 
from td, both wide and narrow meshes are interconnected [263]. In conclusion, all three 
methods (i.e., swelling studies, rheological experiments and NMR spectroscopy) give 
similar estimates of ξavg. Low field NMR measurements might be the preferred method 
when the mesh size distribution is important; on the other hand, swelling studied might be 
most appropriate to determine the mesh size during degradation or drug release. 
Chapter 5 
86 
5.3.2 In vitro release of fluorescein isothiocyanate labeled dextran 
To correlate the determined mesh sizes with release profiles, the in vitro release of 
macromolecules from DA hydrogels was investigated. FD was used as model 
compounds; four different molecular masses (4 kDa, 20 kDa, 150 kDa and 500 kDa) were 
studied. The hydrodynamic radius (Rh) of FDs can be estimated according to 
eqn. (5.18) [264]: 
(5.18) 
where Mr is the relative molecular mass of the FD. The hydrodynamic radii and the 
diffusion coefficients in water (D0), calculated from the Stokes-Einstein equation: 
(5.19) 
are listed in Table 5.3. In eqn. (5.19), k is the Boltzmann constant, T is the temperature 
(310.16 K), and η is the viscosity of water (0.69 mPa s). 
Table 5.3: Relative molecular mass (Mr), hydrodynamic radius (Rh) and diffusion coefficient in water (D0) 
of the studied fluorescein isothiocyanate-labeled dextrans (FDs). The values of Rh were estimated 
according to eqn. (5.18); the values of D0 were calculated from eqn. (5.19). 
Mr (Da) Rh (nm) D0 (cm2 s-1) 
FD4 4,000 1.8 1.80·10-6 
FD20 20,000 3.7 8.90·10-7 
FD150 150,000 8.9 3.69·10-7 
FD500 500,000 15.1 2.18·10-7 
The mobility of solutes in homogenous hydrogels can be described by the obstruction-
scaling model developed by Amsden [265]: 
(5.20) 
where Dg is the diffusion coefficient of the solute in the hydrogel. Based on the results of 
the performed swelling studies and eqn. (5.9), eqn. (5.20) can be used to estimate the 
mobility of FDs within DA hydrogels during the release period (Figure 5.5A). 
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Figure 5.5. (A) Diffusion quotients (Dg/D0) of fluorescein isothiocyanate-labeled dextrans (FDs) vs. time. 
The values of Dg/D0 were calculated from eqn. (5.20). (B) Predicted release of FDs from 10% (w/v) 
8armPEG10k hydrogels. The predictions are based on eqn. (5.21). 
Since Rh is much smaller than ξavg, the diffusivity of FD4 should be high in the non-swollen 
(t = 0) and swollen state (t > 0). The mobility of FD20 should be restricted in the beginning; 
however, the diffusivity of entrapped FD20 should increase with increasing degree of 
swelling. In contrast to this, the Rh values of FD150 and FD500 are much greater than the 
initial ξavg value. Thus, both dextrans will not be free to move through the hydrogel network 
in a spherical conformation. Eqn. (5.20) predicts an extremely low diffusivity at low 
degrees of swelling; however, the diffusivity of FD150 and FD500 should increase during 
swelling once a critical ξavg value is exceeded. Since the Dg values can be calculated from 
eqn. (5.19) and (5.20), the release of entrapped FDs from hydrogel cylinders can be 
described according to eqn. (5.21) [266]: 
(5.21) 
where Mt and M∞ represent the absolute cumulative amounts of FD released at time t and 
infinity, respectively; qn are the roots of the Bessel function of the first kind of zero order, 
and r and h denote the radius and height of the gel cylinder. The increase in r and h due 
to swelling is taken into account, and the predicted release profiles are shown in 
Figure 5.5B. As it is expected from the Dg values, the release of FD4 and FD20 from DA 
hydrogels should be extremely fast; the release should be completed after 1 day and 2 days, 
respectively. Compared to FD4 or FD20, the release of FD150 should be considerably 
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 slower; the maximum release should be reached after 15 days. In contrast to this, a 
sigmoidal release profile is predicted for FD500. Since the mobility of FD500 is 
extremely low during the first 10 days of release, eqn. (5.21) predicts a lag time of 
approximately 5 days; the release of FD500 should be completed after 25 days. To verify 
the validity of our model, the release of FDs from DA hydrogels was experimentally 
determined (Figure 5.6). 
Figure 5.6. Release of fluorescein isothiocyanate-labeled dextrans (FDs) from 10% (w/v) 8armPEG10k 
hydrogels. The symbols represent the experimental data, and the solid lines represent the predictions based 
on eqn. (5.21). The theoretical predictions match the release profiles of FD4 (A) and FD20 (B) very well; 
however, significant differences between the theoretical predictions and the experimental data are observed 
for FD150 (C) and FD500 (D). Data is expressed as mean ± standard deviation based on the results of n = 3 
samples. 
The release of FD4 from DA hydrogels was extremely fast; the incorporated dextran was 
completely released after 2 days (Figure 5.6A). In comparison to FD4, the release of FD20 
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was slightly slower; the maximum release was reached after 5 days (Figure 5.6B). The 
release of FD150 from DA hydrogels was considerably slower than the release of FD4 or 
FD20; 90% of the incorporated dextran was released after 30 days (Figure 5.6C). In 
contrast to FD4, FD20 and FD150, the release profile of FD500 had a sigmoidal shape. 
Approximately 10% of the incorporated FD500 was released during the first day; this was 
followed by a phase of slow release, with approximately 30% of the incorporated dextran 
being release at day 15. Following this, the release rate considerably increased; 90% of 
the incorporated FD500 was released after 30 days (Figure 5.6D). The theoretical 
predictions for the release behavior are shown by the lines in Figure 5.6. In case of FD4 
and FD20, the predicted release profiles match the experimentally determined release 
profiles very well. However, marked differences between the theoretical predictions and 
the experimental data are observed for FD150 and FD500. On the one hand, the developed 
model underestimates the initial “burst” release; on the other hand, it overestimates the 
release rate in the terminal phase of release. These deviations are explained by the 
statistical distribution of ξ in real polymer networks. As shown in Figure 5.3B, A (ξ) spans 
over three decades (from 0.3 nm to 300 nm), while eqn. (5.20) only considers ξavg (5.8 nm 
at t = 0). This simplification may be acceptable when Rh is smaller than ξavg and the 
dextran is free to diffuse throughout the gel network; however, deviations from the 
experimental results occur when Rh is similar to or greater than ξavg. The existence of 
larger meshes (ξ > Rh) can explain the initial “burst” release, while the continued 
existence of smaller meshes (ξ < Rh) may delay the terminal phase of release. 
Furthermore, the values of Rh were estimated from the average molecular mass of the 
FDs, assuming that these molecules were monodisperse. In fact, however, FDs are 
polydisperse, which may also contribute to the observed deviations. In addition, eqn. 
(5.20) assumes that the solutes behave as hard spheres; however, dextran is flexible 
polymer of D-glucopyranose that behaves like a random coil. [264]. When Rh is similar 
to ξ, the dextran may get “trapped” in the larger meshes, where the molecule can extend 
and maximize its conformational entropy (“entropic trapping”) [267]. On the other hand, 
when Rh is greater than ξ, the dextran can migrate through the network in a wormlike fashion 
(“reptation”) [268]. However, both entropic trapping and reptation are not considered by 
eqn. (5.20). And last but not least, it is possible that cross-linking in the presence of 
FD150 or FD500 affects ξavg, given the large Rh of these molecules. The FD molecules 
could be physically entangled with the PEG molecules before cross-linking, which would 
influence the mesh size distribution. 
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5.3.3 In vitro release of bevacizumab 
In the final experiment, the release profiles of bevacizumab and FD were compared. With 
an hydrodynamic radius of 6.5 nm [269], the release of bevacizumab from 10% (w/v) 
8armPEG10k-hydrogels should be comparatively fast; the release profile of bevacizumab 
should fall between those of FD20 (Rh = 3.7 nm) and FD150 (Rh = 8.9 nm). However, the 
experimentally determined release profile differed significantly from those of FD20 and 
FD150. As shown in Figure 5.7, a sigmoidal release profile was observed for 
bevacizumab. 
Approximately 10% of the incorporated bevacizumab was released after 24 h; this is 
attributed to non-entrapped protein molecules located at the surface of the gel cylinders. 
No bevacizumab release occurred during the following 16 days, indicating that the 
protein molecules were entrapped within the hydrogel meshes. However, since ξ is 
increasing during the degradation process, the incorporated bevacizumab was completely 
released between day 17 and 22 after a critical ξ value had been exceeded. No further 
release was observed after day 22. 
The discrepancy in the release profiles can be explained by the different molecular 
configuration (i.e., size, charge, shape and deformability) of proteins and dextran 
molecules. Dextran is a linear, rather flexible polymer of D-glucopyranose; proteins, on 
the other hand, are globular, rather rigid molecules. As a consequence, dextran molecules 
are able to pass through pores smaller than the molecule itself. For example, it has been 
shown that the glomerular sieving coefficient of dextran is approximately sevenfold 
higher than that of a globular protein of equivalent size [264]. Thus, the delayed release 
of bevacizumab is the result of the globular structure and rigidity of the protein. 
Furthermore, it has been shown that 20–30% of the incorporated protein is immobilized 
Figure 5.7. Release of bevacizumab 
from 10% (w/v) 8armPEG10k 
hydrogels. The amount of drug loading 
was 1.25 mg of bevacizumab per 
hydrogel. Data is expressed as mean ± 
standard deviation of n = 3 samples. 
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within the hydrogel by Michael-type addition reaction to 8armPEG10k-maleimide [17]. 
This portion of the protein is not released until the hydrogel dissolves. Depending on the 
number of PEG molecules remaining attached, the antigen binding activity of these 
PEGylated antibodies can be slightly decreased or completely lost [270]. 
Although most controlled release systems for proteins are designed to provide sustained 
release, the delayed release of bevacizumab from DA hydrogels could prove to be 
beneficial for the treatment of AMD. There is increasing evidence that chronic blocking 
of VEGF signaling might have detrimental long-term effects such as the development of 
geographic atrophy, which is accompanied by a massive loss of photo-
receptors [133,134,271]. For that reason, the treatment with VEGF inhibiting antibodies 
should be intermittent to allow the damaged choriocappilaris to recover during drug-free 
intervals. DA hydrogels could provide such intermittent drug release. The first dose 
would be administered together with the hydrogel, while the second dose would be 
released from the gel four to six weeks after injection. 
 Conclusion 
Hydrogels were prepared by cross-linking 8armPEG10k-furan and 8armPEG10k-
maleimide via DA reaction. The mesh size of the formed hydrogels was determined using 
swelling studies, rheology and low field NMR spectroscopy. The in vitro release of 
incorporated FDs and bevacizumab was investigated. In principle, all three methods (i.e., 
swelling studies, rheology and NMR spectroscopy) give similar estimates of ξavg; 
however, low field NMR measurements are the preferred method when the mesh size 
distribution is important. On the other hand, swelling studies are most appropriate to 
determine the time-dependent increase of ξavg during hydrogel degradation or drug 
release. Combined with the hydrodynamic radius of the drug molecule, the determined 
values of ξavg can be used to predict drug release over time. When Rh is smaller than ξavg, 
the predicted release profiles match the experimentally determined release profiles very 
well. However, deviations from the theoretical predictions are observed when Rh is 
similar to or greater than ξavg. These deviations are most likely due to the statistical 
distribution of ξ in real polymer networks. Nevertheless, the model correctly predicts the 
expected sigmoidal shape of the release profile. Furthermore, the structure and rigidity of 
the drug molecule must be taken into account. In contrast to globular proteins (e.g., 
bevacizumab), FDs are able to pass through pores smaller than the molecule itself in a 
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wormlike fashion (“reptation”). Altogether, we believe that the established correlation 
between ξ and the release rate may facilitate a more rational design of controlled release 
systems for antibodies. In the future, the model could be further refined by evaluating the 
mesh size distribution, A (ξ), instead of ξavg.  
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Abstract 
Eight-armed PEG was functionalized with furyl and maleimide groups (8armPEG20k-
Fur and 8armPEG20k-Mal); degradable hydrogels were obtained by cross-linking via DA 
chemistry. To increase the stability to degradation, the macromonomers were modified 
by introducing a hydrophobic Ahx spacer between PEG and the reactive end-groups 
(8armPEG20k-Ahx-Fur and 8armPEG20k-Ahx-Mal). In an alternative approach, the 
number of reactive groups per macromonomer was increased by branching the terminal 
ends of eight-armed PEG with Lys and Ahx residues (8armPEG20k-Lys-Ahx-Fur2 and 
8armPEG20k-Lys-Ahx-Mal2). The hydrolytic resistance of the synthesized 
macromonomers was determined by UV spectroscopy; the obtained hydrogels were 
characterized by rheology and degradation studies. The degradation time of 5% (w/v) 
8armPEG20k-Ahx-hydrogels (28 days) was twice as long as the degradation time of 
5% (w/v) 8armPEG20k-hydrogels (14 days); this is explained by increased hydrolytic 
resistance of the maleimide group. Using dendritic 8armPEG20k-Lys-Ahx-
macromonomers substantially increased the stability of the resulting hydrogels; 
degradation of 5% (w/v) 8armPEG20k-Lys-Ahx-hydrogels occurred after 34 weeks. 
8armPEG20k-hydrogels had the largest mesh size of all tested hydrogels, while hydrogels 
made from dendritic 8armPEG20k-Lys-Ahx-macromonomers had the smallest value. To 
evaluate their potential for the controlled release of therapeutic antibodies, the hydrogels 
were loaded with bevacizumab. The incorporated bevacizumab was released over 10 days 
(8armPEG20k) and 42 days (8armPEG20k-Ahx), respectively; release from 
8armPEG20k-Lys-Ahx-hydrogels was not completed after 105 days. In summary, we 
believe that 8armPEG20k-Ahx- or 8armPEG20k-Lys-Ahx-hydrogels could serve as 
controlled release system for therapeutic antibodies such as bevacizumab.
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 Introduction 
The development of monoclonal antibodies and antibody fragments against VEGF, such 
as bevacizumab and ranibizumab, represents a milestone in the treatment of AMD and 
other vision-threatening diseases [5,9]. While antibodies have several desirable 
characteristics, such as high selectivity and specificity, achieving effective concentrations 
at the target tissue can be challenging. The bioavailability of systemically or topically 
administered antibodies in the posterior segment of the eye is generally low; the ocular 
half-life of antibodies is about 7 to 10 days [11]. To increase the local bioavailability of 
antibodies and minimize undesired side effects, most anti-VEGF drugs are, therefore, 
administered every 4 to 6 weeks by intravitreal injection. However, these injections are 
associated with significant discomfort and rare but severe complications including 
endophthalmitis, retinal detachment and cataract [10]. Using controlled release systems 
that prolong the dosing intervals of antibodies may help to improve the patient compliance 
and reduce the treatment costs.  
Compared to other controlled release systems that have been developed for the posterior 
segment of the eye, such as implants or microspheres, hydrogels may offer several 
advantages [13,14]. For example, they are deemed biocompatible and capable of 
preserving the bioactivity of hydrophilic biomolecules. Hydrogels can, furthermore, 
accommodate high loads of antibodies through in situ encapsulation, a method in which 
drug loading and cross-linking are carried out simultaneously. The mobility of 
incorporated antibodies is limited by the polymer network; the hydrogel matrix forms a 
reservoir from which the antibody is slowly released. Depending on the size of the protein 
and the average mesh size (ξ) of the hydrogel, the release is controlled by diffusion, 
swelling, degradation, or a combination of these mechanisms. Finally, in situ forming 
hydrogels can be administered by minimally invasive techniques; these hydrogels are 
injected in liquid form and turn into a viscoelastic drug depot at the site of application. 
This requires cross-linking reactions that are both effective and non-toxic in vivo. 
Recently, we described the synthesis of in situ forming, biodegradable hydrogels for the 
controlled release of proteins [212,248]. Eight-armed PEG was functionalized with furyl 
and maleimide groups (e.g., 8armPEG20k-Fur and 8armPEG20k-Mal), respectively; the 
obtained macromonomers were cross-linked via DA chemistry (Scheme 1). The DA 
reaction proceeds in water without any metal catalyst or initiator. This is an advantage 
over existing controlled release systems for bevacizumab, which are cross-linked by free 
radical polymerization [135–137]. The reported ξ values would allow the controlled 
6.1
Chapter 6 
96 
release of antibodies; however, the relatively fast degradation within 2 to 9 weeks might 
limit potential applications of DA hydrogels [212]. To effectively prolong the dosing 
intervals of VEGF-neutralizing antibodies, which are typically administered every 4 to 
6 weeks, the hydrogel should be stable for at least 8 to 12 weeks. 
Scheme 6.1. Cross-linking of 8armPEG20k-Fur and 8armPEG20k-Mal via DA reaction. The 
macromonomers were synthesized from eight-armed PEG, molecular mass 20,000 kDa. 
Herein, we report on our efforts to increase the stability of DA hydrogels. Since the 
degradation rate of DA hydrogels is related to the rate of ring-opening hydrolysis of 
maleimide [248], we aimed at generating hydrogels with increased stability to 
degradation by improving the hydrolytic stability of the maleimide group. According to 
the available literature, this can be achieved by introducing a hydrophobic Ahx spacer 
between PEG and the maleimide end-group [224,272–274]. Moreover, it has been shown 
that the degradation rate of DA hydrogels depends on the number of reactive groups per 
macromonomer [212]. To further increase the stability of DA hydrogels we, therefore, 
synthesized macromonomers with an increased number of reactive groups by branching 
the terminal ends of star-shaped PEG with Lys and Ahx residues. These dendritic 
macromonomers should gel more rapidly and yield slow-degrading hydrogels. The 
hydrolytic stability of the macromonomers and the rate constant of the DA reaction were 
determined by UV spectroscopy. The hydrogels were characterized by means of 
rheological, swelling and degradation studies; their ξ values were calculated. Finally, the 
in vitro release of bevacizumab was studied and compared to existing controlled release 
systems. 
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 Materials and methods 
6.2.1 General procedure 
1H-NMR spectra were recorded in CDCl3 at room temperature on a Bruker Avance 300 
spectrometer (Bruker BioSpin GmbH, Rheinstetten, Germany). 
6.2.2 Materials 
Acetyl chloride, deuterated chloroform (CDCl3), N,N’-dicyclohexylcarbodiimide (DCC), 
diisopropyl azodicarboxylate (DIAD), N,N’-diisopropylethylamine (DIPEA), anhydrous 
dimethylformamide (DMF), 3-(2-furyl)propanoic acid, N-hydroxysuccinimide (NHS), 
N-methoxycarbonylmaleimide and piperidine were purchased from Sigma-Aldrich
(Taufkirchen, Germany). Dichloromethane (DCM), anhydrous 1,4-dioxane, sodium
bicarbonate (NaHCO3), anhydrous sodium sulfate (Na2SO4) and triphenylphosphine were
received from Acros Organics (Geel, Belgium). Eight-armed poly(ethylene glycol),
molecular mass 20,000 (hexaglycerol core) was purchased from JenKem Technology
(Allen, TX, USA). Boc-6-aminohexanoic acid and Fmoc-Lys(Boc)-OH were obtained
from Bachem (Weil am Rhein, Germany). Diethyl ether was received from CSC
Jäcklechemie (Nuremberg, Germany). Water was obtained by using a Milli-Q water
purification system from Millipore (Schwalbach, Germany). Bevacizumab (Avastin®,
25 mg/mL, Roche Ltd., Basel, Switzerland) was kindly provided by the hospital
pharmacy, University of Regensburg, Germany, All other chemicals were purchased from
Merck KGaA (Darmstadt, Germany).
6.2.3 Synthesis of macromonomers (Scheme 2) 
Eight-armed PEG-amine, molecular mass 20 kDa (8armPEG20k-NH2) was synthesized 
as previously described [212]. The end-groups of 8armPEG20k-NH2 were functionalized 
with furyl (8armPEG20k-Fur) and maleimide groups (8armPEG20k-Mal) as previously 
described [212]. The synthesis of 8armPEG20k-Ahx-Fur, 8armPEG20k-Ahx-Mal, 
8armPEG20k-Lys-Ahx-Fur2 and 8armPEG20k-Lys-Ahx-Mal2 is described in the 
supplement. 
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Scheme 6.2. Functional end-groups of 8armPEG20k-Ahx-Fur, 8armPEG20k-Ahx-Mal, 8armPEG20k-Lys-
Ahx-Fur2 and 8armPEG20k-Lys-Ahx-Mal2. The macromonomers were synthesized from eight-armed 
poly(ethylene glycol), molecular mass 20,000 kDa. 
6.2.4 Hydrolytic stability of maleimides 
The hydrolytic stability of 8armPEG20k-Mal, 8armPEG20k-Ahx-Mal and 8armPEG20k-
Lys-Ahx-Mal2 was determined by UV spectroscopy as previously described. For this 
purpose, 20 mg of 8armPEG20k-Mal, 8armPEG20k-Ahx-Mal and 8armPEG20k-Lys-
Ahx-Mal2 were dissolved in 2 mL of water or 50 mM phosphate buffer, pH 7.4. The 
decrease in the absorbance at 299 nm (UV maximum of the maleimide group) was 
monitored in 10 mm quartz cuvettes for 1000 min at 37 °C using a Kontron UVIKON® 
941 spectrophotometer (Kontron Instruments S.p.A., Milan, Italy). 
6.2.5 Kinetics of the Diels-Alder reaction 
Equal molar amounts of 8armPEG20k-Fur and 8armPEG20k-Mal, 8armPEG20k-Ahx-
Fur and 8armPEG20k-Ahx-Mal, or 8armPEG20k-Lys-Ahx-Fur2 and 8armPEG20k-Lys-
Ahx-Mal2 were dissolved in water. The overall polymer concentrations were 5% (w/v), 
10% (w/v) and 15% (w/v). Aliquots of these solutions were pipetted into a 96-well quartz 
microplate. The decrease in the absorbance at 299 nm (UV maximum of the maleimide 
group) was monitored at 37 °C using a microplate reader (BMG LABTECH GmbH, 
Ortenberg, Germany). The absorbance values were converted into maleimide 
concentrations. A second-order kinetic model was fitted to the experimental data to 
determine the second-order rate constant (k) of the DA reaction.  
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6.2.6 Characterization of Diels-Alder hydrogels 
For the preparation of hydrogels, equal molar amounts of 8armPEG20k-Fur and 
8armPEG20k-Mal, 8armPEG20k-Ahx-Fur and 8armPEG20k-Ahx-Mal, or 
8armPEG20k-Lys-Ahx-Fur2 and 8armPEG20k-Lys-Ahx-Mal2 were dissolved in water. 
The overall polymer concentrations were 5% (w/v), 10% (w/v) and 15% (w/v). The 
hydrogels were characterized by oscillatory shear experiments on a TA Instruments AR 
2000 rheometer (TA Instruments, Eschborn, Germany) at 37 °C as previously described. 
The crossover of storage modulus (G’) and loss modulus (G”) was regarded as the gel 
point; the absolute value of the complex shear modulus (G*) was determined after the 
maximum value had been reached. The average mesh size (ξ) of the hydrogels was 
determined as previously described [212]. For swelling and degradation studies, gel 
cylinders were immersed in 50 mM phosphate buffer, pH 7.4 and incubated at 37 °C in a 
shaking water bath. The gel cylinders were weighed at regular times as previously 
described [212]. 
6.2.7 In vitro release of bevacizumab 
Equal molar amounts of 8armPEG20k-Fur and 8armPEG20k-Mal, 8armPEG20k-Ahx-
Fur and 8armPEG20k-Ahx-Mal, or 8armPEG20k-Lys-Ahx-Fur2 and 8armPEG20k-Lys-
Ahx-Mal2 were dissolved in 600 µL of water; 150 µL of a solution of bevacizumab 
(c = 25 mg/mL) were added. The overall polymer concentration was 10% (w/v) in all 
groups. Directly after mixing, 250 µL of the solutions were cast into cylindrical glass 
molds (7 mm inner diameter) and allowed to gel for 72 h under standard cell culture 
conditions (37 °C, 95% relative humidity and 5% CO2). The bevacizumab loading was 
1.25 mg per gel cylinder. Afterwards, the gel cylinders were removed from the glass 
molds and incubated in 5 mL of 50 mM phosphate buffer, pH 7.4 at 37 °C in a shaking 
water bath. Samples of 300 µL were withdrawn at regular times and replaced by fresh 
buffer. The samples were stored at 4 °C until completion of the release experiment. The 
amount of released bevacizumab (λex = 280 nm and λem = 335 nm) was determined on a 
PerkinElmer LS 55 Fluorescence spectrometer (Perkin Elmer, Wiesbaden, Germany) 
using a calibration curve.  
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6.2.8 Statistical analysis 
The results are presented as mean ± standard deviation based on the results of n = 3 
samples. The data were analyzed by means of one-way ANOVA followed by Tukey’s 
post-hoc test (GraphPad Prism 5.01, GraphPad Software Inc., La Jolla, CA). The 
differences were considered statistically significant at p < 0.05. 
 Results and discussion 
6.3.1 Synthesis of macromonomers 
Since the DA reaction does not require any metal catalyst or initiator, it is regarded as 
effective and non-toxic cross-linking method for the preparation of in situ forming drug 
delivery systems [56,21,212]. Moreover, it has been demonstrated that DA hydrogels 
made from star-shaped PEG degrade under physiological conditions by rDA reaction and 
subsequent ring-opening hydrolysis of the generated maleimide groups [248]. However, 
the stability of DA hydrogels might not be sufficient to prolong the dosing intervals of 
anti-VEGF drugs, such as bevacizumab or ranibizumab, which are typically administered 
every 4 to 6 weeks. For example, DA hydrogels made from eight-armed PEG were stable 
for 2 to 9 weeks, with the degradation rate depending on the concentration and molecular 
mass of the gel-forming macromonomers [212]. Further increasing the polymer 
concentration can impair the biocompatibility of the hydrogel and affect the stability of 
encapsulated biomolecules [14]; therefore, alternative ways of increasing the gel stability 
must be considered. Furthermore, it would be beneficial to decrease the gel time (tgel) of 
DA hydrogels to ensure the formation of a drug depot in potential applications. 
To increase the stability of DA hydrogels, the macromonomers were modified by 
introducing a hydrophobic Ahx spacer between 8armPEG20k-NH2 and the reactive end-
groups; the alkyl spacer is expected to improve the hydrolytic stability of the maleimide 
group [224,272–274]. The synthesis proved to be straightforward; the macromonomers 
8armPEG20k-Ahx-Fur and 8armPEG20k-Ahx-Mal were obtained in satisfactory yields. 
The degree of substitution with furyl and maleimide groups was 82% and 65%, 
respectively; nevertheless, the degree of endgroup functionalization was high enough to 
enable cross-linking. To further increase the stability and accelerate the gelation of DA 
6.3
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hydrogels, dendritic macromonomers were synthesized by branching the terminal ends of 
8armPEG20k-NH2 with Lys and Ahx residues. In our first approach, 8armPEG20k-NH2 
was reacted with Boc-Lys(Boc)-OH and deprotected; however, the subsequent reaction 
with N-methoxycarbonylmaleimide failed and an insoluble resin was obtained. The 
reactivity of α- and ε-amino groups is apparently different; this could lead to cross-linking 
via aza-Michael additions. Therefore, we tried an alternative strategy of synthesizing 
dendritic macromonomers. In the first step, 8armPEG20k-NH2 was reacted with Fmoc-
Lys(Boc)-OH; the Fmoc group was removed, and the intermediate was reacted with Boc-
Ahx-OH. After complete deprotection, the macromonomers 8armPEG20k-Lys-Ahx-Fur2 
and 8armPEG20k-Lys-Ahx-Mal2 could be synthesized in satisfactory yields. The degree 
of substitution with furyl and maleimide groups was 75% and 86%, respectively, which 
was sufficiently high to enable cross-linking. 
6.3.2 Hydrolytic stability of maleimides 
Ring-opening hydrolysis of maleimide to unreactive maleamic acid has been shown to 
affect both cross-linking and degradation of DA hydrogels [248]. Therefore, the 
hydrolytic stability of 8armPEG20k-Mal, 8armPEG20k-Ahx-Mal and 8armPEG20k-Lys-
Ahx-Mal2 was investigated in water and 50 mM phosphate buffer, pH 7.4 at 37 °C. When 
the macromonomers were incubated in water, the absorbance at 299 nm slowly decreased 
indicating high stability of the maleimide groups (data not shown). In contrast to this, the 
absorbance measurably decreased in phosphate buffer pH 7.4, which indicates fast ring-
opening hydrolysis of maleimide groups (Figure 6.1).  
Figure 6.1. Hydrolytic stability 
8armPEG20k-Mal, 8armPEG20k-
Ahx-Mal and 8armPEG20k-Lys-Ahx-
Mal2 incubated in phosphate buffer, 
pH 7.4 at 37 °C. The experimental data 
is indicated by symbols; the solid lines 
represent the best fits of eqn. (6.1). 
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Assuming that the hydrolysis of maleimide groups follows a pseudo-first-order process, 
rate constants (kobs) and half-lives (t½) can be calculated by fitting the integrated form of 
equation (6.1) to the experimental data. 
(6.1) 
The results listed in Table 6.1 show that 8armPEG20k-Mal, 8armPEG20k-Ahx-Mal and 
8armPEG20k-Lys-Ahx-Mal2 were stable in water; therefore, the cross-linking process 
was carried out in water. Pure water has a slightly acidic pH due to dissolved carbon 
dioxide; furthermore, it is conceivable that small amounts of maleamic acid lower the pH 
of water. The slightly acid pH favors the stability of the maleimide groups; therefore, the 
cross-linking process was carried out in water. In phosphate buffer pH 7.4, the determined 
rate constants were almost two orders of magnitude higher than in water; therefore, the 
cross-linked hydrogels most likely degrade during incubation in phosphate buffer, pH 7.4. 
Interestingly, the half-lives of 8armPEG20k-Ahx-Mal and 8armPEG20k-Lys-Ahx-Mal2 
were more than twice as long as the half-life of 8armPEG20k-Mal. This was observed in 
water and in phosphate buffer, pH 7.4. Apparently, the nature of the N-substituent of 
maleimides influences the rate of hydrolysis [224,272–274]. For example, it has been 
reported that N-(2-methoxyethyl)maleimide is subject to rapid hydrolysis at pH 8.0, 
whereas N-butylmaleimide is more stable under the same conditions [273]. As a result of 
this, 8armPEG20k-Ahx- and 8armPEG20k-Lys-Ahx-hydrogels are most likely more 
resistant to degradation than 8armPEG20k-hydrogels. 
Table 6.1. Calculated rate constants (kobs) of the ring-opening reaction and half-lives (t½) of 8armPEG20k-
Mal, 8armPEG20k-Ahx-Mal and 8armPEG20k-Lys-Ahx-Mal2 at 37 °C. 
Macromonomer Medium kobs / min-1 t½ / min R2 
8armPEG20k-Mal 
water 6.34·10-5 109410 0.8312 
buffer pH 7.4 3.92·10-3 177 0.9706 
8armPEG20k-Ahx-Mal 
water 3.19·10-5 21759 0.8304 
buffer pH 7.4 1.87·10-3 372 0.9760 
8armPEG20k-Lys-Ahx-
Mal2 
water 3.13·10-5 22137 0.8592 
buffer pH 7.4 1.68·10-3 412 0.9893 
6.3.3 Gelation kinetics of Diels-Alder hydrogels 
The kinetics of the DA reaction between complementary macromonomers was 
determined by UV spectroscopy. For this purpose, solutions of the macromonomers were 
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prepared in water and incubated at 37 °C. As shown above, the hydrolysis of maleimide 
groups is minimal in water; therefore, the kinetics of the DA reaction can be determined 
by measuring the decrease in the absorbance at 299 nm. Assuming equal starting 
concentrations of furyl and maleimide groups, the kinetics of the DA reaction can be 
described by the second-order equation (6.2): 
(6.2) 
where [maleimide] is the concentration of maleimide groups and [maleimide]0 the 
concentration of maleimide groups at time t = 0 [233]. The second-order rate constants of 
the DA reaction (k) were calculated by fitting equation (6.2) to the experimental data 
(Figure 6.2). 
Figure 6.2. Gelation kinetics of 8armPEG20k- (A), 8armPEG20k-Ahx- (B) and 8armPEG20k-Lys-Ahx-
hydrogels (C) at 37 °C as a function of the polymer concentration. The experimental data is indicated by 
symbols; the solid lines represent least-squares fits of second-order kinetic models. 
Interestingly, the values of k slightly decreased with increasing polymer concentration 
(Table 6.2). This trend was observed with all tested macromonomers. Most likely, 
increasing the polymer concentration from 5% (w/v) to 15% (w/v) increases the viscosity 
of the system, which consequently results in lower reaction rates. Although statistically 
significant differences in k were observed between the different macromonomers at given 
polymer concentrations, no general trends could be derived for the kinetics of the DA 
reaction. Apparently, introducing Lys and/or Ahx residues between PEG and the reactive 
end-groups only has a minor influence on the reaction rate. The determined values of k 
can be used to predict the time to reach the gel point (tgel). The conversion of functional 
groups at the gel point (α) can be calculated by using the Flory-Stockmayer theory [226]: 
(6.3) 
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According to equation (6.3), gelation of 8armPEG20k- and 8armPEG20k-Ahx-hydrogels 
(f = 8) should occur at approximately 15% conversion of both furyl and maleimide 
groups; gelation of 8armPEG20k-Lys-Ahx-hydrogels (f = 16) should occur at 
approximately 7% conversion. Assuming that cross-linking follows a second-order 
process, tgel can be calculated by: 
(6.4) 
The determined values of tgel can be used to describe the kinetics of cross-linking. In 
general, the predicted values of tgel decreased with increasing polymer concentration 
(Table 6.2). For example, gelation of 5% (w/v) 8armPEG20k-hydrogels should occur 
after 69 min, while 15% (w/v) 8armPEG20k-hydrogels should gel after 29 min. Gelation 
of 8armPEG20k-Ahx-hydrogels should occur at the same rate, with only minor 
differences being predicted. In contrast to that, our calculations predict that gelation of 
8armPEG20k-Lys-Ahx-hydrogels should occur approximately four times faster than 
gelation of 8armPEG20k- or 8armPEG20k-Ahx-hydrogels. For example, gelation of 
5% (w/v) 8armPEG20k-Lys-Ahx-hydrogels should occur after 16 min, while 
8armPEG20k- and 8armPEG20k-Ahx-hydrogels should gel after 69 min and 67 min, 
respectively. The same trends are predicted for the two other polymer concentrations. 
Obviously, increasing the number of reactive end-groups per macromonomer would be 
an effective way to accelerate gelation of DA hydrogels. 
Table 6.2. Second order rate constants (k) of the DA reaction in 8armPEG20k, 8armPEG20k-Ahx and 
8armPEG20k-Lys-Ahx hydrogels. The time to reach the gel point (tgel) was predicted using the determined 
values of k and compared to the rheological results. 
Macromonomers Conc. / % (w/v) k /mol
-1.L.s-1 R2 
tgel / min 
predicted measured 
8armPEG20k-Fur 
+ 
8armPEG20k-Mal 
5 0.2693 ± 0.004115 0.8879 69 129 ± 4 
10 0.2268 ± 0.002943 0.9165 41 54 ± 3 
15 0.2144 ± 0.002806 0.9152 29 34 ± 1 
8armPEG20k-Ahx-Fur 
+ 
8armPEG20k-Ahx-Mal 
5 0.2963 ± 0.007404 0.7441 67 81 ± 4 
10 0.2654 ± 0.003305 0.9226 37 36 ± 4 
15 0.2206 ± 0.0004153 0.9981 30 23 ± 0 
8armPEG20k-Lys-Ahx-Fur2 
+ 
8armPEG20k-Lys-Ahx-Mal2 
5 0.2699 ± 0.002735 0.9477 16 24 ± 0 
10 0.2493 ± 0.001442 0.9822 9 8 ± 1 
15 0.1881 ± 0.001086 0.9823 8 4 ± 1 
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6.3.4 Rheological characterization of Diels-Alder hydrogels 
Oscillatory shear experiments were performed at 37 °C to study the gelation kinetics of 
DA hydrogels. In these experiments, tgel can be approximated by the crossover of G’ and 
G”. In general, the measured values showed the same trends as the calculated values 
(Table 6.2). As shown in Figure 6.3A, the gel time decreased with increasing polymer 
concentration. 
Figure 6.3. Gel time (A) and stiffness (B) of different DA hydrogels. The measurements were performed 
at 37 °C and 1.0 Hz oscillatory frequency. 
For example, tgel of 8armPEG20k-hydrogels decreased from 129 ± 4 min to 34 ± 1 min 
when the polymer concentration was increased from 5% (w/v) to 15% (w/v). With 
increasing polymer concentration, the probability of two macromonomers forming an 
elastically active chain is increasing. Consequently, tgel decreases as predicted by our 
calculations. Interestingly, the gelation of 8armPEG20k-Ahx-hydrogels was significantly 
faster than the gelation of 8armPEG20k-hydrogels. This was unexpected since the rate 
constants of the DA reaction were comparable in both systems. The reason for the faster 
gelation of 8armPEG20k-Ahx-hydrogels is not totally clear; however, it can be speculated 
that the introduction of hydrophobic Ahx spacers between PEG and the reactive end-
groups favors intermolecular interactions between macromonomers. The association of 
macromonomers by hydrophobic interactions might facilitate gelation independent of the 
DA reaction. The gel times of 8armPEG20k-Lys-Ahx-hydrogels were much lower in 
comparison to 8armPEG20k- and 8armPEG20k-Ahx-hydrogels. This was predicted by 
our calculations; the faster gelation of 8armPEG20k-Lys-Ahx-hydrogels can be attributed 
to the higher number of reactive end-groups per macromonomer. Association of 
macromonomers by hydrophobic interactions might additionally contribute to gelation. 
Major differences between the calculated and determined values of tgel were only 
observed in 5% (w/v) 8armPEG20k-hydrogels. Due to the lack of hydrophobic 
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interactions and the lower concentration of reactive end-groups, this system seems to be 
more affected by network imperfections, such as dangling ends, than other hydrogels. 
Furthermore, oscillatory shear experiments can be used to determine the absolute value 
of G*, which relates to the number of elastically active chains in cross-linked hydrogels. 
As shown in Figure 6.3B, the absolute value of G* increased with increasing polymer 
concentration. For example, the absolute value of G* of 8armPEG20k-hydrogels 
increased from 2152 ± 144 Pa to 19,057 ± 1002 Pa when the polymer concentration was 
increased from 5% (w/v) to 15% (w/v). The same trend was observed for 8armPEG20k-
Ahx-hydrogels, where the absolute value of G* increased from 1797 ± 254 Pa to 
19,123 ± 1877 Pa, and for 8armPEG20k-Lys-Ahx-hydrogels, where the absolute value of 
G* ranged between 6748 ± 230 Pa and 40,027 ± 6511 Pa. No significant differences were 
observed between 8armPEG20k- and 8armPEG20k-Ahx-hydrogels. The absolute value 
of G* was similar at all tested polymer concentration; therefore, both types of hydrogel 
obviously have the same number of elastically active chains. In contrast to that, the 
absolute value of G* of 8armPEG20k-Lys-Ahx-hydrogels was 2–3 times higher at all 
studied polymer concentrations. This is explained by the dendritic structure of the 
macromonomers. Branching the terminal ends of star-shaped PEG with Lys and Ahx 
residues increases the number of reactive end-groups per macromonomer and, hence, the 
number of elastically active chains that can be formed during cross-linking. Furthermore, 
the cross-linking density of the formed network is increased by adding new branch points 
to the macromonomers. In summary, gelation of DA hydrogels can be accelerated by 
introducing hydrophobic Ahx spacers between PEG and the reactive end-groups or by 
adding new branch points to the macromonomers. While the first method does not affect 
the mechanical properties of the resulting hydrogels, increasing the number of reactive 
end-groups per macromonomer always increases the absolute value of G*. This may have 
effects on other gel properties, such as the average mesh size and degradation time, which 
in turn affect the release rate of incorporated drugs. 
6.3.5 Determination of the average mesh size 
The ξ value is an important parameter of hydrogels that allows estimating the release rate 
of incorporated drugs [14,13]. Therefore, we calculated the ξ values of different hydrogels 
after swelling in water as previously described [212]. The results listed in Table 6.3 show 
that ξ was influenced by the concentration and type of the macromonomers used for 
hydrogel preparation. 5% (w/v) 8armPEG20k-hydrogels had the largest mesh size with a 
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ξ value of 16.1 ± 0.1 nm, whereas 15% (w/v) 8armPEG20k-Lys-Ahx-hydrogels had the 
smallest mesh size with a ξ value of 6.0 ± 0.2 nm. As shown in rheological measurements, 
increasing macromonomer concentrations resulted in higher cross-linking density; 
accordingly, the ξ values were decreasing with increasing macromonomer concentrations. 
8armPEG20k-hydrogels had the highest ξ values of all tested hydrogels, which is again 
explained by network imperfections such as dangling ends. As expected from rheological 
measurements, 8armPEG20k-Lys-Ahx-hydrogels had the smallest ξ values of all 
hydrogels. This is again explained by the dendritic structure of the macromonomers, 
which increases the cross-linking density of the resulting networks. The results indicate 
that all tested hydrogels may allow controlled release of therapeutic proteins. For 
example, bevacizumab, which served as model protein in our studies, has a hydrodynamic 
diameter of approximately 13 nm [269]. Depending on the ξ value of the hydrogel, the 
release of incorporated bevacizumab may be controlled by diffusion of the protein 
(ξ ≥ 13 nm) or degradation of the hydrogel (ξ ≪ 13 nm). 
Table 6.3. Average mesh size (ξ) of 8armPEG20k, 8armPEG20k-Ahx and 8armPEG20k-Lys-Ahx 
hydrogels derived from swelling data. 
Macromonomers Conc. / % (w/v) ξ / nm 
8armPEG20k-Fur 
+ 
8armPEG20k-Mal 
5 16.1 ± 0.1 
10 12.9 ± 0.9 
15 11.1 ± 0.1 
8armPEG20k-Ahx-Fur 
+ 
8armPEG20k-Ahx-Mal 
5 12.3 ± 0.2 
10 10.3 ± 0.1 
15 9.8 ± 0.1 
8armPEG20k-Lys-Ahx-Fur2  
+ 
8armPEG20k-Lys-Ahx-Mal2 
5 12.7 ± 0.02 
10 7.3 ± 0.1 
15 6.0 ± 0.2 
6.3.6 Swelling and degradation of Diels-Alder hydrogels 
To study the swelling and degradation behavior of DA hydrogels, gel cylinders were 
incubated in 50 mM phosphate buffer, pH 7.4 at 37 °C and weighed at regular times. The 
polymer concentration was 5% (w/v) in all groups. As shown in Figure 6.4, the mass of 
8armPEG20k- and 8armPEG20k-Ahx-hydrogels steadily increased until the gel cylinders 
were completely degraded after 14 days (8armPEG20k-hydrogels) and 28 days 
(8armPEG20k-Ahx-hydrogels), respectively. The swelling behavior of 8armPEG20k-
Lys-Ahx-hydrogels was slightly different. The mass of these hydrogels slowly increased 
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over 34 weeks. After a maximum had been reached, the mass steadily decreased until the 
gel cylinders were completely degraded after 40 weeks.  
It has been reported that DA hydrogels degrade at pH 7.4 by rDA reaction and subsequent 
ring-opening hydrolysis of the generated maleimide groups [8]. The hydrolytic step is 
important as it removes the generated maleimide groups from the DA/rDA equilibrium. 
This causes the DA adducts to revert to the starting materials and induces hydrogel 
degradation. Furthermore, it has been shown that gel stability increases with decreasing 
rate of hydrolysis. Accordingly, the degradation time of 8armPEG20k-Ahx-hydrogels (t½ 
of 8armPEG20k-Ahx-Mal = 378 min) was twice as long as the degradation time of 
8armPEG20k-hydrogels (t½ of 8armPEG20k-Mal = 180 min). However, differences in 
the rate of hydrolysis cannot solely explain the extreme longevity of 8armPEG20k-Lys-
Ahx-hydrogels (t½ of 8armPEG20k-Lys-Ahx-Mal2 = 419 min). Apparently, the number 
of reactive end-groups per macromonomer has a pronounced effect on hydrogel 
degradation. As discussed above, the number of elastically active chains is much higher 
in 8armPEG20k-Lys-Ahx-hydrogels than in 8armPEG20k- or 8armPEG20k-Ahx-
hydrogels. As a consequence, relatively more DA adducts must be broken in 
8armPEG20k-Lys-Ahx-hydrogels before degradation becomes obvious (Figure 6.5). 
Figure 6.5. Network architecture of different DA hydrogels. In 8armPEG20k- and 8armPEG20k-Ahx-
hydrogels (left), less DA adducts must be broken than in 8armPEG20k-Lys-Ahx-hydrogels (right) to cause 
degradation. 
Figure 6.4. Swelling and 
degradation of 5% (w/v) 
8armPEG20k- (●), 8armPEG20k-
Ahx- (○) and 8armPEG20k-Lys-
Ahx-hydrogels (■). Hydrogels 
incubated at 37 °C dissolved after 
14 days (8armPEG20k), 28 days 
(8armPEG20k-Ahx) and 280 days 
(8armPEG20k-Lys-Ahx). 
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This also explains the lower degree of swelling of 8armPEG20k-Lys-Ahx-hydrogels. 
Besides hydrolysis, diffusion of macromonomers from the gel network into the swelling 
medium may also remove furyl and maleimide groups from the DA/rDA equilibrium and 
accelerate degradation. In 8armPEG20k- and 8armPEG20k-Ahx-hydrogels, the 
probability of releasing macromonomers from the gel network is much higher than in 
8armPEG20k-Lys-Ahx-hydrogels; therefore, these gels degrade faster than 
8armPEG20k-Lys-Ahx-hydrogels. Furthermore, it can be speculated that the close 
proximity of two functional groups in 8armPEG20k-Lys-Ahx-Fur2 and 8armPEG20k-
Lys-Ahx-Mal2, respectively, may favor the reformation of DA adducts. This would 
additionally increase the resistance of 8armPEG20k-Lys-Ahx-hydrogels to degradation. 
Taken together, our experiments demonstrate that the stability of DA hydrogels can be 
enhanced by introducing hydrophobic Ahx spacers between PEG and the reactive end-
groups or by increasing the number of reactive end-groups per macromonomer. While 
the first method has only moderate effects, using dendritic macromonomers drastically 
increases the persistence of the resulting hydrogels.  
6.3.7 In vitro release of bevacizumab 
In the final experiment, we studied the in vitro release of bevacizumab from 
8armPEG20k-, 8armPEG20k-Ahx- and 8armPEG20k-Lys-Ahx-hydrogels. The polymer 
concentration was 10% (w/v) in all groups. As shown in Figure 6.6, approximately 
20% to 30% of the incorporated bevacizumab was released within the first 24 h. This 
burst release was observed in all groups; it is most likely caused by non-entrapped protein 
molecules located at the surface of the gel cylinders. After the first 24 h, the release of 
bevacizumab was dependent on the hydrogel formulation. All release profiles were 
sigmoidal; however, their timescales were different. The release of bevacizumab from 
8armPEG20k-hydrogels was comparatively fast; the incorporated protein was completely 
released after 10 days. In comparison to that, protein release from 8armPEG20k-Ahx-
hydrogels was considerably slower; the incorporated bevacizumab was completely 
released after 42 days. The release of bevacizumab from 8armPEG20k-Lys-Ahx-
hydrogels initially followed the same kinetics. Approximately 60% of the incorporated 
protein was released during the first 28 days. This was followed by a second phase of 
slow protein release; after 105 days, approximately 73% of the incorporated bevacizumab 
was released. 
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As discussed above, the release of bevacizumab is controlled by diffusion of the protein 
or degradation of the hydrogel. Furthermore, it has been shown that nucleophilic amino 
acid residues of proteins (mostly Lys residues located on the surface of the protein) can 
react with maleimides in Michael-type additions [17]. Although the nucleophilicity of 
these amino acid residues is low in water due to protonation, approximately 20% to 30% 
of the incorporated protein may react with the gel-forming polymers during cross-linking. 
This covalently bound fraction is immobile and eventually released during degradation. 
Depending on the number of PEG molecules remaining attached, the antigen binding 
activity of these PEGylated antibodies can be slightly decreased or completely lost [270]. 
The ξ value of 10% (w/v) 8armPEG20k-hydrogels (12.9 ± 0.9 nm) has the same 
dimension as the hydrodynamic diameter of bevacizumab (approximately 13 nm). 
Together with the ongoing degradation, this results in fast release of both physically 
entrapped and covalently bound bevacizumab. In contrast to that, the ξ values of 
10% (w/v) 8armPEG20k-Ahx- (10.3 ± 0.1 nm) and 8armPEG20k-Lys-Ahx-hydrogels 
(7.3 ± 0.1 nm) are below the hydrodynamic diameter of bevacizumab. Therefore, 
physically entrapped bevacizumab is slowly released from these hydrogels by diffusion. 
As a result of the starting degradation, protein release from 8armPEG20k-Ahx-hydrogels 
continues until complete release of both physically entrapped and covalently bound 
bevacizumab is reached. In contrast to that, the release of bevacizumab from 
8armPEG20k-Lys-Ahx-hydrogels levels off after 28 days with approximately 60% of the 
incorporated protein being released. The remaining 40% are either physically entrapped 
or covalently bound and not released until gel degradation eventually becomes manifest. 
Several controlled release systems for bevacizumab have been described in the literature, 
with in situ forming hydrogels being most prominent [59,135–137,139,140,275–281]. 
For example, hydrogels based on PEG/polyurethane block copolymers could be injected 
at room temperature and formed a viscoelastic drug depot inside the vitreous cavity [137]. 
Figure 6.6. Cumulative release of 
bevacizumab from 10% (w/v) 
8armPEG20k- (●), 8armPEG20k-
Ahx- (○) and 8armPEG20k-Lys-Ahx-
hydrogels (■). Drug release was 
completed after 10 days (8armPEG20k) 
and 42 days (8armPEG20k-Ahx), 
respectively. Release from 
8armPEG20k-Lys-Ahx-hydrogels was 
not completed after 105 days with 
approximately 73% of the incorporated 
bevacizumab being released. 
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The hydrogels were well tolerated in vivo and sustained the release of bevacizumab for 
2 months. The duration of release could be further extended by using light-activated 
hydrogels made from polycaprolactone dimethacrylate and hydroxyethyl 
methacrylate [279]. The polymer solution was cross-linked for 10 min in the presence of 
UV light and a photoinitiator. The in vitro release of bevacizumab was sustained for 
4 months; the drug was retained in the suprachoroidal space of rats up to 60 days. 
Although 8armPEG20k-Ahx- and 8armPEG20k-Lys-Ahx-hydrogels could not sustain 
the release of bevacizumab over several months, DA hydrogels offer the advantage of 
being cross-linked in the absence of metal catalysts or initiators. Photoinitiators generate 
free radicals during cross-linking, which may induce toxicity and affect the bioactivity of 
proteins [14,17,18]. Moreover, it should be mentioned that volume (0.25 mL) and drug 
content (1.25 mg of bevacizumab) of the herein studied hydrogels might not be 
appropriate for clinical applications. The required bevacizumab dose and the desired 
release profile (e.g., continuous or intermittent release) must be determined by in vivo 
experiments, which are not subject of the present study. Altogether, this pilot study 
demonstrates the potential of DA hydrogels for the controlled release of bevacizumab. 
The release profiles can be further optimized by fine-tuning the mesh size and degradation 
rate of the hydrogels. 
 Conclusion 
In situ forming hydrogels with potential application as intravitreal delivery system for 
anti-VEGF drugs, such as bevacizumab or ranibizumab, were developed. To this end, 
eight-armed PEG was functionalized with furyl and maleimide groups, respectively, and 
cross-linked via DA chemistry. However, the comparatively fast degradation and the slow 
cross-linking process may limit the application of plain 8armPEG20k-hydrogels. 
Introducing hydrophobic Ahx spacers between PEG and the reactive end-groups is 
effective in decreasing the gel time of DA hydrogels; the degradation of 8armPEG20k-
Ahx-hydrogels is significantly prolonged compared to unmodified 8armPEG20k-
hydrogels. The gelation of DA hydrogels can be further accelerated by using dendritic 
8armPEG20k-Lys-Ahx-macromonomers; the resulting hydrogels are characterized by 
enhanced mechanical stability and extreme longevity. Both 8armPEG20k-Ahx- and 
8armPEG20k-Lys-Ahx-hydrogels may serve as controlled release system for therapeutic 
antibodies such as bevacizumab. The hydrogels would be injected in liquid form and 
6.4
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rapidly form a viscoelastic drug depot inside the vitreous cavity. Both gel systems are 
capable of sustaining the in vitro release of bevacizumab for at least 6 weeks. The release 
profiles can be further optimized by fine-tuning the mesh size and degradation rate of DA 
hydrogels, e.g., by using mixtures of different macromonomers. In summary, especially 
8armPEG20k-Lys-Ahx-hydrogels seem promising; the developed hydrogels can possible 
reduce the dosing frequency of anti-VEGF drugs and provide intermittent drug release, 
which would be desirable in anti-VEGF therapy [133,271]. In the next phase, we will 
evaluate the stability and biological activity of released bevacizumab. Moreover, the 
safety and effectiveness of DA hydrogels have to be confirmed in animal models of 
choroidal neovascularization. 
 Supplements
6.5.1 Synthesis of 8armPEG20k-NH2 (1), 8armPEG20k-Fur (2a) and 
8armPEG20k-Mal (2b) 
Eight-armed PEG-amine, molecular mass 20,000 kDa (8armPEG20k-NH2, 1) was 
synthesized from eight-armed PEG as previously described [212]. 8armPEG20k-Fur (2a) 
and 8armPEG20k-Mal (2b) were synthesized from 1 as previously described [212]. 
Scheme 6.3. Functional end-groups of 1, 2a and 2b 
6.5.2 Synthesis of compound 3 
Boc-6-aminohexanoic acid (5.40 mmol, 1.25 g), NHS (5.40 mmol, 0.62 g) and DCC 
(5.40 mmol, 1.11 g) were dissolved in 15 mL of anhydrous DMF and stirred for 30 min 
at 0 °C. Afterwards, the precipitate was filtered off and the filtrate was combined with a 
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solution of 1 (0.34 mmol, 7.00 g) in 55 mL of anhydrous DCM. The reaction mixture was 
neutralized with DIPEA and stirred for 1.5 h at room temperature. The precipitate was 
filtered off and the filtrate was concentrated under reduced pressure. The polymer was 
precipitated at 0 °C by dropwise addition of diethyl ether. The precipitate was collected 
by filtration, washed with cold diethyl ether and dried under vacuum to yield 6.79 g (90%) 
of 3. The degree of end-group conversion was approximately 82% as determined by 1H-
NMR spectroscopy.  
1H-NMR (CDCl3, 300 MHz): δ 1.32 ppm (m, 16H, –C(O)CH2CH2CH2CH2CH2NH–), 
1.42 ppm (s, 72H, –NHC(O)OC(CH3)3), 1.63 ppm (m, 16H, –C(O)CH2CH2CH2CH2CH2NH–), 
2.16 ppm (t, 16H, –C(O)CH2CH2CH2CH2CH2NH–), 3.07 ppm (m, 16H, 
–C(O)CH2CH2CH2CH2CH2NH–), 3.62 ppm (s, –OCH2CH2–).
Scheme 6.4. Synthesis of 3 from 1 and Boc-6-aminohexanoic acid 
6.5.3 Synthesis of compound 4 
Compound 3 (0.30 mmol, 6.79 g) was dissolved in a solution of HCl in methanol 
(obtained by dropwise addition of 7.0 mL of acetyl chloride to 70 mL of ice-cooled 
methanol). The reaction mixture was stirred for 30 min at room temperature. The solvent 
was evaporated under reduced pressure and the residue was dissolved in 35 mL of water. 
The pH of the solution was adjusted with NaOH to 9–10. The raw product was extracted 
with DCM (4 × 35 mL). The combined organic phases were dried over anhydrous 
Na2SO4, filtered and concentrated under reduced pressure. The polymer was precipitated 
at 0 °C by dropwise addition of diethyl ether. The precipitate was collected by filtration, 
washed with cold diethyl ether and dried under vacuum to yield 6.12 g (93 %) of 4. 
1H-NMR spectroscopy indicated complete removal of the BOC group. 
1H-NMR (CDCl3, 300 MHz): δ 1.34 ppm (m, 16H, –C(O)CH2CH2CH2CH2CH2NH2), 
1.49 ppm (m, 16H, –C(O)CH2CH2CH2CH2CH2NH2), 1.64 ppm (m, 16H, 
–C(O)CH2CH2CH2CH2CH2NH2), 2.19 ppm (t, 16H, –C(O)CH2CH2CH2CH2CH2NH2),
2.70 ppm (t, 16H, –C(O)CH2CH2CH2CH2CH2NH2), 3.62 ppm (s, –OCH2CH2–).
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Scheme 6.5. Synthesis of 4 by deprotection of 3 
6.5.4 Synthesis of compound 8armPEG20k-Ahx-Fur (5a) 
8armPEG20k-Ahx-Fur (5a) was synthesized in 94% yield by reacting 4 with a twofold 
excess of 3-(2-furyl)propanoic acid, NHS and DCC as described for 2a. The degree of 
end-group conversion was approximately 82% as determined by 1H-NMR spectroscopy. 
1H-NMR (CDCl3, 300 MHz): δ 1.30 ppm (m, 16H, –C(O)CH2CH2CH2CH2CH2NH–), 
1.45 ppm (m, 16H, –C(O)CH2CH2CH2CH2CH2NH–), 1.61 ppm (m, 16H, 
–C(O)CH2CH2CH2CH2CH2NH–), 2.16 ppm (t, 16H, –C(O)CH2CH2CH2CH2CH2NH–),
2.47 ppm (t, 16H, –C(O)CH2CH2Ar ), 2.95 ppm (t, 16H, –C(O)CH2CH2Ar ), 3.20 ppm
(t, 16H, –C(O)CH2CH2CH2CH2CH2NH–), 3.62 ppm (s, –OCH2CH2–), 6.00 ppm (s, 4H,
Ar), 6.24 ppm (s, 4H, Ar), 7.26 ppm (s, 4H, Ar).
6.5.5 Synthesis of compound 8armPEG20k-Ahx-Mal (5b) 
8armPEG20k-Ahx-Mal (5b) was synthesized in 96% yield by reacting 4 with a fivefold 
excess of N-methoxycarbonylmaleimide as described for 2b. The degree of end-group 
conversion was approximately 65% as determined by 1H-NMR spectroscopy. 
1H-NMR (CDCl3, 300 MHz): δ 1.29 ppm (m, 16H, –C(O)CH2CH2CH2CH2CH2NH–), 
1.61 ppm (m, 32H, –C(O)CH2CH2CH2CH2CH2NH–), 2.14 ppm (t, 16H, 
–C(O)CH2CH2CH2CH2CH2NH–), 3.62 ppm (s, –OCH2CH2–), 6.67 ppm (s, 16H,
–C(O)CH=CHC(O)–).
Scheme 6.6. Functional end-groups of 5a and 5b 
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6.5.6 Synthesis of compound 6 
Compound 6 was synthesized in 90% yield by reacting 1 with Fmoc-Lys(Boc)-OH as 
described for 3. The degree of end-group conversion was approximately 94% as 
determined by 1H-NMR spectroscopy.  
1H-NMR (CDCl3, 300 MHz): δ 1.41 ppm (s, 72H, –NHC(O)OC(CH3)3), 3.07 ppm (m, 
16H, –C(O)C(NHFmoc)HCH2CH2CH2CH2NH–), 3.63 ppm (s, –OCH2CH2–), 4.19 ppm 
(m, 16H, –C(O)C(NHFmoc)HCH2CH2CH2CH2NH– and –NHC(O)OCH2CHR2), 
4.37 ppm (m, 16H, –NHC(O)OCH2CHR2), 7.30–7.74 ppm (m, 104H, Ar). 
Scheme 6.7. Synthesis of 6 from 1 and Fmoc-Lys(Boc)-OH 
6.5.7 Synthesis of compound 7 
Compound 6 (0.27 mmol, 6.38 g) was dissolved in 24 mL of DMF; 6 mL of piperidine 
were added. The reaction mixture was stirred for 30 min at room temperature. The 
polymer was precipitated at 0 °C by dropwise addition of diethyl ether. The precipitate 
was collected by filtration, washed with cold diethyl ether and dried under vacuum to 
yield 5.40 g (92%) of 7. 1H-NMR spectroscopy indicated complete removal of the FMOC 
group. 
1H-NMR (CDCl3, 300 MHz): δ 1.41 ppm (s, 72H, –NHC(O)OC(CH3)3), 1.62 ppm (m, 16H, 
–C(O)C(NH2)HCH2CH2CH2CH2NH–), 1.81 ppm (m, 16H, –C(O)C(NH2)HCH2CH2CH2CH2NH–),
3.08 ppm (m, 16H,–C(O)C(NH2)HCH2CH2CH2CH2NH–), 3.62 ppm (s, –OCH2CH2–).
Scheme 6.8. Synthesis of 7 by deprotection of 6 
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6.5.8 Synthesis of compound 8 
Boc-6-aminohexanoic acid (7.85 mmol, 1.82 g) and DCC (3.92 mmol, 0.81 g) were 
dissolved in 10 mL of anhydrous DMF and stirred for 30 min at 0 °C. Afterwards, the 
precipitate was filtered off and the filtrate was combined with a solution of 7 (0.25 mmol, 
5.40 g) in 45 mL of anhydrous DCM. The reaction mixture was neutralized with DIPEA 
and stirred for 1.5 h at room temperature. The precipitate was filtered off and the filtrate 
was concentrated under reduced pressure. The polymer was crystallized at 0 °C by 
dropwise addition of diethyl ether. The precipitate was collected by filtration, washed 
with cold diethyl ether and dried under vacuum to yield 4.88 g (84%) of 8. The degree of 
end-group conversion was approximately 85% as determined by 1H-NMR spectroscopy. 
1H-NMR (CDCl3, 300 MHz): δ 1.31 ppm (m, 48H, –C(O)C(NHR)HCH2CH2CH2CH2NH– 
and –C(O)CH2CH2CH2CH2CH2NH–), 1.41 ppm (s, 144H, –NHC(O)OC(CH3)3), 
1.62 ppm (m, 32H, –CH2CH2CH2CH2NH–), 1.81 ppm (m, 16H, 
–C(O)C(NHR)HCH2CH2CH2CH2NH–), 2.19 ppm (t, 16H,–C(O)CH2CH2CH2CH2CH2NH–),
3.07 ppm (m, 32H, –CH2CH2CH2CH2NH–), 3.62 ppm (s, –OCH2CH2–) 4.37 ppm (m, 8H,
–C(O)C(NHR)HCH2CH2CH2CH2NH–).
Scheme 6.9. Synthesis of 8 from 7 and Boc-6-aminohexanoic acid 
6.5.9 Synthesis of compound 9 
Compound 9 was synthesized in 92% yield as described for 4. 1H-NMR spectroscopy 
indicated complete removal of the BOC groups.  
1H-NMR (CDCl3, 300 MHz): δ 1.31–1.81 ppm (m, 96H, –CH2CH2CH2CH2NH2), 
2.69 ppm (m, 32H, –CH2CH2CH2CH2NH2), 3.62 ppm (s, –OCH2CH2–), 4.41 ppm (m, 
8H, –C(O)C(NHR)HCH2CH2CH2CH2NH2). 
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Scheme 6.10. Synthesis of 9 by deprotection of 8 
6.5.10 Synthesis of compound 8armPEG20k-Lys-Ahx-Fur2 (10a) 
8armPEG20k-Lys-Ahx-Fur2 (10a) was synthesized in 90% yield by reacting 9 with a 1.5-
fold excess of 3-(2-furyl)propanoic acid, NHS and DCC as described for 2a. The degree 
of end-group conversion was approximately 75% as determined by 1H-NMR 
spectroscopy.  
1H-NMR (CDCl3, 300 MHz): δ 1.30–1.77 ppm (m, 96H, –CH2CH2CH2CH2NH–), 
2.20 ppm (t, 16H, –C(O)CH2CH2CH2CH2CH2NH–), 2.48 ppm (t, 16H,–C(O)CH2CH2Ar), 
2.95 ppm (t, 16H, –C(O)CH2CH2Ar), 3.20 ppm (m, 16H,–CH2CH2CH2CH2NH–), 
3.63 ppm (s, –OCH2CH2–), 4.35 ppm (m, 8H,–C(O)C(NHR)HCH2CH2CH2CH2NH–), 
6.00 ppm (s, 16H, Ar), 6.25 ppm (s, 16H, Ar), 7.27 ppm (s, 16H, Ar).  
6.5.11 Synthesis of compound 8armPEG20k-Lys-Ahx-Mal2 (10b) 
8armPEG20k-Lys-Ahx-Mal2 (10b) was synthesized in 89% yield by reacting 9 with a 
fourfold excess of N-methoxycarbonylmaleimide as described for 2b. The degree of end-
group conversion was approximately 86% as determined by 1H-NMR spectroscopy. 
1H-NMR (CDCl3, 300 MHz): δ 1.29–2.18 ppm (112 H, aliphatic H), 3.62 ppm (s, 
–OCH2CH2–), 4.35 ppm (m, 8H, –C(O)C(NHR)HCH2CH2CH2CH2NH–), 6.68 ppm (s, 
32H, –C(O)CH=CHC(O)–).
Scheme 6.11. Functional end-groups of 10a and 10b 
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 Summary 
The aim of this thesis was the development and characterization of hydrogels with 
potential application as drug delivery systems for the controlled release of antibodies. 
As established gelation methods are associated with several disadvantages minimizing 
the successful use as injectable drug delivery systems, new cross-linking strategies have 
to be developed. For this purpose, chemical cross-linking is favored because hydrogels 
with defined mechanical and physicochemical properties are obtained. For these reasons, 
hydrogels were prepared by step-growth polymerization of star-shaped PEG 
macromonomers modified with maleimide- and furyl-residues via DA cycloaddition 
(Chapter 3). This reaction can be performed under mild conditions (water, 37 °C) 
without using any initiator or catalyst and enables the simple loading of sensitive 
biomolecules, such as antibodies. Rheological experiments indicated a time-dependent 
sol-gel transition making DA hydrogels ideal for injections. In future applications the 
hydrogel could be easily injected into the vitreous cavity as a liquid precursor solution, 
even through small-gauge needles, and form a stable drug depot after application. 
Gelation time and gel stiffness of the prepared hydrogels could be easily tuned by varying 
the concentration, branching factor and molecular weight of the used macromonomers. 
With increasing polymer concentration the gelation time decreased and the gel stiffness 
increased. The same effects were observed by using macromonomers with higher 
branching factor and lower molecular weight. The precise control of gel formation and 
mechanical properties makes the DA cycloaddition a valuable cross-linking mechanism 
for injectable drug delivery systems for antibodies. Swelling experiments of the 
covalently cross-linked hydrogels in aqueous solutions (pH 7.4) at 37 °C showed that 
covalent cross-linked hydrogel degraded within days to several weeks. 
(Figure 7.1) (Chapter 3 and 4).  
NMR studies, swelling studies and SEMD simulations indicated an rDA reaction and 
subsequent OH–-catalyzed hydrolysis of the formed maleimides to unreactive maleamic 
acid derivatives as the reason for the degradation. Since the rDA-rate is increased through 
the consumption of unreacted maleimide according to Le Châtelier’s principle, there is 
no need for high temperatures to incite the rDA reaction. Thus, DA hydrogels already 
degraded under physiological conditions and the additional modification with 
hydrolytically or enzymatically cleavable sites is not necessary to obtain biodegradable 
hydrogels. Consequently, surgical removement of hydrogel after complete drug release 
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Figure 7.1. DA hydrogels degraded due to rDA reaction and subsequent hydrolysis of maleimide to 
unreactive maleamic acid. 
is not necessary. Temperature and pH-value influenced the described degradation 
behavior, as well as cross-linking kinetics (Chapter 4). To ensure high degrees of 
conversion slightly acidic solutions (e.g., at pH 5.5) and temperatures above room 
temperature (e.g., at 37 °C) are preferred. 
Besides suitable cross-linking methods, appropriate swelling and degradation behavior, 
the hydrogel mesh size is an important characteristic to evaluate the suitability of the 
prepared hydrogels as drug delivery systems. Therefore, swelling studies, rheology and 
low field NMR spectroscopy were used to determine ξ of the prepared hydrogels 
(Chapter 5). In principle, similar values of ξavg were determined by all three methods. 
However, swelling studies were preferred to determine the time-dependent increase of 
ξavg during degradation and low field NMR measurements were most appropriate to 
characterize the mesh size distribution. The calculations of the network mesh size 
indicated that DA hydrogels are suitable for controlled release of entrapped, therapeutic 
peptides or proteins. The observed time-dependent increase of ξavg was used to predict 
the release profiles of FDs of different Rh. To proof the theoretical prediction, in vitro 
release profiles of FDs of different molecular weight and hence Rh were determined by 
fluorescence spectroscopy. The observed release profiles matched the prediction when 
Rh < ξavg. Moreover, the release profile of entrapped bevacizumab indicated that besides 
Rh, the globular structure of proteins must be taken into account for theoretical 
considerations. Bevacizumab showed a different release profile in comparison to equal 
sized FDs, since its rigid structure inhibits a worm-like diffusion through small network 
meshes.  
Chapter 7 
122 
The developed hydrogels already fulfilled several requirements for successful intraocular 
drug delivery, such as injectability, transparency, degradability and sustained release of 
entrapped macromolecules. However, the slow cross-linking and comparatively fast 
degradation limited the application of DA hydrogels as in situ gelling drug delivery 
systems due to fast diffusion of entrapped antibodies after injection. To overcome these 
limitations, the reaction kinetics of the DA cycloaddition had to be increased. As shown 
in Chapter 4 the number of reactive groups per macromonomer and the hydrolytic 
stability of maleimides residues influence the reaction kinetics and the degradation 
behavior of the prepared gels. Therefore, hydrophobic Ahx acid spacers were introduced 
between branched PEG and the reactive end-groups to increase the hydrolytic stability of 
the maleimide function. In addition, the number of reactive groups per macromonomer 
was doubled by branching eight-armed PEG with Lys and Ahx residues. This 
modification results in an increased hydrolytic stability of maleimide residues at the same 
time (Chapter 6). 
Rheological studies and swelling experiments indicated accelerated gelation kinetics, 
enhanced mechanical stability and prolonged degradation stability. These effects were 
observed for both modifications. Nevertheless, doubling the branching factor by 
introducing Lys and Ahx was more effective than introducing only Ahx as hydrophobic 
spacer. Their potential for the sustained release of therapeutic antibodies was evaluated 
by loading bevacizumab into the different hydrogels. The gel systems, prepared from the 
modified macromonomers, were able to sustain the in vitro release of bevacizumab for at 
least 6 weeks. The modification with Lys and Ahx seems to be most promising to extend 
the dosing interval of intraocular injection and hence increase the compliance. Moreover, 
sigmoidal release profiles were observed indicating an intermittent drug release, which is 
desired in anti-VEGF drug therapy [133,271]. 
 Conclusion and outlook 
In summary, the DA reaction is an ideal cross-linking method for the preparation of PEG-
based hydrogels for sustained antibody release after intraocular injection. 
The mild reaction conditions of the DA cycloaddition and the high water content of the 
resulting hydrogel offer a simple and effective loading mechanism, even for highly 
sensitive drugs, such as proteins and antibodies. Since rheological studies indicated a 
time-dependent sol-gel transition after mixing the hydrogel precursor solutions, the 
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hydrogel can be easily injected into the vitreous body using small-gauged needles. When 
the PEG macromonomers are branched with Lys and Ahx, a rapid formation of a 
viscoelastic drug depot inside the vitreous cavity is expected. Moreover, the precise 
control of the resulting mesh size guarantees a sustained antibody release over several 
weeks. Finally, the cross-linked hydrogels degrade under physiological conditions 
resulting in a complete drug release. 
In the future, the release profiles of entrapped drugs can be optimized by using mixtures 
of different macromonomers, such as 8armPEG10k and 8armPEG20k, to fine-tune the 
mesh size and degradation rate of the resulting hydrogels. 
However, further experiments are necessary to evaluate the DA hydrogels in more detail. 
As possible reactions or interactions of PEG with entrapped antibodies may influence the 
pharmacological effects of the proteins due to conformational changes, the samples have 
to be analyzed by methods giving more information on protein structure. For instance, 
the percentage of free antibody and PEGylated protein as well as degradation products of 
instable antibodies can be detected by high performance liquid chromatography. 
Moreover, the activity of the released antibodies has to be evaluated to ensure 
pharmacological effects after intraocular injection. Enzyme linked immunosorbent assays 
can be used for the quantitative determination of biologically active forms of 
bevacizumab. 
Although, further investigations are necessary, these first reported experiments 
demonstrate that PEG-based DA hydrogels show great promise as injectable drug 
delivery systems not only for intraocular application. 
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Abbreviations 
ADH ............................................. adipic dihydrazide 
Ahx ................................................ 6-aminohexanoic acid 
AMA ............................................ allyl methacrylate 
AMD ............................................ age-related macular degeneration 
ANOVA ..................................... analysis of variance 
DA ................................................. Diels-Alder 
DCC .............................................. N,N’-dicyclohexylcarbodiimide 
DCM ............................................ dichloromethane 
DIAD ........................................... diisopropyl azodicarboxylate 
DIPEA......................................... N,N’-diisopropylethylamine 
DMAA ........................................ N,N’-dimethyl acrylamide 
DMF ............................................. dimethylformamide 
EDC .............................................. 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EGDMA .................................... ethylene glycol dimethacrylate 
EGF ............................................... epidermal growth factor 
ESHU .......................................... poly(ethylene glycol)-poly-(serinol hexamethylene urethane) 
ETPI ............................................. 3,6-epoxy-1,2,3,6-tetrahydrophthalimide 
1H-NMR .................................... proton nuclear magnetic resonance 
HA ................................................. hyaluronic acid 
HOSu ........................................... N-hydroxysuccinimide 
MC ................................................. methyl cellulose 
HEMA......................................... 2-hydroxyethyl methacrylate 
HPMC ......................................... (hydroxypropyl)methyl cellulose 
IOL ................................................ intraocular lenses 
Lys ................................................. lysine 
MAA ............................................ methacrylic acid 
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MAEBTP .................................. 4-(2-methacryloyloxyethyl)-2-(2H-benzotriazol-2-yl)phenol 
MES .............................................. 2-(N-Morpholino)ethanesulfonic acid 
MPC ............................................. 2-methacryloxyethyl phosphorylcholine 
mPDMS ..................................... monofunctional polydimethylsiloxane 
NCVE .......................................... N-carboxyvinyl ester 
NHS .............................................. N-hydroxysuccinimide 
NVP .............................................. N-vinylpyrrolidone 
PAA .............................................. poly(acrylic acid) 
PBVC .......................................... poly(dimethylsiloxyl)di-(silylbutanol)bis-(vinyl carbamate) 
PCO .............................................. posterior capsule opacification 
PDMS .......................................... poly(dimethylsiloxane) 
PDR .............................................. proliferative diabetic retinopathy 
PEG ............................................... poly(ethylene glycol) 
4armPEG10k-OH ............... four-armed poly(ethylene glycol), molecular weight 10 kDa 
8armPEG10k-OH ............... eight-armed poly(ethylene glycol), molecular weight 10 kDa 
8armPEG20k-OH ............... eight-armed poly(ethylene glycol), molecular weight 20 kDa 
PEPGDMA .............................. poly(ethylene propylene glycol) dimethacrylate 
pHEMA ...................................... poly(2-hydroxyethyl methacrylate) 
PNIPAAm ................................ poly(N-isopropylacrylamide) 
PVA .............................................. poly(vinyl alcohol) 
rDA ............................................... retro-Diels-Alder 
RPC ............................................... retinal progenitor cells 
RSC ............................................... retinal stem cells 
SCL ............................................... soft contact lenses 
SEMD ......................................... semi-empirical molecular dynamics 
SiGMA ....................................... methylbis-(trimethylsiloxy)silylpropylglyceryl methacrylate 
SMA ............................................. sodium methacrylate 
STMP .......................................... trisodium trimetaphophate 
TBHMA ..................................... 4-tert-butyl-2-hydroxycyclohexyl methacrylate 
TRIM ........................................... 1,1,1-tris(hydroxymethyl)propane trimethacrylate 
TRIS ............................................. methacryloxypropyl tris(trimethylsiloxy silane) 
USAN .......................................... United States adopted name 
UV ................................................. ultraviolet 
VEGF .......................................... vascular endothelial growth factor 
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Symbols 
α ...................................... conversion of functional groups at the gel point 
a(T2) ............................. unknown amplitude of the spectral component at relaxation time T2 
Ai .................................... dimensionless pre-exponential factor 
At .................................... measured amplitudes of the echo with the gradient applied 
A0 ................................... measured amplitudes of the echo without the gradient applied 
A0i .................................. fractions of water molecules characterized by Di 
c ...................................... concentration 
cmax ................................ maximum plasma concentration 
𝐶𝐶𝑛𝑛 ................................... Flory characteristic ratio 
𝜒𝜒1 ................................... Flory-Huggins interaction parameter for PEG in water 
Dg ..................................... diffusion coefficient of the solute in the hydrogel 
Di ................................... self-diffusion coefficient 
D0 ................................... diffusion coefficients in water 
δ ...................................... chemial shift 
δ ...................................... dihedral angle 
η ........................................ viscosity of water 
ηi ..................................... viscosity of the dashpot component 
f ....................................... branching factor of the macromonomers 
f ....................................... number of functional groups for cross-linking 
G ..................................... shear modulus 
G’ ................................... storage modulus 
G” .................................. loss modulus 
|G*| ............................... absolute value of the complex shear modulus 
Ge ................................... spring constant of the last, purely elastic Maxwell element 
Gi ................................... spring constant of the ith Maxwell element 
g ...................................... magnetic field gradient 
γ ...................................... gyromagnetic ratio of the protons 
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h ...................................... height of the gel cylinder 
k ........................................ Boltzmann constant 
kobs ................................. hydrolysis rate constants 
kQ ................................... rate constant of the swelling process 
kξ .................................... rate constant of the mesh size increasing process 
Is ..................................... signal intensity 
𝑙𝑙 ....................................... average bond length along the PEG backbone 
λem ................................. emission wavelength 
λex .................................. excitation wavelength 
λi ..................................... relaxation time of the ith Maxwell element 
⟨ℳ ⟩ ............................ relaxation sink strength (length / time) 
Mt ................................... absolute cumulative amounts released at time t 
𝑀𝑀�𝑔𝑔  .................................. average molecular weight between cross-links 
mp ................................... mass of the polymer in the hydrogel 
𝑀𝑀𝑟𝑟  .................................. molecular mass of the PEG repeating unit 
M∞ ................................. absolute cumulative amounts released at infinity 
NA................................... Avogadro constant 
n ...................................... number of considered Maxwell elements 
ω ..................................... angular frequency 
ρx .................................... cross-link density 
φ ..................................... polymer volume fraction of the hydrogel 
Q ..................................... volumetric swelling ratio 
qn .................................... roots of the Bessel function of the first kind of zero order 
R ..................................... universal gas constant 
Rf  ................................... radius of the polymer chain 
Rh ................................... hydrodynamic radius 
r....................................... radius of the gel cylinder 
σ ...................................... oscillatory stress 
T...................................... temperature 
T2 .................................... transverse relaxation time 
⟨1/T2⟩ ........................... average value of the inverse relaxation time 
t ....................................... time 
td ..................................... diffusion time of the water molecules 
t½ .................................... half-live time 
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𝜈𝜈𝑒𝑒  ................................... number of moles of elastically active chains in the hydrogel network 
𝑣𝑣2𝑔𝑔  ................................. polymer fraction of the gel after cross-linking 
𝑣𝑣2𝑔𝑔  ................................. polymer fraction of the gel in the swollen state 
𝑉𝑉1 ................................... molar volume of the swelling agent 
𝑉𝑉𝑔𝑔𝑔𝑔 .................................. gel volume after cross-linking 
𝑉𝑉𝑔𝑔𝑔𝑔 .................................. gel volume after swelling 
𝑉𝑉𝑝𝑝 .................................... volume of the dry polymer 
ξ ...................................... network mesh size 
ξavg................................. average network mesh size
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